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Structure-Function Studies of Conserved
Sequence Motifs of Cytochrome b5 Reductase
Louis J. Crowley
ABSTRACT

NADH:Cytochrome b5 Reductase (cb5r) catalyzes the two electron reduction of
the iron center of the heme cofactor found within cytochrome b5 (cb5) utilizing reducing
equivalents of the nicotinamide adenine dinucleotide (NADH) coenzyme.

Cb5r is

characterized by two domains necessary for proper enzyme function: a flavin-binding
domain and a pyridine nucleotide-binding domain. Within these domains are highly
conserved “motifs” necessary for the proper binding and orientation of both the NADH
coenzyme and the FAD cofactor.
To address the importance of these conserved motifs site-directed mutagenesis
was utilized to generate a series of variants upon residues found within the motifs to
allow for the full characterizations. Second, naturally occurring recessive congenital
methemoglobinemia (RCM) mutants that are found within or in close proximity to these
highly conserved motifs were analyzed utilizing site-directed mutagenesis.
The flavin-binding motif “91RxYSTxxSN97” was characterized by the generation of
variants T94H, T94G, T94P, P95I, V96S, and S97N. In addition to this, the naturally
occurring double mutant P92H/E255- was fully characterized to establish a role of the
P92 residue giving rise to RCM.
xiv

The role of the “124GRxxST127” was determined by the introduction of a positive
charge, charge reversal, and conserved amino acid mutations through site-directed
mutagenesis of the G124, K125, and M126 residues. Based on the data presented here,
each of the residues of the

G
S
Rxx T

motif are directly involved in maintaining the proper

binding and orientation of the cb5r flavin prosthetic group.
Analysis of the NADH-binding motif “273CGxxx-M278” was accomplished
through the characterization of the type II RCM variant M272- and the type I RCM
variant P275L. This demonstrates that the deletion of the M272 residue causes a frame
shift leading to the inability of the NADH substrate to bind. The introduction of the
P275L variant showed that substrate affinity was diminished, yet

turnover was

comparable to wild-type cytochrome b5 reductase, indicating that although P275 is
required for proper substrate binding it is not essential for overall catalytic function.
Finally, analysis of the naturally occurring double mutant G75S/V252M provided
the first insight into a methemoglobinemia variant that possessed mutations in both the
FAD-binding and NADH-binding domains.

xv

1. INTRODUCTION

Cytochrome b5 Reductase
NADH: Cytochrome b5 reductase (cb5r,

EC 1.6.6.2) is a member of the

flavoprotein transhydrogenases [1] which catalyze the transfer of reducing equivalents
between the two electron carrying nicotinamide dinucleotides and one electron carriers.
Other members of this family include ferrodoxin:NADP+ reductase (FNR) [2], plant and
fungal NAD(P)H: nitrate reductases [3], NADPH: cytochrome P450 reductase [4],
NADPH: sulphite reductase, phthalate dioxygenase reductase [5], nitric oxide synthase
[6], and various other flavoproteins. The enzymes found within this flavoprotein family
have been demonstrated to comprise both flavin-binding domains and pyridine
nucleotide-binding domains. The overall function of cytochrome b5 reductase is to serve
as an electron donor for cytochrome b5 through a hydride ion transfer from the reduced
coenzyme, NADH, to the non-covalently bound cytochrome b5 reductase flavin adenine
dinucelotide (FAD) cofactor.
Cytochrome b5 reductase is encoded by the DIA1 gene (Figure 1), located on the
human chromosome 22q13-qter [7, 8] and transcribes two isoforms of cb5r produced by
the use of alternative promoters [9, 10]. Each isoform is localized to separate regions of
the cell and thus, performs separate functions. The first isoform is the microsomal
isozyme which comprises the majority of transcribed cb5r and is generated through the
1

A.

5’

1a 1b

B.

5’

1a 2

3

4

5 6 7

8

9

3’ Membrane-bound cb5r (ubiquitous)

C.

5’

2

3

4

5 6 7

8

9

3’ Soluble cb5r (erythrocyte)

2

3

4

5

6

7

8

9

3’

Figure 1. Structure of the Human DIA1 Gene that Encodes Cytochrome b5
Reductase. The DIA1 gene (A) is composed of exons 1-9 [11]. There are two alternate
transcription start sites, 1a and 1b, which yield the two isoforms of cb5r. (B) represents
the membrane-bound cb5r isoform containing exon 1a-9, but not 1b, and consists of 300
amino acids (GAQLÆCFVF), including the myristoylation signature in exon 1a. (C)
represents the soluble cb5r isoform containing exons 2-9, but not exon 1, and consisting
of the 275 amino acids that comprise the diaphorase domain (LFQRÆCFVF).
transcription of all 9 exons of the DIA1 gene. The microsomal isozyme comprises 300
amino acids residues with a molecular weight of ~34 kDa, and contains a myristoylated
25 amino acid N-terminal hydrophobic region that serves as the membrane anchoring
domain [12-14]. This membrane bound isozyme is localized to the cytosolic face of the
endoplasmic reticulum as well as the mitochondrial, nuclear, and plasma membranes of
somatic cells.

The electron transfer process between the microsomal cb5r and

cytochrome b5 are required for a variety of metabolic transformations that include: steroid
biosynthesis [15], desaturation and elongation of fatty acids, cholesterol biosynthesis [16,
17], and P450-dependent reactions [18]. More recently, it has also been shown to be part
of the microsomal cytochrome b5 reductase-cytochrome b5 pathway directly involved in
the reductive detoxification of arylhydroxylamine carcinogens in human liver [19].
In the second isoform, only exons 2-9 are transcribed from the DIA1 gene
producing a 275 amino acid residue soluble form of cb5r.
2

Soluble cytochrome b5

reductase is comprised of an N-terminal FAD-binding domain and a C-terminal NADHbinding domain [20, 21]. The NAD-binding domain forms a three-layered α-β-α fold,
which is common for pyridine dinucleotide-binding regions, while the FAD-binding
domain has an antiparallel β-barrel topology. This isozyme is a flavoprotein with a
molecular mass of ~31 kDa is primarily found within the circulating erythrocytes where
it is involved in the reduction of methemoglobin to hemoglobin [22, 23] through an
interaction with cytochrome b5.
The mechanism of electron transfer for the soluble form of cb5r from the
physiological substrate, NADH and the FAD cofactor of cb5r is shown in Figure 2. In
this schematic, two electrons are first transferred from NADH to FAD by hydride ion
(H-) transfer. The two-electron reduced enzyme-NAD+ complex (E-FADH—NAD+) sub
sequentially transfers two electrons to two molecules of cytochrome b5 by the anionic red
semiquinone form (E-FAD·- - NAD+), returns the reduced enzyme to its oxidized state
[24]. The reduction of FAD by NADH has been determined to be the rate-limiting step
in the electron transfer process catalyzed by cytochrome b5 reductase [25-27]. In the
porcine variant of cytochrome b5 reductase, it was also determined that the anionic red
semiquinone of FAD is stabilized by the binding of NAD+ [28, 29]. Further studies by
Meyer et al. [30] confirmed that the binding of NAD+ is involved in the stabilization of
the red semiquinone of cb5r and also showed that it modulates the electron transfer to
cytochrome b5 [30], thus demonstrating the importance of the anionic red semiquinone
form of cb5r (E-FAD·- - NAD+) in the catalytic process. Recent studies by Iyanagi et al.
[24] have generated a new scheme for the electron transfer sequence of cytochrome b5
reductase involving the neutral blue semiquinone form and the oxidized
3

cb5rox (FAD)

A.

cb5rred (FADH2)

NADH + 2cb5(Fe3+)

NAD+ + H+ + 2cb5(Fe2+)

(1)

NADH

B.

E-FAD-.NAD+

E-FAD

E-FAD- -NAD+
e-

e- NAD+

H+

Figure 2. Mechanism of Cytochrome b5 Reductase Mediated Cytochrome b5
Reduction. (A) represents the chemical reaction (equation 1) catalyzed by cb5r. (B)
illustrates the mechanism of cb5r transfer where each electron (e-) reduces one molecule
of cb5 [31].

NAD+ E-FAD

NADH
(i)

E-FAD-NADH-NAD+

E-FAD-NADH
(viii)

NADH

H- transfer

(vii)

(ii)

(vi)

E-FAD-NAD+

E-FADH- - NAD+

E-FAD-NADH*
(iii)
(v)

E-FAD●--

-NAD+

e-

H+

(iv)
E-FADH●

-NAD+
e-

Figure 3. New Model of the Reaction Sequence of Cytochrome b5 Reductase. This
new model represents the reaction sequence of cytochrome b5 reductase containing the
neutral blue semi-quinone form and the oxidized enzyme-NADH-NAD+ ternary complex
as intermediates [24].
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enzyme-NADH-NAD+ ternary complex (Figure 3). This scheme involves the following
seven-step process: (i) formation of the oxidized enzyme-NADH complex (E-FADNADH), (ii) conversion of E-FAD-NADH to a form that has the ability to transfer a
hydride ion (E-FAD-NADH), (iii) hydride (H-) transfer from NADH to FAD, (iv) the
first one-electron transfer from the two-electron reduced enzyme complex (E-FADH NAD+), (v) rapid conversion of the neutral blue semiquinone form (E-FADH· -NAD+) to
the anionic red semiquinone form (E-FAD· -NAD+), (vi) the second one-electron
transfer from E-FAD· -NAD+, (vii) formation of the oxidized enzyme-NADH-NAD+
ternary complex (E-FAD-NADH-NAD+) by binding of NADH, and (viii) release of
NAD+.
Similar to the binding interaction between NADH and cytochrome b5 reductase,
the binding interaction between cytochrome b5 reductase and its one electron acceptor,
cytochrome b5, has also been extensively studied [26, 35-38, 112]. Cytochrome b5 is also
transcribed as both a soluble and microsomal isozyme, comprised of 97 and 133 amino
acid residues, respectively, by the CYB5 gene located on human chromosome 18q23 and
has a molecular weight of ~11 kDa. The electron acceptor of cytochrome b5 is the iron
center of a single protoheme IX prosthetic group which also gives cb5 its characteristic
red color. Cytochrome b5 is an acidic molecule with 21 surface accessible carboxylic
acid residues and possesses an isoelectric point (pI) of 4.90 [32], whereas the isoelectric
point (pI) of cytochrome b5 reductase is 7.15, thus suggesting a role for charge
complimentarity between cytochrome b5 reductase and cytochrome b5 complex
formation. This was confirmed through studies by Salemme [33] utilizing a best-fit
computer program based on the crystallographic data for cytochrome b5, indicated that
5

GLU48
GLU47

GLU52

Heme propionate
group

ASP64
GLU60

Figure 4. Structure of Cytochrome b5 Generated in silico. The molecular model of
cytochrome b5 displaying the negatively charged residues and exposed heme propionate
group determined to be involved in the binding interaction with cytochrome b5 reductase
was generated utilizing the molecular modeling software Web Lab Viewer Pro [34]. This
model represents a surface representation of cb5 (1CYO ) where the acidic residues are
red, basic residues are blue, and neutral residues are displayed as white clouds.
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LYS41

LYS163
LYS162

LYS125

Figure 5. Structure of Cytochrome b5 Reductase Generated in silico. The molecular
model of cytochrome b5 reductase displaying the positively charged residues K41, K125,
K162, and K163that have been determined to be involved in the binding interaction with
cytochrome b5 was generated utilizing the molecular modeling software Web Lab
Viewer Pro [34]. This model represents a surface representation of cb5 reductase (1IB0 )
where the acidic residues are red, basic residues are blue, and neutral residues are
displayed as white clouds.
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electron transfer involved interactions through the charge pairing of the surface
accessible carboxyl residues E-47, E-48, E-52, E-60, D-64 (shown in Figure 4) and the
exposed heme propionate group of the active site. Further confirmation was established
by Dailey and Strittmatter [35] utilizing selective carboxylate group modification to
reveal that these same carboxyl groups, located in the active site of cytochrome b5, were
involved in the electron transfer interaction between cytochrome b5 reductase, NADPHcytochrome-P450, and stearyl-CoA desaturase [35, 36]. In order to establish the charge
pairing of cytochrome b5 reductase residues, Ozols and Strittmatter determined that the
lysyl residues of cytochrome b5 reductase played a significant role in the interaction
between cytochrome b5 and cytochrome b5 reductase. Modification of only seven lysyl
residues of cb5r resulted in a loss of catalytic activity utilizing cb5 as the final electron
acceptor, whereas no change in catalytic activity was demonstrated through the
modification of the lysyl residues on cytochrome b5. Furthermore, through the selective
acylation of several lysyl residues on cytochrome b5 reductase, cytochrome b5 reduction
was inhibited [37].

Sequence analyses of protease-generated cross-linked peptides

demonstrated that four essential lysine residues in cytochrome b5 reductase involved in
forming charge pairs with the active site carboxyl groups of cytochrome b5 and included:
K-163, K-41, K-125, and K-162 [38] (Figure 5).

Crystal Structure of Cytochrome b5 Reductase
High resolution crystal structures of the soluble, diaphorase domain of R.
norvegicus cytochrome b5 reductase was recently solved in the absence (2.0 Å, PDB
1I7P) and presence (2.3 Å, PDB 1IB0) of bound NAD+ [21] (Figure 6). The structures
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displayed a classical bi-domain arrangement, comprised of an amino terminal FADbinding lobe (amino acid residues I33-R142) and a carboxy-terminal NADH-binding lobe
(amino acid residues K172-F300). Residues G148-V171 comprise what has recently
been termed the “linker” or “hinge” region. This 28 amino acid residue segment forms a
three-stranded, anti-parallel β-sheet that has been demonstrated to be of critical
importance in determining the correct orientation and modulation of electron transfer
between that of the FAD- and NADH-binding domain [39, 40].
The amino-terminal FAD-binding domain (Figure 7) is comprised of a seven-stranded
antiparallel β-barrel, labeled as Fβ1-Fβ7, oriented towards the si-face of the flavin
isoalloxazine ring and capped by a single α-helix found in the FAD-binding domain. A
majority of the interactions with the FAD- prosthetic group occur via the adenine
dinucleotide moiety of the flavin and with a long loop of the FAD-binding domain which
is comprised of amino acid residues K110-K125 forming a “lid” and is situated between
Fβ6 and the α-helix. The NADH- binding domain (Figure 8) is composed of a canonical
Rossman fold [41] formed by 3 α/β/α layers arranged into a five-stranded parallel β-sheet
that is oriented towards the re-face of the isoalloxazine ring of the FAD prosthetic group.
The isoalloxazine ring is the only region of the FAD- cofactor that forms interactions via
hydrogen bonds between the NADH-binding site and the isoalloxazine ring. This occurs
through the FAD-binding domain loop strands Fβ3 and Fβ4 (amino acid residues P92K110) and the NADH-binding domain Nβ1-NαA (amino acid residues T181-T184). The
“hinge” or “linker” region (Figure 9) is situated between the FAD-binding and NADHbinding domains and is comprised of a three-stranded anti-parallel β-sheet structure
designated as Hβ1-Hβ3. Studies of this linker region by Davis et al. [40] demonstrated
9

Figure 6. The Tertiary Structure of Rat Cytochrome b5 Reductase. The 2.0Å
resolution X-ray crystal structure derived from soluble recombinant rat liver cb5r (PDB
1IB0) [21] is illustrated as a schematic model where the red portions represent α-helices,
the yellow ribbons with directional arrows represent β-sheet structures, and the green
tubes are indicative of random coils and flexible loop structures. The FAD cofactor (left)
and NAD+ (right) are shown in stick configurations with standard CPK coloration.
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“Lid”

Fα1

Fβ1b
Fβ6
Fβ1a

Fβ2

FAD
Fβ4

Fβ5
Fβ3

Figure 7. The Structure of the FAD-Binding Domain of Cytochrome b5 Reductase.
A view of the N-terminal FAD-binding domain of rat cb5r (PDB 1IB0) with FAD bound.
The re-face of the isoalloxazine ring faces towards the right. FAD is shown in stick
configuration with standard CPK coloration. The polypeptide backbone is shown in
green with the single α-helix in red and β-sheets colored yellow and are labeled
accordingly.
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NAD+
NαD

NαC

Nβ2

NαB

Nβ5
Nβ4
NαA
Nβ3

Nβ1

Figure 8. The Structure of the NADH-Binding Domain of Cytochrome b5
Reductase. A view of the C-terminal NADH-binding domain of rat cb5r (PDB 1IB0)
with NAD+ bound. NAD+ is shown in stick configuration with standard CPK coloration.
The polypeptide backbone is shown in green with the single α-helix in red and β-sheets
colored yellow and are labeled accordingly.
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Fβ6

Hβ1

Hβ2

Nβ1
Hβ3

Figure 9. The Structure of the “Hinge” Region of Cytochrome b5 Reductase. A
view of the “Hinge” region of rat cb5r (PDB 1IB0) located between the FAD and NADHbinding domains. The polypeptide backbone is shown in green with the β-sheets colored
yellow and are labeled accordingly.
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that allows for efficient electron transfer to occur. These studies also demonstrated that it
is this “linker” region which is actively involved in properly orienting the FAD- and
NADH-binding lobes of cb5r towards efficient electron transfer and suggested that any
disruption within the conformation of the β-sheet architecture would lead to a significant
decrease in catalysis.

Recessive Congenital Methemoglobinemia
In 1943 Quenton Gibson of Queen’s University, Belfast, described the first
hereditable trait that was associated with a specific enzyme deficiency [43]. In patients
with a familial incidence of idiopathic cyanosis, Hitzenberger later established a
diagnosis of congenital, familial methemoglobinemia [42]. Based on this diagnosis,
Gibson determined that the inability of circulating erythrocytes to reduce the pools of
methemoglobin would give rise to familial idiopathic methemoglobinemia [43]. In 1948,
Gibson further elucidated the pathway involved in the actual reduction of methemoglobin
which directly involved the enzyme methemoglobin reductase [44], now referred to as
NADH: cytochrome b5 reductase (cb5r).
Methemoglobin is the derived form of hemoglobin in which the iron center of the
heme prosthetic group is in its oxidized state. In the ferric heme state the iron center is
unable to efficiently bind oxygen and the oxygen affinity of the accompanying ferrous
hemes in the hemoglobin tetramer is decreased, thereby impairing oxygen delivery.
Methemoglobin is constantly generated physiologically due to the deoxygenation of the
molecule, however, endogenous enzymatic hemoglobin reduction pathways maintain
methemoglobin levels at or below 3% of total hemoglobin. Inability to efficiently reduce
14

the levels of methemoglobin gives rise to the disease termed methemoglobinemia. The
primary pathway that converts methemoglobin to hemoglobin involves the reduced form
of NADH: cytochrome b5 reductase.

In this pathway, reducing equivalents are

transferred from the pyridine dinucleotide, NADH to the FAD- prosthetic group of cb5r,
followed by the reduction of two molecule of cytochrome b5. In circulating erythrocytes,
cytochrome b5 directly transfers one electron to the iron center of the heme prosthetic
group in methemoglobin thereby reducing it to hemoglobin.
The most common cause of recessive congenital methemoglobinemia (RCM)
directly results from a deficiency of cytochrome b5 reductase. Individuals with RCM
have an inability to effectively reduce methemoglobin which is constantly being formed
through the deoxygenation of hemoglobin in circulating erythrocytes. Defects in the
expression of cytochrome b5 reductase give rise to two forms of methemoglobinemia
known as type I and type II which are classified based on the patient pathophysiology.
In type I, the prevalent symptom is mild cyanosis which results in headaches,
fatigue and shortness of breath during exercise and is restricted to the soluble isozyme of
cb5r found in circulating erythrocytes. This form of methemoglobinemia is inherited in
an autosomal recessive pattern and is found worldwide, however, it has been determined
to be endemic in certain populations such as the Athabascan Alaskans, Navajo Indians,
and Yakutsk natives of Siberia. Compound heterozygotes or homozygotes that express
type I RCM have methemoglobin concentrations ranging from 10 to 40% and are
relatively asymptomatic where cyanosis is the only symptom. Life expectancy is not
affected in these patients.
Type II methemoglobinemia has been established in 10 to15% of cases for RCM
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and is the more severe form of the disease in which the deficiencies of cb5r are present in
the membrane-bound form of cb5r in somatic cells.

The symptoms of type II are

expressed with severe developmental abnormalities including mental retardation,
microcephaly, opisthotonus, strabismus, and generalized hypertonia often leading to
premature death [45-47].
Cytochrome b5 reductase is encoded by the DIA1 gene. It is because of this that it
is believed that patients expressing type I methemoglobinemia are producing the
abnormal gene product at a normal rate, but it is unstable. Thus, only the mature red
blood cells, which can not synthesize proteins, are affected. In patients expressing type II
methemoglobinemia, mutations in the DIA1 gene give rise to decreased expression or
reduced catalytic activity of cytochrome b5 reductase and the deficiency is ubiquitous.
Thus far, about 40 amino acid mutations have been identified within the DIA1 gene
giving rise to either type I or type II methemoglobinemia [10, 31, 48-50].

The Ferredoxin: NADP+ Reductase Family of Flavoprotein Oxidoreductases.
Through a sequence alignment utilizing the X-ray crystal structure of spinach
ferredoxin-NADP+ reductase [51], a family of flavin-dependent oxidoreductases have
been identified which include: cytochrome b5 reductase, cytochrome P-450 reductase,
methionine synthase reductase, ferredoxin:NADP+ reductase, as well as many others. Of
significant interest was the pattern of conserved residues that were detected within the
flavin- and nucleotide- binding domains which were characteristic of the FNR family
(Figure 10). These conserved sequences or “motifs” are essential for the proper
characterization of FNR proteins that share a common evolution, structure, or catalytic
16

Figure 10. Alignment of Conserved Flavin-Binding and NADH-Binding Motifs from
Various Enzymes Belonging to the “FNR Family” of Flavoprotein
Transhydrogenases. Each of the published amino acid sequences was obtained from the
GenBank protein database [52] with the corresponding accession number and reference.
The superscripted numbers indicate the amino acid positions of the first and last residue
of each motif within the full-length sequence of each protein. Abbreviations are: CB5R,
cytochrome b5 reductase, NR, nitrate reductase, FNR, ferredoxin:NADP+ reductase,
CPR, cytochrome P450 reductase, NOS, nitric oxide synthase, PDR, phthalate
dioxygenase reductase, MSR, methionine synthase reductase, SR, sulfite reductase, FHG,
flavohemoglobin, B5B5R, cytochrome b5-cytochrome b5 reductase fusion protein, ETP,
electron transfer protein, NDR, naphthalene dioxygenase reductase, PH, phenol
hydroxylase, NFR, NADPH:flavin reductase, CDPGR, CDP-glucose dehydratase
reductase, CMR, p-cymene monooxygenase reductase, XMR, xylene monooxygenase
reductase, NMR, nitrotoluene monooxygenase reductase, DQMR, dihydorquinoline
monooxgenase reductase, MMOR, methane monooxygenase reductase, ADR,
anthranilate dioxygenase reductase, TDR, toluate dioxygenase reductase, BDR, benzoate
dioxygenase reductase, HBDR, hydroxybenzoate dioxygenase reductase, NQR1, Na+
translocating NADH:quinone reductase 1, UNK1, unknown M. loti gene product, UNK2,
unknown Halobacterium sp. NRC-1 gene product, HYPR, hypothetical Xanthobacter
reductase.
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Enzyme

Motif 1

Motif 2

Motif 3

Motif 4

CB5R

91

125

GKMS128

181

GTGIT-P186

274

CGPPP-M279

NR

722

RAYTPPS728

755

GVMS758

805

GTGIT-P810

898

CGPPP-M903

FNR

139

RLYSIAS145

176

GVCS179

217

GTGIA-P222

318

CGLKG-M323

CPR

454

RYYSIAS460

488

GVAT491

534

GTGVA-P539

629

CGDARNM635

NOS

1178

PDR

51

MSR

478

RPYSCAS484

514

SR

386

RLYSIAS392

FHG

204

B5B5R

289

ETP

56

NDR

142

RPYSMAG148

165

PH

149

RAFSLAN155

173

NFR

58

CDPGR

141

RSYSIAN147

164

CMR

159

RSYSFAN165

XMR

160

NMR

RPYTPVS97

RYYSISS1184

RNYSLSN57

1214

GTGIA-P1260

1354

CGDVT-M1359

GIGIT-P128

202

CGPRPLM208

GVCT517

573

GTGIA-P578

677

CGDKANM683

420

GASS423

461

GTGIA-P466

552

CGDANRM558

RQYSLTR210

227

GQVS230

268

GVGQT-P273

362

CGPVGFM368

KPYTPVS295

323

GLFT326

364

GTGFT-P369

458

CGPTPFT464

120

GSGIA-P125

203

CGPEPFM209

GRVT168

206

GTGLA-P211

295

CGAPA-M300

GAAT176

214

GSGLSSP220

306

CGPPP-M311

123

GTGFSYA129

212

AGRFE-M217

GQMS167

204

GTGFA-P209

292

CGSPV-M297

185

GEFT188

225

GSGLA-P230

315

CGPPP-M320

RSYSFAT166

184

GIFS187

224

GTGLA-P229

315

CGPPP-M320

161

RSYSFSA167

185

GVFS188

225

GTGLA-P230

316

CGPPP-M321

DQMR

155

RSYSPSS161

179

GAMS182

221

GTGLA-P226

310

CGPQP-M315

MMOR

159

RSYSPAN165

183

GRFS186

224

GTGLA-P229

314

CGPPG-M319

ADR

154

RSYSFAN160

178

GVMS181

218

GTGLS-A223

307

CGPPP-M312

TDR

153

RAYSFSS159

176

GLMS179

216

GTGLA-P221

304

CGPPP-M309

BDR

166

RSYSFSS172

189

GKMS192

229

GTGIA-P234

317

CGPVP-M322

HBDR

152

RAYSYSS158

175

GKMS178

215

GTGLA-P220

305

CGPPP-M310

NQR1

222

KAYSLAS228

259

GVCS262

298

GAGSSFG304

401

CGPPLHN407

UNK1

168

RLYLVST174

201

GSSP204

383

GIGIT-P388

471

SGPQA-M476

UNK2

51

102

GEPS105

112

GPGVG-P117

188

CGAATDA194

HYPR

142

166

GAGT169

207

GSGLA-P212

297

AGPAP-M302

Consensus

RxYTSxxSN

RPFSMAS64

RYYTLSS57
RAYSVAN148

80

77

RGGS87

1255

123

RCYSITS62

83

GVCS1217

GRVS83

GASE80

GxxST (FAD)
RxxSN (FMN)

GxGxxP

18

CGxxx-M

GenBank
Accession/Ref
NP_620232 /
[8]
P23312 /
[53]
P10933 /
[54]
P16435 /
[55]
P29475 /
[56]
Q05182 /
[5]
Q9UBK8 /
[57]
P38038 /
[58]
P24232 /
[59]
NP_596918 /
[60]
BAA12809 /
direct submission
AAD02134 /
[61]
AAA25944 /
[62]
AAN83224 /
[63]
P26395 /
[64]
AAB62300 /
[65]
AAB70826 /
direct submission
AAC38360 /
[66]
CAA73201 /
[67]
P22868 /
[68]
AAC34815 /
[69]
AAD31449 /
direct submission
P07771 /
[70]
Q51603 /
[71]
Q9Z723 /
[72]
NP_107088 /
[73]
NP_279534 /
[74]
CAA09916 /
[75]

function. The structural motif of members of the FNR family is that of a two-domain
module with one binding the flavin and the other binding the pyridine nucleotide. In
regards to function, the FNR family is classified by the two electron reduction of a flavin
prosthetic group (FAD/FMN) by a pyridine dinucleotide coenzyme (NAD(P)(H)),
followed by the sequential transfer of electrons in one electron reactions with carriers.
An additional feature of the proteins found within the FNR superfamily is the
varying levels of complexity based on the structural domains and modulation of electron
transfer [2]. Cytochrome b5 reductase and FNR are examples of the simplest members of
the FNR family in that they each consist of only two domains and reduce molecules
which are able to bind and then rapidly disassociate following electron transfer. In
contrast, cytochrome P450 reductase, sulfite reductase-α, and PDR represent more
complex enzymes. Although the structures also consist of two domains, the one-electron
acceptor molecule is actually fused to the two-domain core by a linker region. Finally,
the most complex members of the FNR family contain additional sequences and
prosthetic groups which is indicative of more than three structural domains, these
enzymes include: nitrate reductase and nitric oxide synthase [2].
The conservation of the “RxYTSxxSN”, “GRxxST”, “GxGxxP”, and “CGxxx-M”
sequence motifs found within the members of the FNR flavoprotein family, clearly
demonstrates the importance of these motifs towards the interactions of flavin- cofactor
and pyridine nucleotide binding and utilization.
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Research Aims and Approaches
The general goal of this research was to gain further insight into the roles of the
conserved motifs found within cytochrome b5 reductase that are involved in either FAD
or NADH-binding.

Through the analyses of these motifs, naturally occurring

methemoglobinemia variants which occur in relation to these motifs were also
investigated.

To achieve this goal, variants were generated utilizing site-directed

mutagenesis of an affinity-tagged R. norvegicus cytochrome b5 reductase construct [76].
Each mutant enzyme generated was then subsequently characterized through biophysical,
potentiometric, and enzymological techniques.
The initial specific aim was to further establish the role of the conserved
“91RxYSTxxSN97” motif in regards to binding of the FAD- cofactor and overall
cytochrome b5 reductase catalysis. Previous studies had already established a role for the
R91, P92, and Y93 amino acid residues [76, 77]. These authors concluded that none of
the mentioned residues were “essential” for proper flavin incorporation but did in fact
modulate the catalytic and thermodynamic properties within the active site of cytochrome
b5 reductase. In order to fully characterize the remaining residues of this motif, a series
of variants were generated corresponding to amino acids that have been demonstrated to
occur at the same residue positions within other members of the FNR family to include:
T94H, T94G, T94P, P95G, P95I, V96S, and S97N. Through the analysis of the crystal
structure of cytochrome b5 reductase (PDB - 1IB0) we hypothesized that the introduction
of a mutation to residue T94 would have the most significant impact due to the fact that
the backbone nitrogen of this residue forms a hydrogen bond with the N5 atom of the
FAD- cofactor isoalloxazine ring and is also positioned near the NADH-binding site. A
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second important feature of the T94 residue was demonstrated in the porcine cb5r
structure where it was shown that the corresponding T66 residue was involved in the
formation and stability of the NAD+-FAD complex [24].
The naturally occurring double mutant P92H and E255- allowed for further
characterization of the “RxYSTxxSN” motif as well as examination of the effects of a
methemoglobinemia double mutant occurring in both the FAD- and NADH-binding
domains. The E255- variant was previously detected [78] in the family with cyanosis
first described in 1943 [43] who were found to be deficient in cytochrome b5 reductase
[44]. In the P92H variant, homology modeling displayed that the side chain would be
oriented towards the FAD isoalloxazine ring and the introduction of a histidine at this
position would lead to a steric clash thereby resulting in the decrease of catalytic function
of the enzyme. E255 is positioned within the amino-terminus of an α-helix that is
involved in properly positioning the carboxyl-terminal region of cb5r that contains the
“CGxxxM” motif which has been demonstrated to be essential for NADH-binding.
Deletion of this residue therefore would result in a decrease in substrate binding affinity
as shown previously [79]. It can be hypothesized that the introduction of a double mutant
occupying position in both the FAD- and NADH-binding lobes of cytochrome b5
reductase would lead to the more severe type II RCM.
The second aim focused on the highly conserved FAD/FMN specificity motif “124
G
S 127
”,
Rxx T

specifically the residues G124, K125, and M126. The amino acid S127 has

been previously characterized through the analysis of the naturally occurring type II
RCM variant, S127P. This mutation was the first RCM variant to be resolved by X-ray
crystallography and demonstrated that the introduction of this mutation directly affects
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NADH substrate binding due a phenomenon known as “flavin flexibility” where the
FAD- cofactor of cytochrome b5 reductase is displaced into the NADH-binding cleft [80].
Through further analysis of the crystal structure of cytochrome b5 reductase the critical
importance of the “GRxxST” motif can been visualized. This motif is located within the
only α-helix of the FAD-binding lobe of cb5r and each residue of the motif forms either a
hydrophobic or electrostatic interaction with the FAD prosthetic group.

Thus, it is

important to fully develop an understanding of the molecular role of each residue of the
“GRxxST” motif in regards to the flavin environment as well as proper cofactor binding
and orientation.
The third aim of this research involved the investigation into the conserved
“273CGxxxM278” motif which is located within the NADH-binding domain of cytochrome
b5 reductase and is involved in the regulation of NADH-binding. A different approach
was used for the analysis of this motif. Two methemoglobinemia variants have been
previously described that are directly involved in the “CGxxxM” motif, the type II RCM
variant M272- [81] and type I RCM variant P275L [78] and it is through these two
mutations that the role of the motif was established. Although M272 is not technically
considered to be part of the “CGxxxM” it has been found to be highly conserved in
higher eukaryotes. The importance of studying the role of this residue was twofold, in
that it directly precedes the C273 residue which has been found to be “essential” towards
NADH-binding affinity and orientation [12] and the deletion of M272 has also been
shown to give rise to type II RCM.

Upon the deletion of M272, a frame-shift is

introduced to the motif that should cause a detrimental effect upon the affinity for the
NADH substrate to the extent that it is capable of causing type II RCM. Further analysis
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of the molecular role of M272 involved the generation of variants of M272 based on
amino acid residues that have been demonstrated to occur at the equivalent position
within other members of the FNR superfamily.
Based on the crystal structure of cytochrome b5 reductase in complex with NAD+,
a structural role for amino acid residue P275 was demonstrated [21]. It was shown that
the conformation of the NAD+ was primarily determined by the proline side chain with
the pyrophosphate chain packed against P275 and the NAD+ nicotinamide proximal
ribose was packed parallel to the proline ring. We predicted that the replacement of this
proline side chain with a leucine would have a significant adverse effect upon the proper
orientation and binding of the NADH substrate. The characterization of the P275L
variant would therefore provide insight into the role of the P275 residue in regards to
NADH substrate binding and orientation as well as providing a molecular basis for
disease.
The final specific aim was based upon the identification and characterization of a
novel FAD-binding domain variant, G75S. The G75S mutation was found in a patient
who was compound heterozygous for the G75S mutation as well as the previously
characterized V252M mutation [82-84] and exhibited a phenotype characteristic of type I
methemoglobinemia. It was hypothesized that possessing a mutation in both the FADand NADH-binding domains of cytochrome b5 reductase would result in the development
of the more severe type II methemoglobinemia. Although the patient was heterozygous
for the double mutation, the G75S/V252M mutation was generated in order to investigate
the synergistic effects of the double mutant on the enzyme’s structural and catalytic
properties. The generation of both the single and double mutants being associated with
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the FAD and NADH-binding domains could therefore be utilized to provide further
insight as an aid to determine the development of type I versus type II RCM status.
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2. MATERIALS & METHODS

MATERIALS
Molecular Biology Reagents
Restriction enzymes were purchased from New England Biolabs (Beverly, MA). Kits for
plasmid preparation and agarose gel extraction were purchased from Qiagen Inc.
(Valencia, CA).

Oligonucleotide primers were obtained from Integrated DNA

Technologies (Coralville, IA). Native Pfu and Pfu Turbo Polymerases as well as
Epicurian coli BL21(DE3)-RIL cells were obtained from Stratagene (La Jolla, CA). The
pET-23b vector was purchased from Novagen (Madison, WI). T4 DNA ligase was
purchased from Promega (Madison, WI). Rapid DNA ligation kits were purchased from
Roche Scientific (Palo Alto, CA). Triton X-100 and Hot Start Micro 50 PCR tubes were
obtained from Molecular-Bio Products Inc. (San Diego, CA). DMSO and pCMB were
obtained from Sigma Chemical Co. (St. Louis, MO). The Molecular Biology Core
Facility at the H. Lee Moffitt Cancer Center and Research Institute performed nucleotide
sequencing.
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Microbiology and Protein Purification Reagents
Plastic and glassware were purchased from Fisher Scientific (Pittsburg, PA),
VWR International (Suwannee, GA), and Midwest Scientific (St. Louis, MO). Tryptone
and yeast extract were obtained from EM Science (Gibbstown, NJ) and “Ultrol” grade
MOPS buffer was purchased from Calbiochem (La Jolla, CA). IPTG and Ampicillin were
obtained from Research Products International (Mt. Prospect, IL). Ni-NTA agarose was
purchased from Qiagen Inc. (Valencia, CA). PMSF was purchased from Sigma Chemical
Co. (St. Louis, MO).

Enzyme Assay and Spectroscopy Reagents
Chemicals including NADH, NAD+, 5’-ADP-agarose, 2’5’-ADP, ADP-ribose,
K3Fe(CN)6, glucose, dithionite, FAD, cytochrome c (Type VI from horse heart), bovine
serum albumin, potassium phosphate, riboflavin, ferric citrate and trifluoroacetic acid
were obtained from Sigma Chemical Co. (St. Louis, MO).

Tetrahydronicotinamide

adenine dinucleotides (H4-NAD and H4-NADP) were synthesized according to the
protocol described by Murataliev and Feyereisen [85] by bubbling molecular hydrogen
through a stirred solution of 100 mM NAD+ or NADP+ contained in 50 mM Tris-HCl
buffer, pH 8.0, in the presence of palladium catalyst (5 mg/mL). Sinapinic acid (3,5dimethoxy-4-hydroxy cinnamic acid) was purchased from Aldrich Chemical Co.
(Milwaukee, WI).
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METHODS
Protein Expression and Purification
Expression of the wild-type and mutant cb5r or NCR variants was accomplished
using E. coli BL21(DE3)-RIL cells harboring either the pH4CB5R [76], or mutant
constructs. Cells were grown aerobically in TB media supplemented with riboflavin (100
µM), ferric citrate (100 µM), and ampicillin (125 µM) overnight at 37 °C, and
recombinant protein expression was induced by addition of IPTG (0.4 mM) followed by
an additional 6-8 h incubation at 25 °C. The cells were pelleted by centrifugation
(5000xg, 10 min.), resuspended in lysis buffer (50 mM Tris-HCl, containing 300 mm
NaCl and 5 mM imidazole, pH 8.0) and disrupted by sonication in the presence of PMSF
(1.2 mg/ml). Lysates were clarified by centrifugation (30,000xg, 30 min.) at 4oC followed
by incubation with Ni-NTA agarose with gentle agitation (1 ml matrix/10 ml lysate) for
up to 1h at 4°C. The His-tagged-(cb5r or NCR)-Ni-NTA matrix suspension was collected
by centrifugation (1000xg, 5 min.), washed twice with 25 mM phosphate buffer,
containing 300 mM NaCl and 5 mM imidazole, pH 8.0 and transferred to a
chromatography column (2.5 x 10 cm).

Bound proteins were eluted with 25 mM

phosphate buffer, containing 300 mM NaCl and 250 mM imidazole, pH 8.0. Fractions
were pooled, assayed for NADH:FR activity and concentrated centrifugally using 10,000
MWCO concentrators (Fischer Scientific, Pittsburg, PA).

Final purification was

achieved by size-exclusion FPLC using either a Superdex 75 or Superdex 200 column (1
x 30 cm) equilibrated with 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0.
Fractions exhibiting NADH:FR activity were pooled, concentrated, beaded and stored
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under liquid N2 until required. Wild-type NCR concentrations were estimated using
ε413nm = 130 cm-1 mM-1 and wild-type cb5r concentrations were estimated using ε461nm =
10.6 cm-1 mM-1.
The recombinant soluble, heme domain of rat cytochrome b5 was produced as
described by Beck-von Bodman et al., [86] using an expression construct provided by Dr.
Steven Sligar (University of Illinois, Urbana, IL). Briefly, E. coli BL21(DE3) cells
harboring the pUC18 expression construct, which contained a codon-optimized gene
encoding the soluble heme-containing domain of rat cb5, were grown overnight at 37°C
in TB medium supplemented with ferric citrate (100 µM) and ampicillin (125 µM).
Protein expression was induced at 25°C by addition of IPTG (0.4 mM), and the cells
were harvested 8 hours later by centrifugation, yielding pink pellets. Lysis of the cells
was achieved as described for cb5r. During fractionation of the cleared lysate, however,
cb5 was precipitated by 95% (w/v) (NH4)2SO4. The pellet was resuspended in the
minimum volume of low ionic strength phosphate buffer and dialyzed twice against a
large volume the same buffer before separation on DE52 anion exchange
chromatographic media. Elution was achieved by a gradient of 0-1M NaCl before final
purification by FPLC on a Superdex 75 10/30 HR column. Red fractions containing cb5
protein were pooled, concentrated, beaded, and stored under liquid N2.
SDS-polyacrylamide gel electrophoresis was performed as described by Laemmli
[87] using 12.5% acrylamide/bis-acrylamide gels. 2-5 µg of protein was solubilzed in up
to 30 µL of SDS loading buffer (10 mM Tris-HCl, pH 6.8, containing 1% SDS, 10%
glycerol, 1 mM DTT, and 0.1% bromophenol blue) by boiling in water for 5 minutes
before loading the gel. Gels were run at 150 volts in SDS running buffer (25 mM Tris28

HCl, pH 8.3, containing 192 mM glycine, 0.1% SDS) until the blue dye front traversed
the gel. Gels were stained with Coomassie Brilliant Blue dye to visualize protein bands.

Site-directed Mutagenesis
The pH4CB5R [76] expression construct was specifically mutagenized using a
modification of the Stratagene QuikChange™ (La Jolla, CA) protocol.
Mutagenic Oligonucleotide Primer Design
Complementary oligonucleotide primers (30-40 mers) containing the desired
codon change as well as silent mutation (either inserting or deleting a restriction enzyme
recognition

sequence)

were

designed

using

the

Primer

Generator

program

(http://www.med.jhu.edu/medcenter/primer/primer.cgi) [88]. The sense strand annealing
primers used in the construction of the various mutant proteins are listed in Table 1.
Vector Polymerase Chain Reaction
Vector PCR was performed using Pfu Turbo polymerase (1.25 units) in the presence of
cloned Pfu buffer (20 mM Tris-HCl, pH 8.8 containing 2 mM MgSO4, 10 mM KCl, 10
mM (NH4)2SO4, 0.1% Triton® X-100, and 0.1 mg/ml nuclease-free BSA) containing 10
ng vector DNA (pH4CB5R or pH6NCR), 125 ng of each synthetic primer, 5% DMSO,
and 200 µM dNTP’s with cycling parameters (20 cycles) of 1 min at 94 °C, 1 min at 55
°C, 10 min at 68 °C. DpnI restriction enzyme was added directly to the cooled PCR
reaction tube following the PCR cycling reaction to cleave only the methylated template
DNA. This step greatly reduced the percentage of wild-type background transformants.
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Table 1. Mutagenic Oligonucleotide Primers.
Nucleotides in bold encode the
mutated bases generated to introduce the proper mutation. Silent mutations in italics add
(+) or eliminate (-) the indicated restriction site.
Mutation
G75S
P92A
P92H
T94G
T94H
T94P
P95A
P95G
P95H
P95I
V96S
S97N
G124A
G124H
G124K
G124R
K125A
K125D
K125E
M126C
M126F
M126G
M126P
M126S
E255V252M
M272M272A
M272I
M272L
M272R
P275L

Primer Sequence (5’→ 3’)
CCT
GGC
TGG
GTC
GTC
GTC
CCC
ATT
GTC
ATT
ATT
CGT
GTT
GTT
GTT
GTT
GCG
CCC
CCA
GCT
AAG
GCT
GCT
GCT
TTC
GCC
GAG
GAG
CTG
CTG
CTG
CTG

GGG
AAC
GTG
ATT
ATT
ATT
TAC
CGT
ATT
CGT
CGT
CCC
TCC
TCC
TCC
TCC
GGA
AAG
GCG
GGA
TTT
GGA
GAA
GGA
GTG
AAG
ACA
ACA
ATA
ATT
ATT
ATG

CCT
TTG
ATT
CGT
CGT
CGT
ACC
CCC
CGT
CCC
CCC
TAC
AGC
AGC
AGC
AGC
GGG
TTT
GGA
GGG
CCA
GGG
GGG
GGG
AAT
GCT
CTG
CTG
CTG
CTG
CTG
TGT

TCC
GTC
CGT
CCC
CCC
CCC
GCG
TAG
CCC
TAC
TAC
ACC
CGG
TGG
TGG
TGG
GCA
CCA
GGG
AAA
GGG
AAA
AGG
AAG
GAG
TCA
ATA
ATA
ATC
CTG
AGG
GGA

TAT
GCC
CAC
TAC
TAC
TAC
GTG
ACC
TAC
ACC
ACC
CCA
AGC
ACA
AAA
ACG
ATG
GCA
GAA
TGT
AGG
GGG
GAA
TCG
ATG
TGA
CTG
CTG
TGT
TGT
TGT
CTC

CAG
TAC
TAC
GGC
CAC
CCC
TCT
GGT
ACC
ATT
CCT
GTG
GAA
CAA
GAA
GAA
TCT
GGC
ATG
TCT
GAA
TCT
ACC
TCT
ATC
ATG
- GCA
GGA
GGA
GGA
CCA
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Restriction Site

TCA ACA CAT CTA CCT
ACC CCT GTG TCT
ACC CCT GTG TCT AGT
CCT GTG TCT AGT GAT
CCT GTG TCT AGT GAT
CCT GTG TCT AGT GAT
AGT GAC GAT GAC AGG
GTG TCT AGT GAT GAT
CAC GTG TCT AGT GAT
GTT TCT AGT GAT GAT
TCG TCT AGT GAT GAT
AAT AGT GAT GAT GAC
AAT GTC TCA GTA C
AAT GTC TCA GTA CC
AAT GTC TCA GTA CCT
AAT GTC TCA GTA CC
CAG TAC CTG
GAC ATG TCT CAG TAC
TCT CAG TAC CTG
CAG TAC CTG GAA AAC
ATT CTC TCA GTA CCT
CAG TAC CTG GAA AAC
GTC TCA GTA CCT GGA
CAG TAC CTG GAA AAC
AGG GAC CAT CTT CCA
AGG AGA TGA TCA GGG
- TGT GGA CCC CCA CCG
TGT GGA CCC CCA CCG
CCC
CCC
CCC
CCG ATG ATC CAG

+HincII
-BsmFI
+HinFI
-MslI
-MslI
-MslI
+MaeIII
+BsaWI
+AflIII
-MslI
-MslI
+HincII
-BpmI
-BpmI
-BpmI
-BpmI
-BpmI
+NspI
+NspI
+BsmAI
+ApoI
+BsaI
+BsmBI
+BsmBI
+HincII
+BspHI
NA*
+NspI
+TfiI
+TfiI
+TfiI
+PleI

PCR products were subsequently purified using the Qiagen PCR Cleanup Kit. Products
were eluted in 30µL of sterile elution buffer and stored at -20°C until ready for use.
Preparation of Competent Cells and Linear DNA Transformation
Competent E. coli DH5α cells were prepared according to the protocol by
Yuckenberg et al. [89] for storage at -70°C. In brief, an overnight culture of bacteria,
grown in LB, was used to inoculate 250 mL of fresh LB medium. The culture was
incubated with shaking until an O.D.600nm of approximately 0.9 was reached. Cells were
then harvested by centrifugation at 0°C and washed in a solution of ice-cold 100 mM
MgCl2. Cells were again harvested and resuspended in ice-cold 100 mM CaCl2, where
they were then incubated on ice for 90 minutes. Cells were finally harvested and
resuspended in 85 mM CaCl2 containing 15% glycerol before being snap frozen in
liquid N2 and stored at -80°C prior to use. This protocol was also used for the preparation
of all other competent E. coli strains.
Competent E. coli DH5α cells were transformed with linear DNA constructs
according to the protocol provided with the Quikchange™ Mutagenesis Kit (Stratagene)
Frozen cells were thawed slowly on ice and 50 µL aliquots were transferred to sterile 15
mL polypropylene conical tubes maintained on ice. Up to 10 µL of the purified linear
DNA construct was mixed carefully with the cells by swirling the pipette tip as the DNA
was expelled. The mixture was then incubated on ice for 20 minutes before being heatshocked at 42°C for 45 seconds and then returned to ice for 2 more minutes. Finally, 1
mL of SOB media was added and the cells were allowed to recover for 1 hour at 37°C
with gentle shaking before being plated on the appropriate selection media.
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Mutagenic Screen by DNA Restriction Digest
Following overnight incubation at 37°C on ampicillin-containing SOB-agar plates,
colonies were subcultured into 5 mL of liquid SOB media, containing ampicillin (125
µM). Clones were analyzed and screened for the silent mutations, introduced during
mutagenesis, by restriction enzyme digestion using the appropriate enzymes listed in
Table 3 and 4. Each digest was separated using polyacrylamide gel electrophoresis or
agarose gel electrophoresis and the restriction pattern visualized by EtBr staining of the
gel. Figure 14 illustrates the result of a typical gel observed during screening of mutants.
Mutant constructs exhibiting the predicted pattern that differentiated them from the wildtype construct were verified by nucleotide sequencing in both the forward and reverse
directions. Positive constructs were subsequently used to transform competent E. coli
BL21(DE3)-RIL cells to proliferate the generation of the mutant enzymes.

Ultraviolet and Visible Absorbance Spectroscopy
Absorbance spectra in the far (190-250 nm) and near UV (250-350 nm), visible
(360-750 nm), and near IR (750-1000 nm) wavelength range were obtained for wild type
and mutant enzymes using a Hewlett Packard (Agilent Technologies, Palo Alto, CA)
8453 diode-array spectrophotometer utilizing microcuvettes of either 90 µL or 200 µL
capacity and with 1 cm pathlength.

Ultraviolet and Visible Circular Dichroism Spectroscopy
UV and visible CD spectra were obtained using a JASCO (Easton, MD) J710
spectropolarimeter calibrated for both signal intensity and wavelength maxima using an
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aqueous solution of d-10-camphosulfonic acid [90]. UV CD spectra were obtained in 10
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0 using a cylindrical quartz cell
of 0.1 cm path length (300 µl total volume) while visible CD spectra were obtained in 10
mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0 using a 1 cm pathlength cell (90 µl
total volume). All spectra were corrected for the appropriate buffer contributions and are
expressed in terms of molar ellipticities (M-1 cm-1).

Fluorescence Spectroscopy
Fluorescence spectra were obtained using a Shimadzu Scientific Inst. Inc. RF5301PC spectrofluorophotometer. Excitation and emission spectra were obtained using a
slit width of 3 nm and emission and excitation wavelengths of 520 nm and 450 nm,
respectively. Following acquisition of the wild type and mutant spectra, the enzymes
samples were heated to 100oC for 30 min, centrifuged to remove protein aggregates and
the corresponding spectra for the liberated FAD were subsequently recorded. All spectra
were corrected for the appropriate buffer contribution.

Steady-State Enzyme Activities
NADH:FR and NADH:CR activities were determined at 25°C under conditions of
constant ionic strength and pH in 116 mM MOPS buffer (µ = 0.05), containing 0.1 mM
EDTA, pH 7.0, while NADH:BR activities were determined at 25°C under conditions of
constant ionic strength and pH in 10mM potassium phosphate buffer (µ = 0.01),
containing 0.1mM EDTA, pH 7.0. NADH:FR activities were typically determined as the
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decrease in absorbance at 340 nm in the presence of NAD(P)H (250 µM) and
ferricyanide (500 µM). NADH:BR activity was determined as the increase in absorbance
at 423 nm in the presence of NADH (250 µM) and rat cb5 (30 µM). All substrates were
quantitated spectroscopically using the calculated molar extinction coefficients for
NADH, H4NAD, NAD+, cb5, 2’-5’, and ADP-ribose (Siegel 1959, Beck von Bodman
1986, The Merck Index 1989, Murataliev 2000). Activities are expressed as initial rates
for the oxidation of NAD(P)H (µmol of NAD(P)H consumed/min/nmol FAD). Initial rate
data at varying NAD(P)H, ferricyanide, or cb5 concentrations were analyzed using the
software “ENZFIT” (Elsevier Biosoft, Ferguson, MO) to determine apparent kcat and Km
values.

Charge-transfer Complex Determination
Reductive titrations were performed under anaerobic conditions as described by
Foust [91]. Enzyme samples (50 µM FAD) in 116 mM MOPS buffer, containing 0.1 mM
EDTA, pH 7.0, and NADH solutions (100 mM) were prepared by repeated evacuation
and flushing with oxygen-free argon. Enzyme samples were titrated with NADH and
monitored for increased absorbance in the near IR wavelength range from 700-900 nm.
Titrations were determined to be saturating when the absorbance at 800 nm ceased to
increase and no further bleaching of the flavin spectra occurred upon NAD(P)H addition.

Spectral Binding Constant Determination by Differential Spectroscopy
Spectral binding constants, Ks, for various NADH analogs were determined by
differential spectroscopic titrations as described by Sancho and Gomez-Moreno [92] and
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Barber et al. [93]. A Shimadzu UV2501-PC was used to measure the difference spectra
of samples in matched split-cell quartz cuvettes with 0.439 cm pathlength and 2.5 ml
capacity. Enzyme and NADH analogs were suspended in 10mM phosphate buffer, pH
7.0, containing 0.1mM EDTA for all spectral determinations. All analog concentrations
were

determined

spectrophotometrically

using

previously

published

extinction

coefficients.
The reference cuvette contained 50 µM enzyme (as determined by FAD
concentration) in the front compartment and analog-titrated buffer in the rear
compartment. The sample cuvette contained analog-titrated enzyme (50 µM) in the front
compartment and buffer in the rear compartment. The appropriate buffer was added to
the enzyme compartment of the reference cuvette to correct for the dilution caused by
analog addition to the enzyme compartment of the sample cuvette. Following sample
addition, each compartment was stirred briefly to insure thorough mixing. Spectra were
then recorded over the wavelength range from 300-800 nm depending on the titration.
The magnitude of the absorbance change was determined for each spectrum via peak to
trough subtraction in order to compensate for any baseline drift between spectra.
Absorbance changes were plotted versus nucleotide concentration and the resulting plots
were fit to the hyperbolic equation:
∆Absorbance = ∆Absorbancemax*[nucleotide] / [Ks + (nucleotide)]
in order to determine the spectral binding constant (Ks), which was defined as the
concentration of analog at which half maximal spectral perturbation was observed.
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Thermal Stability Measurements
Thermal stabilities of wild type and mutant enzymes were determined as
described by Trimboli et. al. [67] by monitoring both the release of the FAD prosthetic
group, as indicated by the change in flavin fluorescence, and the loss of NADH:FR
activity over the temperature range from 0-100°C.

Determination of Flavin Midpoint Potential
Flavin midpoint potentials were determined by dye equilibration using the method
of Massey [94]. Xanthine (30 µM) and xanthine oxidase (50 nM) were used to reduce a
mixture of enzyme (40 µM FAD) and the indicator dye, phenosafranine (15 µM) in 100
mM phosphate buffer containing 0.1 mM EDTA, first made anaerobic by repeated
evacuation and flushing with oxygen-free argon. Benzyl viologen (6 µM) and methyl
viologen (1 µM) were included to facilitate equilibration of the system. Visible
absorbance spectra were collected over the course of each 3-hour equilibration. Flavin
reduction was monitored at 410 nm while phenosafranine reduction was monitored at 530
nm. E0’ values were calculated by graphical analysis of the plot [log (ox)/(red)]phenosafranine
versus [log (ox)/(red)]FAD using the published midpoint potential of phenosafranine of –
252 mV [94].
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3. RESULTS AND DISCUSSION

Analysis of the conserved “RxYS/TxxS/N” FAD binding motif
Multiple

sequence

alignments

of

the

members

of

the

flavoprotein

transhydrogenases family have revealed four distinct regions, each containing a high
level of sequence and structural conservation. These regions are found within both the
flavin- and pyridine nucleotide-binding regions of the ferrodoxin:NADP+ reductase
(FNR, EC 1.18.1.2) superfamily (Figure 10) [5]. The first of these conserved sequences,
corresponding to “RxYSTxxSN”, is a flavin-binding motif comprised of the residues
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RPYTPVS97 in R. norvegicus cytochrome b5 reductase sequence. It is considered to be

one of the most highly conserved of the known flavin-binding motifs.
Site-directed mutagenesis studies of R91, P92, and Y93 have demonstrated these
residues to be non-essential for flavin cofactor incorporation. However, amino acid
residues R91 and Y93 do modulate the spectroscopic, catalytic, and thermodynamic
properties of cb5r, and are critical in maintaining proper structure and orientation of the
active site of the enzyme [76, 77]. Additionally, formation and stability of the NAD+FAD- semiquinone complex during NADH turnover has also recently been shown to be
controlled by the fourth residue in the “RxYSTxxSN” motif, corresponding to T66 in
porcine cytochrome b5 reductase, through the generation of the T66S and T66V variants
[24].
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To further probe the structural and functional characteristics of this highly
conserved flavin-binding motif, a series of variants were created through site-directed
mutagenesis, utilizing the rat cytochrome b5 reductase expression system previously
generated by Marohnic et al. [76]. The variants generated corresponded to alternate
amino acid residues that occur at the same residue position within additional GenBank
sequences of other members of the FNR superfamily and include: T94H, T94G, T94P,
P95G, P95I, V96S, and S97N.
The fidelity of each variant was confirmed by nucleotide sequencing in both
forward and reverse directions and the mutant proteins were then recombinantly
expressed in BL21 (DE3)-RIL cells. Purification to homogeneity was carried out through
the utilization of a combination of Ni-NTA affinity and gel filtration chromatography for
the mutant proteins and with the exception of T94G and T94P, all were expressed at
levels comparable to that of the wild-type domain as observed by the appearance of
single protein bands following SDS-PAGE analysis. Neither the T94G nor T94P mutants
yielded viable proteins for subsequent characterization, in each case the flavin cofactor
failed to properly incorporate to yield a stable flavoprotein.
UV/visible absorption spectra were obtained for oxidized samples of each of the
purified variants together with wild-type cytochrome b5 reductase and are presented in
Figure 11A.

The P95G, P95I, V96S, and S97N mutants each displayed spectra

comparable to that of the wild-type domain, attributable to protein-bound flavin with an
aromatic absorption maxima detected at 272 nm in the UV region of the spectrum and a
peak at 461 nm with a pronounced shoulder within the range of 485-500 nm in the visible
region of the spectrum. The T94H mutant however, produced visible absorption spectra
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Figure 11. Ultra-Violet, Visible, and Circular Dichroism Spectra of Wild Type,
T94H, P95G, P95I, V96S, and S97N Proteins of Cytochrome b5 Reductase. (A)
Oxidized samples of wild-type and mutants cb5rs (20µM), (B) 7µM, and (C) 60µM FAD
in 10mM phosphate with 0.1mM EDTA, pH 7.0 buffer. The inset shows an expanded
region of the visible spectrum where the flavin cofactor makes a major contribution.
Individual spectra correspond to (____) H4cb5r; (____ ____) T94H; (__ __ __) P95G; (_ _ _ _)
_____
P95I; (. . . . .) V96S; (__.__.__) S97N and free flavin (
).
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that was significantly altered with a red-shifted λmax of 467 nm compared to that of the
wild-type cytochrome b5 reductase visible λmax of 461 nm. Shifts within the visible
absorption spectra of flavoproteins have previously been attributed to changes in the
hydrophilicity of the flavin environment near the N(5) locus of the isoalloxazine ring
[76]. The absorption ratios (A276/A461) for each viable mutant were within a range of 5.5
to 5.9 which indicated a full flavin complement.
To examine the effects of each mutation upon the secondary structure of the
protein, UV circular dichroism spectra were determined in the UV wavelength range (190
– 300 nm). As shown in Figure 11B, all of the mutants generated displayed line shape
comparable to wild-type cytochrome b5 reductase with positive CD from 190-210 nm and
negative spectra from 210-250 nm. Although these results were in good agreement with
the wild-type domain, both the T94H and V96S variants displayed a negative CD
intensity greater than that of the wild-type protein at 222 nm. The alteration displayed for
the T94H and V96S UV CD spectra indicated an adverse structural change within the
overall α-helical or β-sheet components of the two variants. In order to examine the
flavin environment of each variant, visible CD spectra were obtained as shown in Figure
11C. Representative spectra demonstrated that each variant retained a similar line shape
as that of wild type cytochrome b5 reductase with positive maxima at 310 and 390 nm
and negative maxima at 460 and 485 nm, respectfully. However, both the T94H and
P95G variants displayed an altered flavin environment within the region of 450 – 485 nm
which is in agreement with the observation from the x-ray crystal structure, that T94
forms a hydrogen bond with the isoalloxazine ring of the FAD- prosthetic group and the
mutation of P95 to a glycine could lead to flexibility within the secondary structure
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altering the FAD- cofactor conformation. No significant changes were observed in the
visible CD spectra for either the V96S or S97N variants demonstrating that neither
residue is required for correct flavin orientation.
To establish if the alterations observed in the flavin environment from the UV/Vis
and CD spectra affected the catalytic function of the enzyme, initial-rate kinetic
parameters for NADH:FR and NADH:BR assays were determined for the wild-type
cytochrome b5 reductase and for each purified variant. The values obtained for the
NADH:FR and NADH:BR assays are presented in Table 2. NADH catalytic efficiencies
(kcat/KmNADH) for all variants ranged between 22 and 62% compared to wild-type
cytochrome b5 reductase, with T94H yielding the lowest catalytic efficiency.
Interestingly, it was only the kcat for each of the variants that lead to the decrease
observed in the overall catalytic efficiency, while the KmNADH of each mutant was either
comparable to the wild-type domain or slightly enhanced as seen in the T94H variant
indicating a higher affinity for the NADH substrate. Similar results were observed in the
NADH:BR assays in which the overall catalytic efficiency was decreased primarily due
to the decreased rate of turnover (kcat) for each variant. This was to be expected since the
residues within the “RxYSTxxSN” motif are not involved in or located within close
proximity to the amino acids that participate in cytochrome b5 reductase - cytochrome b5
complex formation.
From the kinetic data obtained it was demonstrated that each of the variants
generated displayed a KmNADH that was highly comparable to wild-type cytochrome b5
reductase or, as mentioned previously, in the case of the T94H the affinity for substrate
was enhanced almost 2-fold over the wild-type domain. To further establish the binding
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Table 2. NADH:FR and NADH:BR Kinetic Constants of T94H, P95G, P95I, V96S,
S97N, and Wild Type Cytochrome b5 Reductase.
Mutant

NADH:FR
KmFeCN6 kcat/KmNADH
(µM)
(µM)
(s-1 M-1)

kcat
(s-1)

KmNADH

H4cb5r

800 ± 21

6±1

8±1

T94H

102 ± 21

4±1

P95G

326 ± 25

P95I

NADH:BR
KmCyt b5 kcat/KmCytb5
(µM)
(µM)
(s-1 M-1)

1.4 ± 0.3 x 108

kcat
(s-1)

KmNADH

600 ± 10

2±1

13 ± 1

4.7 ± 0.5 x 107

7±1

2.8 ± 0.1 x 107

94 ± 2

2±1

3 ± 0.3

3.0 ± 0.3 x 107

7±1

8±1

4.2 ± 0.2 x 107

244 ± 15

3±1

11 ± 2

2.3 ± 0.5 x 107

232 ± 10

6±1

8±1

4.0 ± 0.1 x 107

137 ± 6

3±1

12 ± 1

1.2 ± 0.2 x 107

V96S

637 ± 27

8±1

7±1

8.0 ± 0.6 x 107

465 ± 20

2±1

16 ± 1

3.0 ± 0.4 x 107

S97N

296 ± 5

5±1

8±1

5.7 ± 0.6 x 107

567 ± 36

3±1

24 ± 1

2.4 ± 0.4 x 107

affinity of the substrate NADH and the product NAD+, spectroscopic binding constants
were determined utilizing differential spectroscopy.
As stated in “Methods and Materials”, the isoteric analog 1,4,5,6-tetrahydro-NAD
(H4NAD) was utilized as an alternative substrate analog to evaluate the affinity for the
physiological substrate NADH [85].

Differential spectroscopy was used to monitor

complex formation during titrations with either H4NAD or the physiological product
NAD+ as shown in Figure 12 and Figure 13. Spectra obtained for each of the titrations
carried out in the presence of H4NAD displayed a line shape comparable to wild-type
cb5r with the exception of the P95I variant. This indicated that for P95I, the isoteric
substrate analog bound in an altered conformation due to the distorted environment of the
FAD- prosthetic group as observed in the visible CD spectra. Values observed for the
spectroscopic binding constant (Ks) for each of the H4NAD titrations, shown in Table 3,
demonstrated that the binding affinity for each of the variants was not significantly
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Figure 12. Spectroscopic Titrations of H4cb5r and the T94H, P95G, P95I, V96S, and
S97N Variants in the Presence of H4NAD. Titrations of all mutants (50mM) were
performed in split cell optical cuvettes in 10mM phosphate buffer containing 0.1mM
EDTA, pH 7.0 at 23 °C. Difference spectra were recorded following the addition of
solution containing H4NAD (30µM). The inset panel corresponds to a plot of the
magnitude of the spectral perturbations at the indicated wavelengths versus pyridine
nucleotide concentration where a difference spectrum was observed. Plots of the relative
absorbance changes observed are as follows: (A) H4cb5r; (B) T94H; (C) P95G; (D) P95I;
(E) V96S; and (F) S97N.
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Figure 13. Differential Spectroscopy of H4cb5r, T94H, P95G, P95I, V96S, and S97N
cb5rs in the Presence of H4NAD. Titrations of all mutants (50mM) were performed in
split cell optical cuvettes in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at
23 °C. Difference spectra were recorded following the addition of solution containing
NAD+ (30µM). The inset panel corresponds to a plot of the magnitude of the spectral
perturbations at the indicated wavelengths versus pyridine nucleotide concentration
where a difference spectrum was observed. Plots of the relative absorbance changes
observed are as follows: (A) H4cb5r; (B) T94H; (C) P95G; (D) P95I; (E) V96S; and (F)
S97N.
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Table 3. Spectral Binding Constants Obtained for Wild Type cb5r and the T94H,
P95G, P95I, V96S, and S97N Variants.
Mutant
H4cb5r
T94H
P95G
P95I
V96S
S97N

Ks H4NAD
(µM)
45 ± 10
122 ± 16
53 ± 13
116 ± 4
62 ± 8
114 ± 11

KsNAD+
(µM)
760 ± 30
13 ± 2
491 ± 15
196 ± 14
1503 ± 140
775 ± 121

KiNAD+
675 ± 23
23 ± 2
360 ± 16
225 ± 14
ND
ND

altered, with the P95G and V96S mutants yielding values comparable to wild-type
cytochrome b5 reductase and the T94H, P95I, and S97N displaying Ks values ~ 2-fold
greater than that of the wild-type domain values.
These results indicated that the affinity for the substrate analog H4NAD is not
significantly affected through the perturbations observed in the spectroscopic properties
of the FAD prosthetic group. Unlike the spectra seen in the H4NAD titrations, all of the
generated variants retained a line shape for the NAD+ titrations compared to that of wildtype cytochrome b5 reductase displaying positive maxima at 410 and 510 nm, and
negative maxima at 430, 460, and 485 nm. However, Ks values were markedly altered
for the P95G, P95I, and T94H variants displaying an enhanced binding affinity for the
NAD+ product with the T94H variant displaying a Ks value of 13 µM compared to that of
the wild-type domain value of 800 µM (Table 3). Values obtained for the V96S and
S97N variants were ~ 2-fold greater than or comparable to wild-type cytochrome b5
reductase, respectively. These results are in good agreement with the kinetic values
obtained in that the substrate H4NAD is still able to bind efficiently as is the product
NAD+. However, the enhanced binding affinity of NAD+ for the T94H, P95G, and P95I
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variants combined with the reduced kcat kinetic values, indicated that the NAD+ is unable
to dissociate from the NADH binding domain efficiently which has been demonstrated to
be a critical step in the reaction mechanism of cytochrome b5 reductase [24].
To further probe the properties of product inhibition, initial rate enzyme kinetics
were performed, as described previously, in the presence of varying concentration of
NAD+ to determine if the competitive inhibition properties of the NAD+ product was
capable of giving rise to the alterations observed in the overall catalytic efficiencies and
Ks values of the T94H, P95G, and P95I variants.

As shown in Figure 14, the

Lineweaver-Burke plots obtained for wild-type cytochrome b5 reductase and the T94H,
P95G, and P95I mutants all displayed a model of competitive inhibition represented by a
single intercept at the y-axis showing no change in Vmax in the presence of varying
concentrations of NAD+. Ki values [x-intercept = -(Ki)] were established for the wildtype cytochrome b5 reductase and corresponding variants through the secondary plot of
the Km values for each assay against that of the concentration of the NAD+ inhibitor.
Table 3 shows the Ki values obtained which corresponded to 675, 23, 360, and 225 µM
for the wild-type domain, T94H, P95G, and P95I, respectively. These results are in good
agreement with the catalytic efficiencies and Ks values obtained and confirmed that
NAD+ is not able to disassociate from the complex efficiently and thus acts as an
inhibitor in the cytochrome b5 reductase reaction pathway.
Protein stability was evaluated by monitoring the thermal NADH:FR inactivation
profile coupled with the increase in intrinsic flavin fluorescence and emission intensity of
each of the variants which was compared to values obtained for wild-type cytochrome b5
reductase. The results obtained for the thermal denaturation profiles and change in
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Figure 14. Enzyme Inhibition Assessment with NAD+ for the T94H, P95G, and P95I
Variants. Panels A-D represent the Lineweaver-Burke plots obtained from the initial
rate kinetic analyses in the presence of various concentrations of NAD+. Concentrations
of NAD+ correspond to (●) 0 µM; (■) 50 µM; (▲) 100 µM; (▼) 250 µM; (♦) 500 µM;
and (+) 1000 µM for panel (A) [wild-type cb5r], (●) 0 µM; (■) 25 µM; (▲) 50 µM; (▼)
100 µM; and (♦) 500 µM for panel (D) [P95I], and (●) 0 µM; (■) 25 µM; (▲) 50 µM;
(▼) 100 µM; (♦) 250 µM; and (+) 500 µM for panels [B and C] [T94H and P95G],
respectively. Panel (E) represents a replot of the observed KmNADH determined from each
Lineweaver-Burke plot in (A-D) versus the concentration of inhibitor (NAD+) where the
inhibition constant (Ki) can be determined by the equation: x-intercept = -(Ki), and the yintercept = Km.
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Figure 15. Temperature Stability Profiles of cb5r and the T94H, P95G, P95I, V96S,
and S97N Mutants. Oxidized samples of T94H, P95G, P95I, V96S, S97N, and wildtype H4cb5r (5 µM FAD) were incubated at the indicated temperatures, and aliquots were
withdrawn and assayed for both residual NADH:FR activity (closed symbols) and
intrinsic flavin fluorescence (open symbols) in 10 mM phosphate buffer, containing 0.1
mM EDTA, pH 7.0 using excitation and emission wavelengths of 450 nm and 523 nm,
respectively. Points correspond to: (●,○) H4cb5r; (■, □) T94H; (▲, ∆) P95G; (▼, )
P95I; (♦, ◊) V96S; and (+) S97N.
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Table 4. T50 Values of the Wild-Type Cytochrome b5 Reductase, T94H, P95G, P95I,
V96S, and S97N Variants.
Mutant

T50
(°C)
56
50
43
47
50
50

H4cb5r
T94H
P95G
P95I
V96S
S97N

intrinsic flavin fluorescence are shown in Figure 15. T50 values (the temperature at which
50% of maximum fluorescence and 50% retention of NADH:FR activity was detected)
for each of the mutants indicated a decreased protein thermostability compared to the T50
value of 56 °C for wild-type cytochrome b5 reductase. Both the P95G and P95I variants
showed the greatest decrease in thermostability with T50 values of 43 °C and 47 °C,
respectively, while the remaining T94H, V96S, and S97N variants yielded a T50 value of
50 °C. These results indicated that any substitution of the P95 residue may lead to
conformational changes in the protein’s secondary structure resulting in protein
instability.
To examine the effects of potential structural changes on the properties of the
flavin prosthetic group, oxidation-reduction potentials for the FAD cofactor were
determined utilizing dye-equilibration titrations in the presence of phenosafranine (E°′ = 252 mV) since the variants generated were based on residues within the “RxYSNxxST”
motif and thus could affect the flavin reduction potentials due to their close proximity to
the FAD- cofactor. Flavin midpoint potentials (E°′, n = 2) for the FAD/FADH2 couple
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were determined for the variants alone and in the presence of NAD+. Spectra obtained
during a representative titration of the T94H variant are shown in Figure 16. The flavin
redox potentials (n = 2) for the wild-type cytochrome b5 reductase and generated variants
for the FAD/FADH2 couple were determined from the Nernst semi-log plots of the log
([oxidized]/[reduced])FAD versus potential (mV) and are shown in Figure 16.

The

standard midpoint potential values obtained are shown in Table 5. For the standard flavin
midpoint potentials in the absence and presence of NAD+, all potentials were nearly
identical for the wild-type domain, P95G, and S97N variants, indicating that the
introduction of structural alterations of these two variants did not have a dramatic effect
on the flavin midpoint potential. The V96S variant displayed a flavin midpoint potential
comparable to the wild-type domain in the absence of NAD+ indicating that the mutation
of V96S had no effect on the electron transfer potential. Upon the addition of the product
NAD+ however, a negative shift was observed yielding a midpoint potential -217 mV,
comparable to the value obtained for the midpoint potential of free flavin (-220 mV) [95].
Much the opposite was observed with the P95I variant, in that in the presence of NAD+ a
midpoint potential of -193 mV was established which is in good agreement with the wildtype cytochrome b5 reductase value of -190 mV. In the absence of NAD+ the P95I
mutant displayed a positive shift by 65 mV to -207 mV, a shift that, as mentioned,
demonstrates a midpoint potential like that seen in the potential of free flavin. T94H
yielded the most significant results by displaying a midpoint potential of -219 mV both in
the absence and presence of NAD+, indicating the introduction of a T94H variant causes
a structural displacement of the flavin prosthetic group that leads to standard midpoint
potential corresponding to that of free flavin.
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Figure 16. Potentiometric Titrations of the T94H, P95G, P95I, V96S, S97N, and
Wild-Type Cytochrome b5 Reductases. Reductive dye titrations were performed at 25
°C as described in “Materials and Methods” using phenosafranine as the indicator dye in
100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0. Nernst plots in the absence
(A) and presence (B) of 2 mM NAD+. Plots correspond to (●) H4cb5r; (■) T94H; (▲)
P95G; (▼) P95I; (♦) V96S; and (+) S97N.
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Table 5. Flavin Midpoint Potentials (E°′) Obtained for Wild-Type, T94H, P95G,
P95I, V96S, and S97N cb5rs.
Enzyme

E°′ FAD/FADH2
(mV)

Slope
(mV)

E°′ FAD/FADH2
(mV)

-NAD+
H4cb5r
T94H
P95G
P95I
V96S
S97N

-272
-218
-267
-207
-276
-272

Slope
(mV)

+NAD+
-30
-60
-61
-57
-30
-35

-190
-219
-201
-193
-217
-197

-30
-31
-50
-32
-23
-55

Summary of Analysis of the conserved FAD binding motif 91RxYS/TxxS/N97
Previous studies based on the crystal structure of NADH-cytochrome b5 reductase
derived from pig liver microsomes described by Nishida et al. [39] revealed a highly
conserved β-barrel structure for the binding motif of the flavin prosthetic group through
the structural homology comparisons of the porcine cb5r, ferredoxin-NADP+ reductase
(FNR) [96], phthalate dioxygenase reductase (PDR) [5] and the FAD- containing
fragment of nitrate reductase [6]. Through these comparisons it was revealed that the
overall barrel foldings are similar to each other and that three conserved residues, (R, Y,
and S/T) were in a specific arrangement and necessary for correct flavin binding and
orientation. These three residues correspond to R91, Y93, and S127 within the rat model
of cytochrome b5 reductase and provided the first insight into the highly conserved
“91RxYSTxxSN97” flavin-binding motif. Since the description of this motif, mutagenesis
studies have been performed in order to elucidate the roles of these residues in
maintaining proper flavin incorporation and overall function. Previous studies by
Marohnic et al. [76] demonstrated that although R91 is not essential for flavin
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incorporation, the removal of the positively charged side chain results in the phenomenon
known as “flavin flexibility”. In this case, production of the R91A and R91L variants
resulted in the displacement of the ADP portion of the flavin prosthetic group into the
ADP region of the NADH-binding site, thus acting as its own inhibitor. Analysis of the
P92 and Y93 variant indicated the roles in which these residues modulated the flavin
midpoint potential, spectroscopic properties of the protein-bound cofactor, and the
catalytic efficiencies of cytochrome b5 reductase [77]. Mutagenic studies of the porcine
T66V and T66S variants (corresponding to T94 in rat cytochrome b5 reductase) by
Kimura et al. [24] established that this residue is involved in the stabilization of
semiquinone intermediates within the reaction mechanism of cytochrome b5 reductase.
In order to fully elucidate the role of each residue, a series of variants were
generated corresponding to naturally occurring substitutions observed within the FNR
superfamily [5] that included T94G, T94H, T94P, P95G, P95I, V96S, and S97N. The
results presented here give further insight into the role of this motif towards correct
orientation and binding of the FAD prosthetic group. While the V96S and S97N variants
gave results that were comparable to that of wild-type cytochrome b5 reductase, the
T94H, P95G, and P95I variants all displayed significant deviations in the biophysical
properties of the enzyme.
T94 has been considered to be a critical residue within the “91RxYSTxxSN97” motif
due to its location within the FAD-binding lobe of cytochrome b5 reductase. As shown in
Figure 17, T94 forms a backbone hydrogen bond to the N5 of the isoalloxazine ring of
the FAD prosthetic group and is situated near the potential binding site of the
nicotinamide ring of NADH [97, 98]. T94 also lies within 4.02Å of residue T184 of the
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Figure 17. Electrostatic Interaction of Amino Acid Residue T94 with the FAD
Cofactor of Cytochrome b5 Reductase. (A) Ligplot [99] of 1IB0. C, O, N, S, and P
atoms are represented as white, blue, red, yellow, and violet spheres, respectively, while
covalent bonds are green sticks within FAD and blue sticks within amino acid residues of
the FAD-binding lobe. Hydrogen bonds are drawn as dashed lines with distances
between atoms labeled.
Residues contributing to hydrophobic interactions are
represented as arcs with rays and colored blue. (B) Structural model of residue T94 and
its orientation and hydrogen bonding interaction to FAD (atoms colored in CPK).
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NADH-binding lobe that forms essential hydrogen bond contacts from the OG1 atom of
T184 to both the O4 and N5 of the isoalloxazine ring of the FAD- cofactor.
The importance of the P95 residue has been demonstrated through the resolved
crystal structure of cytochrome b5 reductase [21]. P95 is localized in a hydrophobic core
of the FAD-binding domain, together with L72 and V105. This triad is approximately
6Å away from the active site making it a critical area in regards to enzyme function.
Homology modeling software (GENO3D) [100] was utilized to generate a
structural model of the T94H, P95G, and P95I variants in order to compare the structural
models with the results obtained Figure 18. As described previously, various attempts
were made to generate the T94G and T94P variants which resulted in limited success.
The introduction of a glycine residue into a protein has been shown to “relax” the
backbone secondary structure, thus the P95G variant may result in the perturbed flavin
environment as observed in the visible CD spectra. The introduction of a proline causes
the opposite effect, introducing a “kink” into the backbone. Both of these mutations may
lead to an altered conformation of the protein. This demonstrates that the position of the
T94 and P95 residues at the carboxy terminus of the Fβ4 strand and the hydrogen
bonding of the T94 residue with the FAD isoalloxazine ring is necessary for correct
flavin incorporation.
Although there is no side chain interaction involved with the T94 residue the
introduction of a histidine imidizole group removes the polarity of the T94 hydroxyl
group and replaces it with a positively charged, bulky side chain. We predicted that the
effects of this would have a significant effect on the environment of the flavin prosthetic
group and results obtained from the red shift seen in the Uv/visible spectra and the
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Figure 18. Structure of the Wild-type cb5r, T94H, P95G, and P95I Variants
Generated in silica. The models of wild-type cytochrome b5 reductase with T94, P95,
and V96 and the T94H, P95G, and P95I mutants were generated using the modeling
software GENO3D and SWISS-MODEL [100, 101]. Panel (A) is a structure of 1IB0
[21] focused in on the region of the RxYSTxxSN motif, specifically on amino acid residues
T94, P95 and V96, where the polypeptide backbone is cyan and the FAD cofactor and
amino acid residues are colored by element (N=blue and O=Red). Panel B is the
GENO3D theoretical structure of the T94H variant, where the FAD cofactor is colored in
yellow and T94H in green. Panel C represents the P95G variant colored in orange, and
Panel (D) represents the P95I variant colored in red.
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perturbed visible CD spectral data clearly demonstrated this. We proposed that the T94H
variant generated a steric hindrance that affects the interaction of the T94 residue with the
FAD isoalloxazine ring as well as the hydrogen bonding interaction of the T184 residue
with the N5 atom of the FAD- prosthetic group isoalloxazine ring. The alteration in the
FAD environment was further confirmed by the results of the oxidation/reduction
potential of the FAD/FADH2 couple which yielded a midpoint potential comparable to
that of free flavin (-220 mV) in the absence and presence of NAD+ suggesting an
unfavorable electron transfer efficiency.
As mentioned previously, T94 and P95 are located near the potential binding site
of the nicotinamide ring of NADH and the effects of the T94H, P95G, and P95I variants
upon substrate binding yielded interesting results. The spectra obtained for both the
isoteric analog H4NAD and the product NAD+ displayed a line shape comparable to that
of wild-type cytochrome b5 reductase indicating that no severe conformational changes
occurred in the binding of either H4NAD or NAD+. However, upon examination of the
spectroscopic binding constants (Ks) for the T94H and P95I variants, the binding affinity
for H4NAD had increased almost 3-fold compared to that of the wild-type domain
showing a reduced binding affinity for the analog, whereas the Ks values obtained for the
product NAD+ were significantly decreased for all three variant with the greatest impact
observed of the T94H variant yielding a Ks value of 13 µM compared to that of 667 µM
obtained for wild-type cytochrome b5 reductase. Thus the spectral binding constants
suggest that the NADH substrate binds with an altered efficiency compared to that of the
wild-type domain yet the NAD+ product is not able to readily disassociate from the
NADH-binding site and therefore acts as a potential inhibitor in the cytochrome b5
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reductase reaction pathway. The diaphorase activities associated with the T94H, P95G,
and P95I variants were the first indication that this hypothesis was correct, in that the
overall catalytic efficiency (kcat/Km) was only 22%, 32%, and 31%, respectively, that of
wild-type cytochrome b5 reductase, yet this was only due to the poor rate of turnover
(kcat) while the KmNADH was comparable to that of wild-type cytochrome b5 reductase for
each mutant. Competitive inhibition assays further confirmed this by determining initial
rate enzyme kinetics in varying concentrations of NAD+.

Lineweaver-Burke plots

generated from these assays revealed a model of competitive inhibition for the three
variants as indicated by the increase in KmNADH with no change in the Vmax. Ki values
obtained from these assays were also in agreement, being significantly lower than that of
wild-type. These results are in good agreement with those in the previously reported
T94V variant [24], in that the blue neutral semiquinone of FAD (FADH·) has a hydrogen
atom on the N5 atom of the isoalloxazine ring, and release of a proton from the N5
position is required for conversion of the blue neutral semiquinone to the anionic red
semiquinone [102] and the introduction of the T94H, P95G, and P95I variants would lead
to a conformational change and hindrance towards the release of the proton from the N5
position of the FADH· semiquinone thus causing a perturbed effect on the cytochrome b5
reductase- cytochrome b5 electron transfer process.

Type I recessive congenital methemoglobinemia associated with a double mutation,
the novel P92H and previously described E255-, in the cytochrome b5 reductase gene
Recently, a family was identified where two siblings suffered from type I RCM
suggesting that both parents were carriers. Screening of the DIA1 gene for molecular
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defects in the 2 year old sister detected a novel homozygous C to A mutation in exon 4
and a heterozygous 3 bp in frame deletion of GAG in exon 9, causing a loss of glutamic
acid at position 255. Thus, one allele uniquely possessed a double mutation. The exon 4
mutation predicted a proline to histidine exchange at residue 92, corresponding to a P92H
variant. In addition, the same amino acid change at a nearby residue, corresponding to
P95H, had previously been described in a patient with type II RCM [103]. The relative
locations of both of these residues in the cb5r structure, with respect to the FAD
prosthetic group and the complexed NAD+, together with indications of the degrees of
conservation of these residues in different cb5r’s, is shown in Figure 19. The E255mutation has been previously detected [78] in the family first diagnosed with cyanosis
described in 1943 [104], who were subsequently found by Gibson in 1948 to be deficient
in cb5r [44]. Since half of the cb5r enzyme synthesized would have mutations in both the
flavin- and substrate- binding domains, it would suggest a severe clinical phenotype type
I. With this knowledge, utilizing the previously characterized heterologous rat expression
system [105] could provide insight into the function of naturally occurring variants of
cb5r [106] [79] [107], we prepared both the P92H and double P92H/E255- variants. By
performing initial-rate kinetic, thermostability, substrate affinity, and thermodynamic
studies we were able to assess the impact of each mutation on the function of cb5r. In
addition, we also characterized the P95H variant and compared the results to the data
previously generated for the E255- mutant [79].
Sequencing of the DIA1 gene in a cyanotic patient detected a heterozygous
deletion of GAG, bases 27,100 to 27,102 (NCBI accession number NT_011520) in exon
9 resulting in the loss of E255 (Figure 20). This mutation has been previously described
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Figure 19. X-ray Crystallographic Structure of Cytochrome b5 Reductase. (A) A
ribbon diagram of the structure of the rat cb5r diaphorase domain in complex with NAD+
(PDB=1IB0) is depicted showing the structural elements that comprise the FAD- and
NADH-binding lobes and the connecting “hinge” region. The FAD prosthetic group and
the bound NAD+ are shown in the “stick” representation with the individual atoms
colored using the standard “CPK” coloring scheme. The positions of the three mutated
residues, corresponding to P92, P95 and E255, are shown in “ball and stick”
representation. (B) Graphical representation (sequence logo) of the amino acid residues
present at positions 89 to 99 in the primary sequences of 56 cb5r sequences deposited in
GenBank. A multiple sequences alignment was constructed using ClustalX [108],
manually adjusted for maximum sequence conservation and used for the logo generation.
The logo consists of stacks of symbols (one stack for each position in the sequence) with
the overall height of the stack indicating the sequence conservation at that position and
the height of the symbols within the stack indicating the relative frequency of each amino
acid at that position [109]. (C) Graphical representation of the amino acid residues
present at positions 251 to 259 in the primary sequences of 56 cb5r sequences deposited
in GenBank.
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as compound heterozygous with the G291D mutation in the original family with type I
RCM disease [78] as described by Gibson [44]. In addition, a homozygous C to A
change at base 16,076 (C16,076A) in exon 4 predicting an amino acid change of to
histidine at codon 92 (Figure 20). Uniquely, in this case one allele carried a double
mutation. The P92H mutation is located in the FAD- binding lobe of cb5r while the
E255-

mutation

is

present

in

the

carboxy-terminal

NADH-binding

domain.

Consequently, 50% of cb5r synthesized would have mutations in both the prosthetic
group- and the substrate binding lobes of the enzyme. To investigate how the double
mutation would impact on the function of cb5r, the P92H and E255- variants were
synthesized individually and as a P92H/E255- double mutant using a heterozygous
expression system.
The plasmid encoding either the wild-type or the variant forms of the soluble,
diaphorase domain of rat cb5r, corresponding to residues I33 to F300, was used to
transform E. coli BL21 (DE3)-RIL cells. The cells were disrupted by sonication and the
five (P92A/H, P95A/H, and P92H/E255-) cb5r variants were purified to homogeneity by
a combination of metal-affinity chromatography and gel filtration FPLC as previously
described [21]. Evaluation of the expression yield of the various P92 and 95 variants
indicated that all the proteins were efficiently expressed with yields comparable to those
obtained for the wild-type domain. All five cb5r variants were purified to homogeneity as
evident by the presence of single protein bands following SDS-PAGE analysis of the
final FPLC fractions as shown in (Figure 21), which also confirmed molecular masses
(Mr) of approximately 32 kDa for all five variants, identical to the wild-type cb5r.
UV/visible absorbance spectra were obtained for oxidized samples of the five
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Figure 20. Detection of the G255- and P92H Mutations in the DIAI Gene.
Sequencing of exon 9 of the DIA1 gene revealed a heterozygous deletion of GAG from
bases 27,100 to 27,102 (NT_011520) in the child (A) as indicated by arrow in
chromatogram, when compared to the wild type sequence (B). In addition, a homozygous
base change of C to A at nucleotide 16,076 was detected in exon 4 in the child (C)
indicated by arrow in chromatogram when compared to normal sequence (D). Bases are
as follows: G = black; A = green; T = red; C = blue.
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Figure 21. SDS-PAGE Analysis of the Different P92, P95 and E255 cb5r Variants.
Samples (2 µg protein) obtained following isolation of wild-type cb5r (A), the P92A (B),
P92H (C), P95A (D), P85H (E) and the P92H/E255- double mutant (F) were analyzed
using a 12.5 % polyacrylamide gel as described in “Methods”. The outer lanes
correspond to protein molecular weight markers with the indicated molecular masses
(kDa).

purified P92 and P95 variants and were compared with the spectra obtained for the
corresponding wild-type domain in (Figure 22A). The P92A and H and the P95A and H
cb5r variants exhibited spectra identical to that of the wild-type domain that were
characterized by and absorption maximum detected at 273 nm in the UV range of the
spectrum, and a peak at 461 nm with an associated pronounced shoulder in the range of
485-500 nm in the visible region of the spectrum, the latter peak attributable to proteinbound flavin. The A273

nm/461 nm

absorbance ratios of the P92 and P95 variants were

within the range of 5.5 ± 0.2 which was comparable to values previously obtained for
wild-type rat cb5r of 5.6 ± 0.2 [77], indicating a full complement of the FAD prosthetic
group.
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Figure 22. UV/Visible Absorption and CD Spectra of cb5r and the Various P92, P95
and E255 Mutants. (A) UV/visible absorption spectra were obtained for oxidized
samples of cb5r and the various P92, P95 and E255 mutants at equivalent flavin
concentrations (1.7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH
7.0. The inset shows an expanded region of the visible spectrum where the flavin
prosthetic group makes a major contribution. Individual spectra correspond to P92A ( ---- ); P92H ( ….. ); P95A ( -.-.- ); P95H ( - - -); P92H/E255- (-..-..-) and wild-type cb5r (
____ );. (B) UV CD spectra were recorded using enzyme samples (7 µM FAD) in 10 mM
phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible CD spectra were
recorded using enzyme samples (50 µM FAD) in 10 mM phosphate buffer, containing
0.1 mM EDTA, pH 7.0. Line styles shown in “B” and “C” are the same as those depicted
in “A”.
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To assess any alterations in the secondary structural content of the different P92
and P95 cb5r variants, circular dichroism spectra were recorded in the UV wavelength
range (190-300 nm). As shown in Figure 22B, all five P92 and P95 variants exhibited
positive CD spectra from 190-210 nm and negative CD spectra from 210-250 nm with
the spectra retaining both positive and negative intensities very similar to that of the wildtype domain. The absence of any significant differences between the spectra of various
mutants and the wild type domain suggested conservation of the secondary structure
architecture and that none of the amino acid substitutions or deletions had any substantial
effects on the folding of the protein. Visible CD spectroscopy was utilized to examine
the environment of the FAD prosthetic group. As shown in Figure 22C, all five variants
generated exhibited visible CD spectra that were virtually indistinguishable from that of
wild-type cb5r, indicating that none of the amino acid substitutions or deletions had any
significant effect on the conformation of the bound FAD prosthetic group.
To examine the influence of the various amino acid substitutions on the stability
of the resulting proteins, thermal denaturation profiles were generated for the P92A and
H, P95A and H and P92H/E255- variants by measuring both changes in the intrinsic
flavin fluorescence emission intensity (λex = 450 nm, λem = 523 nm) and retention of
NADH:FR activity following incubation of the protein at temperatures ranging from 0100 °C (Figure 23). Changes in the intrinsic fluorescence of the cofactor or the retention
of NADH:FR activity following thermal denaturation was an effective indicator of the
stability of the core structure of the protein. T50 values (the temperature at which 50% of
maximum fluorescence and 50% retention of NADH:FR activity was detected) ranged
from a low of 41 °C for the P92H/E255- mutant to a high of 57 °C for the P92A variant.
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These values can be compared to a T50 of 56 °C obtained for wild-type cb5r.
Initial-rate kinetic analyses were performed for the P92 and P95 cb5r variants to
evaluate the effects of the various residue substitutions and deletions on both NADH and
cytochrome b5 utilization. Values derived for the various kinetic constants for both the
NADH:FR and NADH:BR activities are given in Table 6. The single variants of P92A
and H and P95A and H demonstrated a minor reduction in the overall catalytic efficiency
compared to that of wild-type cb5r for both the NADH:FR and NADH:BR assays
whereas in the P92H/E255- variant the kcat (s-1) was decreased four fold for each assay
and the Km for NADH was increased 33 fold. These results for the P92H/E255- variant
correlated with the previously published data on the E255- mutant [79] indicating that a
deletion of residue E255 in the carboxy terminus of cb5r significantly affects NADH
substrate utilization.
To compare the interaction of the different P92 and P95 cb5r variants with either
H4NAD or NAD+, differential spectroscopy was utilized to monitor complex formation.
Examples of alterations of the flavin visible absorbance difference spectrum following
nucleotide binding are shown in Figure 24.

The formation of spectrally-detectable

complexes was observed for the diaphorase domain during titrations of the majority of
the mutants with both H4NAD and NAD+. For H4NAD, the tetrahydronicotinamide
derivative did not function as a hydride donor when substituted for NADH in either the
NADH:FR or NADH:BR assays but provided a valuable tool for estimating the binding
affinity for NADH. The H4-nucleotide is a close isosteric analog and is assumed to
involve the same contacts at the active site as NADH, but lacks the positive charge on
nicotinamide ring that is present on NAD+. The spectral changes observed following
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Figure 23. Thermal Stability Profiles for the Various P92, P95 and E255 cb5r
Mutants. Oxidized samples of the various P92, P95 and E255 variants (5 µM FAD)
together with wild-type cb5r in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH
7.0, were incubated at the indicated temperatures, aliquots withdrawn and assayed for
both residual NADH:FR activity (closed symbols) and intrinsic flavin fluorescence (open
symbols), the latter using excitation and emission wavelengths of 450 nm and 523 nm,
respectively. The plots correspond to, P92A (+, +; T50=55+1 oC), P92H (▲, U;
T50=45+1 oC), P95A (▼, V, T50=47+1 oC), P95H (, , T50=46+1 oC), P92H/E255(, , T50=42+1 oC) and wild type cb5r (z, {; T50=55+1 oC). NADH:FR activities are
relative to a sample of each protein maintained at 0 oC. Excitation and emission spectra
were scaled relative to that of a sample of free FAD (5 µM) which was assigned a
fluorescence intensity of 100 %.
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Table 6. Kinetic Constants Obtained for the Different P92 and P95 cb5r Mutants.

kcat
(s-1)

Mutant
cb5r

800 + 21

P92A
P92H
P95A
P95H
P95H/E255

458 + 7
571 + 6
420 + 9
367 + 6
190 + 15

NADH:FR activity
KmNADH KmFeCN6 kcat/KmNADH
(s-1 M-1)
(µM)
(µM)
6+1
9+1
12 + 1
12 + 1
28 + 1
293 + 44

kcat
(s-1)

NADH:BR activity
Kmb5
kcat/Kmb5
(s-1 M-1)
(µM)

8+1

1.4 + 0.3 x 108

600 + 16

13 + 3

4.9 + 1.3 x 107

8±1
7±1
8±1
7±1
7±1

7

404 + 7
470 + 12
375 + 7
275 + 8
112 + 6

14 ± 1
15 ± 1
14 ± 1
13 ± 1
15 ± 1

2.9 + 0.3 x 107
2.7 + 0.2 x 107
2.1 + 0.2 x 107
1.6 + 0.2 x 107
7.5 + 0.9 x 106

5.0 + 0.5 x 10
4.6 + 0.2 x 107
3.7 + 0.4 x 107
1.3 + 0.1 x 107
7.5 + 1.8 x 105

H4NAD binding were identical to those previously detected for the corresponding
titrations of the rat enzyme and yielded positive absorbance changes with maxima at 421,
449, and 481 nm and negative absorbance changes at 396, 466, and 497 nm, respectively.
The value obtained for the spectroscopic binding constant (Ks), shown in Table 7, was
comparable to that obtained from wild-type cb5r and indicated that H4NAD bound to the
domain twelve times stronger than NAD+. For the binding of NAD+, differential flavin
spectra were observed for all of the variants with the exception of the P92H/E255- double
mutant, which showed no detectable spectral changes at NAD+ concentrations up to 5
mM. In contrast, the remaining mutants exhibited spectral changes that were similar to
those of the wild-type domain, with positive absorbance maxima at 407 nm and 509 nm
and negative absorbance maxima at 456 nm and 487 nm respectively. The Ks values
(NAD+ µM) were comparable to that obtained for the rat domain for each of the single
mutants.
To examine whether the thermodynamic properties of the flavin prosthetic group
were similar to those of the corresponding wild-type domain, potentiometric titrations
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Figure 24. Flavin difference spectra observed following binding of pyridine
nucleotides to the different P92, P95 and E255- cb5r variants. Difference spectra were
obtained for the various P92, P95 and E255 cb5r mutants at equivalent flavin
concentrations (50 µM FAD) in 20 mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0
following titrations with either H4NAD (left panels) or NAD+ (right panels) as described
in “Methods”. (A and E) P92H; (B and F) P95H; (C and G) P92H/E255-; (D and H) wildtype cb5r. The insert panels correspond to plots of the magnitudes of the observed
spectral perturbations (peak to trough measurements at the indicated wavelengths) versus
ligand concentration. The corresponding Ks values are given in Table 7.
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Table 7. Spectral Binding Constants Obtained for Wild Type cb5r and the P92A,
P92H, P95A, P95H, and P92H/E255- Variants.
Mutant
H4cb5r
P92A
P92H
P95A
P95H
P92H/E255-

Ks H4NAD
(µM)
45 ± 10
58 ± 5
93 ± 5
54 ± 4
115 ± 8
ND

KsNAD+
(µM)
760 ± 30
800 ± 40
764 ± 44
594 ± 39
1873 ± 230
ND

were performed using the dye equilibration method for the different P92, P95 and E255
cb5r variants in the presence of phenosafranine (E°’ = -252mV) as an indicator. Spectra
obtained during a representative titration of the P92A mutant are shown in Figure 25.
Qualitative analysis of the individual spectra obtained from the various titrations
indicated that the majority of phenosafranine was reduced prior to FAD reduction in the
majority of the cb5r variants, suggesting that the flavin midpoint potential was more
negative than that of phenosafranine. In contrast, the titration spectra obtained for the
P92H variant suggested that the enzyme-bound flavin was reduced in tandem with the
dye, indicating a positive shift in the potential for the flavin prosthetic group in the P92H
variant. The flavin redox potentials (n=2) for the different cb5r variants were determined
from the Nernst semi-log plots, shown in Figure 25. The standard midpoint potentials
obtained for the FAD/FADH2 couple in the native enzyme (E°’= -272±5 mV) was
comparable to values obtained for the P92A, P95A and P95H variants. Estimates of the
flavin potential in the P92H/E255- double mutant could not be obtained owing to the
significant instability of the enzyme.
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Figure 25. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the Different P92, P95 and E255 cb5r Variants. Reductive dye-equilibration
titrations of the different P92, P95, E255 mutants and wild-type cb5r (40 M FAD) were
performed as described under “Methods” in 100 mM phosphate buffer, containing 0.1
mM EDTA, pH 7.0 in the presence of phenosafranine (15 M, Eo’=-252 mV) [Marohnic
et al, 2003]. Individual spectra were collected at 2-3 min intervals during the time course
of the titrations. A. Selected spectra obtained during the dye-mediated redox titration of
the P92A variant in the presence of phenosafranine are shown. B. The corresponding
Nernst plots are shown for the titrations of the various mutants and correspond to P92A
(, Eo’=-278+5 mV), P92H (S, Eo’=-240+5 mV), P95A (, Eo’=-265+5 mV), P95H
(▼, Eo’=-265+5 mV), P92H/E255- (Eo’=ND) and wild-type cb5r (z, Eo’=-272+5 mV).
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Summary of the RCM Variants Pro92His and E255Our comparative biophysical studies of the P92H, P95H, and the P92H/E255double mutant have yielded results that could be accurately predicted from the knowledge
of the detailed structural organization of the enzyme. Residues P92 and P95 are both
members of a conserved “RxYTSxxSN” flavin-binding sequence motif that has been
identified in all cb5r sequences deposited to date in addition to the other members of the
FNR superfamily of flavoprotein transhydrogenases. While the side-chains of P92 and
P95 do not contribute any direct contacts to the flavin prosthetic group, in contrast to the
side-chains of other motif members, such as R91 and Y93 that provide direct hydrogenbonding interactions with oxygen atoms that are part of the flavin pyrophosphate and
ribityl moieties, respectively, P92 is involved in a back-bone hydrogen bond between the
carbonyl oxygen and the oxygen atom of the ribityl C2 and participates in providing a
portion of the hydrophobic network that is also important for flavin binding.
A multiple sequence alignment revealed that while P92 is not conserved in all the
known cb5r primary structures, serine [22] and alanine [103] residues are the only known
substitutions, it is present in thirty-three of the fifty-seven various sequences that have
been deposited in Genbank for that portion of the polypeptide chain. However, in
contrast, P95 is conserved together with the other motif members, Y93 and T94.
The results of homology modeling studies, shown in Figure 26, illustrate the
effects of the P92H and P95H substitutions on the respective protein structures. In
contrast to the orientation of the side chain of P92 in the native enzyme, where the
proline side-chain is oriented parallel to the dimethylbenzyl moiety of the flavin
isoalloxazine ring (Figure 26), in the P92H variant, modeling suggests that the imidizole
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side chain would be oriented directly towards the dimethylbenzyl ring producing a steric
clash that could be alleviated by a modest displacement of the isoalloxazine ring into the
solvent cleft between the flavin- and NADH- binding lobes. This displacement would be
expected to result in a decrease in the efficiency of substrate utilization, as shown by the
ten-fold decrease in the P92H specificity constant, while the increased exposure of the
isoalloxazine ring to solvent would be expected to result in an increase in redox potential
of the flavin prosthetic group, towards that exhibited by free flavin (E°’ =-219 mV) [111],
as shown by the +32 mV increase for the mutant compared to wild-type cb5r.
The modeling studies suggest that substitution of histidine for proline at residue
95 would be expected to have only a modest impact on the functional properties of the
enzyme. P95 is situated at the C-terminal end of β-strand Fβ4 which is part of a sixstranded antiparallel β-barrel that comprises the flavin binding lobe. The proline amide
nitrogen is located 6.1 Å distant from the N5 of the isoalloxazine ring and the side chain
is oriented away from the flavin prosthetic group. While the histidine substitution at
residue 95 would not be expected to have any significant impact on the properties of the
flavin, as confirmed by the absence of any changes in redox potential, the decrease in
activity and increase in the Km for NADH may be due to small local changes in the
folding of the polypeptide backbone.
In contrast to P92 and P95, which are part of a well established flavin-binding
motif, E255 does not comprise part of a specific sequence motif of defined function and
is located within a relatively non-conserved sequence region.

E255 is a solvent-

accessible surface residue located at the amino terminus of a short α-helical segment (H7)
that participates in correctly orienting the carboxyl-terminal portion of the protein that
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Figure 26. Structural Models of the P92H and P95H cb5r Variants. A. The structures
of the P92H and P95H variants were modeled using SWISS-MODEL [101] and are
shown superimposed on the X-ray structure of wild-type cb5r (PDB=1IB0). The
structures are shown as “ribbon” models with the P92H shown in blue, the P95H in red
and the wild-type cb5r in yellow. Deviations (RMS) between the P92H and P95H models
and the wild-type structure corresponded to 0.96 Ao and 0.97 Ao, respectively. The FAD
prosthetic group and complexed NAD+ in the wild-type structure are shown in “stick”
configuration with “CPK” coloring. B. An enlarged view of the superimposed structures
in the region of the flavin prosthetic group showing the P92H and P95 substitutions. C. A
portion of the superimposed P92H and wild-type structures showing a “ribbon” diagram
of the region of the sequence between residues R91 and S97, corresponding to the
“RxYTSxxSN” conserved motif, together with the sidechains of the wild-type proline, the
mutant histidine and the FAD prosthetic group. D. As for “C”, except the sidechains of
P95 and the histidine substitution are shown.
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contains the “CGxxxM” motif and which is critical to NADH/NAD+-binding. Thirty-two
of the fifty-seven cb5r sequences deposited in Genbank share a glutamate at this position
while another eighteen retain an aspartate residue. The three base pair deletion of the
codon corresponding to E255 would be anticipated to have a substantial impact on the
interaction of cb5r with either NADH or NAD+, since the carboxy-terminal portion of the
protein is primarily involved in interactions with the reducing substrate. Removal of any
residue prior to and in close proximity to the conserved “273CGxxxM278” motif, which
provides a number of critical contacts for the reducing substrate, would significantly
decrease substrate affinity, by as much as two-orders of magnitude, as has been
previously shown [79] for the discrete E255- variant. In addition, the resulting incorrect
orientation of the bound substrate would reduce the catalytic efficiency by over 50%.
Thus, combining the effects of P92H on the properties of the flavin prosthetic group with
the results of the E255 deletion on substrate affinity and utilization would be anticipated
to significantly impact enzyme functionality, as evident by the 103 decrease in the
specificity constant (kcat/KmNADH) for the P92H/E255- double mutant.

The role of the FAD/FMN specificity binding motif “124GRxxST127”
Within the cb5r primary structure is a four residue sequence motif

124G
S 127
Rxx T

which, through the analysis of structural and sequence alignments within the flavoprotein
transhydrogenase family, has demonstrated a high level of conservation. A primary
feature of this motif is the proposed regulation of FAD or FMN cofactor specificity [5].
This specificity is potentially regulated by residue 124 where, in the majority of FNR
family members, including cytochrome b5 reductase, FAD is incorporated as the cofactor
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and contains the motif “GxxST” whereas those members of the FNR family that utilize
FMN, such as aniline dioxygen reductase, exhibit the “RxxST” motif. This motif is
located within the only α-helix in the flavin-binding domain of cytochrome b5 reductase
known to be directly involved with correct binding and orientation of the flavin prosthetic
group (Figure 27B). In viewing the ligand binding plot for cytochrome b5 reductase and
FAD- binding (Figure 27A) the importance of each amino acid within the “GRxxST” motif
is demonstrated with residue G124 having a hydrophobic interaction and residues K125,
M126, and S127 all forming a backbone hydrogen bond with the pyrophosphate moiety
of the FAD- prosthetic group. Thus, it can be theorized that any mutations introduced
into this motif could result in perturbations of the flavin environment and disruption of
correct flavin binding and orientation. This was previously demonstrated by Bewley et
al. [80] in the type II methemoglobinemia variant S127P, which was the first RCM
variant structure to be solved by X-ray crystallography and revealed that a mutation
within the FAD-binding domain can lead to alterations in the NADH substrate binding
behavior. The X-ray structure of S127P revealed that the ADP moiety of the FADcofactor was displaced into the corresponding ADP substrate binding site, thus inhibiting
efficient substrate binding. This phenomenon has been referred to as “flavin flexibility”.
A second observation in the S127P crystal structure related to the amino acid
residue K125. K125 has been demonstrated to be a critical residue within the GxxST
motif in that the backbone nitrogen of K125 forms a hydrogen bond contact with the
adenine moiety of FAD, through an ionic interaction K125 forms contacts in binding
between the active sites of cytochrome b5 reductase and cytochrome b5 [112] , and K125
comprises part of a 13 residue (F113 – K125) surface exposed loop region which is part
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Figure 27. Structural Representation Displaying the 124GRxxST127 Motif by the FAD
Cofactor Ligand Binding Plot and Secondary Structure of Wild-Type Cytochrome
b5 Reductase. (A) LIGPLOT [99] of 1IB0. C, O, N, S, and P atoms are represented as
white, blue, red, yellow, and violet spheres, respectively, while covalent bonds are green
sticks within FAD and blue sticks within amino acid residues of the FAD-binding lobe.
Hydrogen bonds are drawn as dashed lines with the distances between atoms labeled.
Residues contributing to hydrophobic interactions are represented as arcs with rays and
colored blue. Panel (B) is a WirPlot rendering of rat cytochrome b5 reductase with
corresponding labels for secondary structures pertaining to the NADH-binding domain
(blue), the FAD-binding domain (red), and also the “hinge” region (green) for
completion. The location of the “124GRxxST127” motif is highlighted in red.
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of the amino terminal flavin binding lobe which form a “lid” structure capping a portion
of the cleft between the FAD- and NADH- binding domains. In the crystal structure of
the S127P variant this region underwent a conformational change and was displaced by
6Å and led to perturbations in the adenine binding pocket and pyrophosphate binding site
of the flavin prosthetic group demonstrating the importance of proper conformation of the
“lid” structure.
Residue M126 of cytochrome b5 reductase forms a hydrogen bond with the
backbone nitrogen and the O1P of the FMN pyrophosphate moiety of the FAD- cofactor.
Previous clinical information diagnosed a patient possessing the mutation of M126V,
corresponding to a A→G transversion of codon 126 (ATG→GTG), as a mutation capable
of giving rise to type II methemoglobinemia. However, this patient was compound
heterozygous and a second mutation in the DIA1 gene revealed the presence of an
intronic A→G (ISV4-2A→G) alteration which lead to the skipping of exon 5 [84].
Biochemical characterization of the M126V variant by Davis [40] has recently
established that the mutation introduced by M126V would only result in type I
methemoglobinemia and the type II RCM observed in the patient was direct result of the
intronic alteration leading to the skipping of exon 5 or a combination of the two
mutations. Through a direct hydrogen bond of the M126 nitrogen backbone with the
pyrophosphate of the FMN moiety of the FAD- prosthetic group the M126 residue is
believed to be a key residue in maintaining the integrity of the FAD binding pocket
together with residues R91 and S127P [76]. The introduction of a valine substitution at
residue 126 did not exemplify this. However, both methionine and valine are non-polar
and neutral amino acids, thus, the replacement of methionine to valine would be a
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conservative mutation and more extensive and non-conservative mutations would need to
be introduced in order to gain a full understanding of the role of the M126 residue and its
interaction with the FAD- cofactor.
In order to fully elucidate the role of each residue in the “124GRxxST” motif, a
different approach was directed towards each of the residues, based on their biochemical
properties within cytochrome b5 reductase. As mentioned, FAD/FMN specificity is
proposed to be regulated by residue 124 through a G to R substitution. To properly
examine the effects of flavin binding and specificity on residue G124, a mutation of
G124R was generated along with G124A, G124H and G124K, corresponding to a
conservative uncharged control substitution and two other positively charged residues,
respectively. In the case of the K125 residue, specific charge reversal variants, K125D
and K125E, and a control mutation, K125A, were introduced to establish the effects of
charge in relation to correct flavin binding and orientation as well as the ionic interaction
of cytochrome b5 reductase - cytochrome b5 binding. Finally, for the M126 residue, a
series of variants were created which corresponded to amino acids that have been
demonstrated to occur within other members of the FNR superfamily and included:
M126C/F/G/P/S.

Characterization of G124A/H/K/R and K125A/D/E
Mutant constructs encoding for the variants G124A/H/K/R and K125A/D/E
corresponding to the introduction of a positive charge at position 124 and charge reversal
of residue 125, respectively, were generated through site-directed mutagenesis as
described in “Methods and Materials” utilizing the original four-histidine tagged
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cytochrome b5 reductase expression construct and the corresponding oligonucleotide
primers listed in Table 1. Nucleotide sequencing in both directions confirmed the correct
sequence and proper introduction of each mutation, and each variant was further
expressed in the E. coli strain BL21 (DE3)-RIL and purified to homogeneity via Ni-NTA
agarose chromatography and size exclusion FPLC. Expression yields for each of the
variants were comparable to that of wild-type cytochrome b5 reductase and all were
yellow in color indicating the stability of each mutant generated and stable incorporation
of the flavin prosthetic group. Purification to homogeneity was further confirmed by
SDS-PAGE analysis as demonstrated by the appearance of single protein bands, which
displayed molecular masses comparable to that of wild-type cytochrome b5 reductase (Mr
= 31 kDa).
UV/visible absorption spectra were obtained for oxidized samples of wild type
cytochrome b5 reductase and each of the variants generated and are shown in Figure 28A.
Each of the variants displayed an absorption spectra comparable to that of the wild-type
domain by an aromatic absorption maxima at 272 nm in the UV region and peaks in the
visible region at 386, 460, and a pronounced shoulder at 485 nm, all characteristic of
simple flavoproteins. This initial data suggested that none of the variants generated had
any significant effects on the spectroscopic properties of the flavin prosthetic group. In
order to establish the effects of each mutation upon the secondary structure of the
oxidized protein, far UV CD spectra were recorded in the range of 190–300 nm for each
variant and wild-type cytochrome b5 reductase. As shown in Figure 28B spectra of all of
the G124 and K125 mutants correlated well to the wild-type domain by displaying
positive CD maxima at 196 nm and negative maxima at 222 nm, indicating that the
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mutations introduced had no effect on the overall global folding of the protein. In
contrast, the visible CD spectra obtained displayed perturbations for each variant showing
that the introduction of a positive charge at residue 124 and the charge reversal of K125
resulted in alterations in the environment of the FAD- cofactor. As illustrated in Figure
28C, the spectra for the G124 variants each displayed an increased intensity within the
region of 310-370 nm with the line shape of G124H and G124K showing a reversed
polarity. Each of the G124 variants also showed an alteration in the 460-485 nm region
with a slight blue shift for each mutation indicating a change in the hydrophilicity of the
flavin environment [77].

For the K125 variants, K125A only displayed a minor

perturbance with a minor blue shift in the 450-485 nm region, whereas the K125D and
K125E variants showed a significant alteration with a decreased intensity in the region of
350-410 nm in addition to a minor alteration in line shape from 470-485 nm. These
findings are not unexpected since all of the mutations introduced are involved with either
a hydrophobic or electrostatic interaction with the FAD cofactor.
To analyze the overall protein stability of each of the variants, thermal
denaturation profiles were generated utilizing thermal NADH:FR profiling in tandem
with the loss of intrinsic flavin fluorescence emission quenching, following incubation of
the proteins at temperatures ranging from 0-100 ºC. Changes in the intrinsic fluorescence
of the FAD prosthetic group monitored together with the retention of NADH:FR activity
following thermal denaturation yielded a T50 value, the temperature at which there is 50%
of maximum fluorescence or 50% retention of NADH:FR activity. T50 values obtained
are represented in Figure 29. All G124 variants demonstrated decreased temperature
stabilities with T50 values of 47, 49, and 50 ºC for the G124R, G124A/K, and G124H
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variants, respectively, while each of the K125 mutations yielded T50 values of 53 and 56
ºC for the K125E and K125A/D variants, comparable to the wild-type cytochrome b5
reductase T50 of 55 ºC. These results indicated that the introduction of a charge reversal
mutation at residue K125 did not significantly affect the thermostability of the protein in
regards to flavin binding, whereas the introduction of a positive charge at residue 124
resulted in a lowered T50 value with G124R causing the most dramatic decrease to 47 ºC.
Thus, the substitution of G124 with the positively charged arginine, lysine, and histidine
has a more significant effect on the overall protein stability indicating the most altered
flavin environment in regards to binding and orientation.
In order to determine how the G124 and K125 variants affected the overall
catalytic efficiency, initial-rate kinetic analyses were performed as described in “Methods
and Materials”. Kinetic values obtained from these assays are reported in Table 9. As
expected, all of the generated variants resulted in a decreased specific activity when
compared to wild-type cytochrome b5 reductase. For the NADH:FR assays the catalytic
efficiencies, kcat/KmNADH, for the G124A, G124H, G124K, and G124R variants were
determined to be only 1.2 to 2.6% that of the catalytic efficiency of the wild-type domain.
These results were due to both a dramatic increase in the KmNADH and decrease in the kcat,
indicating that the introduction of a positive charge at position 124 leads to a decreased
affinity for the NADH substrate resulting in decreased turnover, possibly due to the
displacement of the FAD cofactor. Likewise, the K125 charge reversal variants, K125D
and K125E displayed a significant increase in the Km

NADH

, however, only a modest

decrease in kcat was observed for each variant, showing that turnover was not significantly
perturbed in these variants upon substrate binding. Results for the NADH:BR assays also
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Table 8. T50 Values of the Wild-Type Cytochrome b5 Reductase, G124A, G124H,
G124K, G124R, K125A, K125D, and K125E Variants.
Mutant

T50
(°C)
55
49
50
49
47
56
56
53

H4cb5r
G124A
G124H
G124K
G124R
K125A
K125D
K125E

Table 9. NADH:FR and NADH:BR Kinetic Constants Obtained for G124A,
G124H, G124K, G124R, K125A, K125D, K125E, and Wild-Type cb5rs.
Mutant
kcat
(s-1)

NADH:FR
KmFeCN6 kcat/KmNADH
(µM)
(µM)
(s-1 M-1)

KmNADH

NADH:BR
KmCyt b5 kcat/KmCytb5
(µM) (µM)
(s-1 M-1)

kcat
(s-1)

KmNADH

H4cb5r

800 ± 21

6±1

8±1

1.4 ± 0.3 x 108

600 ± 10

2±1

13 ± 1

4.7 ± 0.5 x 107

G124A

355 ± 33

226 ± 30

7±1

1.6 ± 0.4 x 106

226 ± 12

4±1

19 ± 0.3

1.2 ± 0.2 x 107

G124H

185 ± 4

55 ± 3

8±1

3.4 ± 0.3 x 106

160 ± 15

5±1

9±2

1.8 ± 0.4 x 107

G124K

145 ± 5

88 ± 6

8±1

1.7 ± 0.2 x 106

259 ± 22

3±1

21 ± 3

1.2 ± 0.3 x 107

G124R

260 ± 10

115 ± 1

7±1

2.3 ± 0.3 x 106

321 ± 15

3±1

18 ± 2

1.8 ± 0.3 x 107

K125A

871 ± 16

27 ± 1

8±1

3.3 ± 0.3 x 107

55 ± 2

2±1

15 ± 1

3.7 ± 0.5 x 106

K125D

697 ± 16

20 ± 2

8±1

3.4 ± 0.4 x 107

308 ± 12

4±1

56 ± 9

5.6 ± 1.1 x 106

K125E

658 ± 30

423 ± 1

8±1

1.6 ± 0.2 x 106

89 ± 9

5±1

82 ± 12

1.1 ± 0.3 x 106
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correlated well to what we had hypothesized. As mentioned, K125 is not only involved
in a electrostatic interaction with the pyrophosphate moiety of the flavin prosthetic group
but is also one of the critical positively-charged lysine residues that are involved in the
charge pairing ionic interaction in cytochrome b5 reductase-cytochrome b5 complex
formation. The effects of the K125 charge reversal variants are reflected in the kcat/Km
values retaining only 2, 8, and 12% of wild-type cb5r efficiency for the K125E, K125A,
and K125D variants, respectively.

The results shown in the decreased catalytic

efficiencies for the K125 variants are best reflected in the increased Kmcb5 leading to the
significant decrease in kcat. Correlating well with the values obtained for the NADH:FR
activities, overall catalytic efficiencies ranged between 26 to 38% of wild-type
cytochrome b5 reductase for each of the G124 variants which was only due to a decrease
in the kcat values while the Km values for cytochrome b5 binding were unaffected. This
was to be expected since residue G124 is not involved in the cytochrome b5 reductasecytochrome b5 binding interaction so that the lowered catalytic efficiencies observed for
the G124 variants was the direct result of the decreased affinity for NADH.
As demonstrated through the kinetic analyses, each of the G124 and K125
variants displayed a decreased affinity for the NADH substrate. Therefore, spectral
binding constants were determined for each of the mutants utilizing differential
spectroscopy in order to compare the affinities for both the substrate NADH and product
NAD+. As described in “Methods”, the NADH isosteric analog H4NAD was utilized to
monitor complex formation and establish a spectral binding constant [85]. Differential
spectroscopy was utilized to monitor complex formation during titrations with either
H4NAD or NAD+ and is illustrated in Figure 30 and Figure 31. The G124 variant
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titrations performed in the presence of H4NAD yielded spectra with a line shape similar
to that of wild-type cytochrome b5 reductase (Figure 30) with a negative maxima at 395
nm and a shifted positive maxima at 495 nm compared to the wild-type spectra
possessing positive maxima spectra at 410, 450, 480, and 515 nm and negative maxima at
395 and 500 nm. In contrast to the similar complex formation observed for the analog
H4NAD, all titrations performed for the G124 variants in the presence of the product
NAD+ produced a spectra more comparable to the spectral changes observed in the
H4NAD titrations (Figure 31). The values obtained for the respective binding constants
(Ks) for all G124 variants are given in Table 10. Interestingly, the Ks values obtained for
the G124A, G124H, G124K, and G124R variants in the presence of H4NAD were 23, 14,
46, and 31µM, respectively, compared to the wild-type cb5r value of 45µM, indicating a
mode of binding comparable to or more efficient that the wild-type domain. Much of the
same effect was witnessed in the titrations carried out in the presence of NAD+ with the
G124 variants, yielding Ks values of 534, 436, 794, 651µM, respectively, all being lower
or comparable to the wild-type value of 760µM. With regard to the K125 charge reversal
variants, both K125A and K125D displayed differential spectra for H4NAD comparable
to that of wild-type cytochrome b5 reductase. Titrations performed in the presence of
H4NAD generated spectra with positive maxima at 410, 450, 480, and 515 nm, and
negative maxima at 395 and 500 nm. However, the K125E variant displayed only minor
spectroscopic changes, suggesting an altered affinity for H4NAD.

This data was

confirmed in the determination of the spectral binding constants for the K125A, K125D,
and K125E variants yielding Ks values of 76, 65, and 380µM, respectively, demonstrating
a slightly altered binding affinity for the K125A and K125D mutations while the
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Figure 30. Spectroscopic Titrations of H4cb5r, G124A, G124H, G124K, G124R,
K125A, K125D, and K125E cb5rs with H4NAD. Titrations of all mutants (50mM) were
carried out as previously described in 10mM phosphate buffer containing 0.1mM EDTA,
pH 7.0 at 23 °C. Difference spectra were recorded following the addition of solution
containing H4NAD (30µM). The inset panel corresponds to a plot of the magnitude of
the spectral perturbations at the indicated wavelengths versus pyridine nucleotide
concentration where a difference spectrum was observed. Plots of the relative
absorbance changes observed are as follows: (A) H4cb5r; (B) G124A; (C) G124H; (D)
G124K; (E) K125R; (F) K125A; (G) K125D; and (H) K125E.
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Figure 31. Spectroscopic Titrations of H4cb5r, G124A, G124H, G124K, G124R,
K125A, K125D, and K125E cb5rs with NAD+. Titrations of all mutants (50mM) were
carried out as previously described in 10mM phosphate buffer containing 0.1mM EDTA,
pH 7.0 at 23 °C. Difference spectra were recorded following the addition of solution
containing NAD+ (30µM). The inset panel corresponds to a plot of the magnitude of the
spectral perturbations at the indicated wavelengths versus pyridine nucleotide
concentration where a difference spectrum was observed. Plots of the relative
absorbance changes observed are as follows: (A) H4cb5r; (B) G124A; (C) G124H; (D)
G124K; (E) K125R; (F) K125A; (G) K125D; and (H) K125E.
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Table 10. Spectral Binding Constants Obtained for Wild Type cb5r and the G124A,
G124H, G124K, G124R, K125A, K125D, and K125E Variants.
Mutant
cb5r
G124A
G124H
G124K
G124R
K125A
K125D
K125E

Ks H4NAD
(µM)
45 ± 10
23 ± 2
14 ± 2
46 ± 7
31 ± 6
76 ± 11
65 ± 8
380 ± 60

KsNAD+
(µM)
760 ± 30
534 ± 84
436 ± 57
994 ± 113
651 ± 121
451 ± 70
820 ± 86
1182 ± 142

introduction of the K125E variant displayed a binding constant 8-fold greater than that of
the wild-type domain.

Similar behavior was observed for the differential spectra

generated in the titrations performed with the product NAD+. Again, the K125A and
K125D variants displayed differential spectra comparable to wild-type cytochrome b5
reductase, with positive maxima at 410 and 510nm, and negative maxima 430, 460, and
490nm. This indicated that the K125A and K125D variants exhibited similar complex
formation upon the binding of NAD+. However, the differential spectra generated from
the K125E variant with NAD+ displayed absorbance change magnitudes which were
greatly reduced indicating a decreased binding affinity. The Ks values reported in Table
10 agreed well with the differential spectra obtained in that the kinetic binding constants
increased on the order of 451, 820, and 1183µM for the K125A, K125D, and K125E
variants, respectively, compared to the value of 760µM for wild-type cytochrome b5
reductase.
Based on the data and structural modeling of the G124 and K125 variants we
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hypothesized that the mutations introduced would lead to alterations within the flavin
environment of the enzyme. To examine the effects of these predicted structural changes
on the flavin prosthetic group of each variant, oxidation-reduction potentials for the FAD
cofactor were determined utilizing the dye-equilibration potentiometric titration method
for wild-type cytochrome b5 reductase and the G124 and K125 mutants in the presence of
phenosafranine (E°′= -252 mV).

Flavin midpoint potentials (Eº′, n=2) for the

FAD/FADH2 couple were determined both in the absence and presence of NAD+ from
the linear Nernst plots of the log [FADox/FADred] versus the potential (mV) and are
shown in Figure 32. Values established for all redox potentials are shown in Table 11.
Analysis of the midpoint potentials of the G124 variants in the absence of any pyridine
nucleotide indicated that FAD reduction occurred after the reduction of phenosafranine
which is represented by a positive shift in the midpoint potential values obtained
corresponding to -252 mV for the G124K variant and -260 mV for the G124A, G124H,
and G124R variants compared to the standard midpoint potential of -272 mV for
cytochrome b5 reductase. Correlating well with the standard redox potentials, midpoint
titrations carried out in the presence of NAD+ all displayed a more negative shift in the
redox behavior for each of the G124 variants yielding values of -222, -219, -209, and 227 mV for the G124A, G124H, G124K, and G124R variants, respectively. These values
obtained in the presence of NAD+ are similar to the reported value of -220 mV for that of
free flavin [95]. Another interesting aspect of the xanthine oxidase titrations for all of the
G124 variants with NAD+ was observed in the analysis of the slopes of each Nenrst plot.
The Nernst plot for cytochrome b5 reductase oxidation- reduction reaction in the presence
of NAD+ yielded a slope of -30mV, representative of a n=2, two- electron reduction.
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Figure 32. Potentiometric Titrations of the G124A, G124H, G124K, G124R, K125A,
K125D, K125E and Wild-Type Cytochrome b5 reductases. Reductive dye titrations
were performed at 25 °C as described in “Materials and Methods” using phenosafranine
as the indicator dye in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0.
Nernst plots in the absence (A) and presence (B) of 2 mM NAD+. Plots correspond to (●)
H4cb5r; (■) G124A; (▲) G124H; (▼) G124K; (♦) G124R; (hexagon) K125A; (. . . . .)
K125D; and (+) K125E.
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Table 11. Flavin Midpoint Potentials (E°′) Obtained for Wild-Type, G124A,
G124H, G124K, G124R, K125A, K125D, and K125E cb5rs.
Enzyme

E°′ FAD/FADH2
(mV)

Slope
(mV)

E°′ FAD/FADH2
(mV)

-NAD+
cb5r
G124A
G124H
G124K
G124R
K125A
K125D
K125E

-272
-260
-260
-252
-260
-272
-286
-270

Slope
(mV)

+NAD+
-30
-30
-30
-30
-30
-30
-20
-30

-190
-222
-219
-209
-227
-201
-200
-220

-30
-10
-15
-20
-10
-38
-30
-42

However, the slopes obtained for the G124 variants all displayed a shift ranging between
10 to 20mV slopes as shown in Figure 32. The negative potential shifts displayed for the
G124 mutants in the presence of NAD+, the alterations in the slopes, and negative
potentials in the absence of product indicated that the introduction of a positive charge
resulted in a structural displacement of the FAD cofactor leading to a destabilization of
substrate binding and inhibition of efficient electron transfer from the NADH substrate to
the flavin prosthetic group.
In contrast to the results obtained for the G124 variants, the K125 mutations
exhibited a different behavior. In the absence of NAD+, the standard redox potentials and
Nernst plot slopes obtained were all comparable to the wild-type domain with standard
redox potential values of -272, -282, and -270mV for the K125A, K125D, and K125E
variants, respectively, with slopes of 30mV. In the presence of NAD+ however, both the
K125A and K125D exhibited midpoint potentials with only a minor shift compared to the
potential for wild-type cytochrome b5 reductase yielding potential values of -201 and 98

200 mV, respectively. The slopes derived for each mutant were also comparable to the
-30 mV slope of the wild type domain

A more dramatic shift was observed for the

K125E variant with a midpoint potential of -220 mV which is in agreement of the Km
value obtained in the NADH:FR assay for this variant indicating that the low affinity for
NADH also had an effect on the efficiency of electron transfer represented by the
midpoint potential in the presence of NAD+. The alteration in the mode of electron
transfer for K125E was also exemplified by a slope of -42 mV which is similar to that of
an n=1 system represented by a slope of -60 mV. These results provided evidence that
the conformation change introduced into the flavin environment caused by the charge
reversal variant K125E results in a decrease in the efficiency of electron transfer from the
NADH substrate to the FAD cofactor.

Characterization of the amino acid residue M126
In order to establish the molecular basis of the disease methemoglobinemia for the
previously characterized RCM variant M126V [40], five more variants were generated to
complement the M126V analysis. The variants were chosen based on residues that
naturally occur at position 126 in other members of the ferredoxin:NADP+ reductase
superfamily and corresponded to M126C, M126F, M126G, M126P, and M126S. It was
hypothesized that alterations of the M126 residue would lead to a conformational
disruption of the flavin environment due to the hydrogen bonding of the M126 backbone
with the AMP phosphate moiety of the FAD cofactor, possibly resulting in the
displacement of the flavin prosthetic group into the substrate binding cleft as observed in
the type II methemoglobinemia variant S127P.
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The M126 variants were generated through site-directed mutagenesis of the rat
H4CB5R expression construct as described in “Methods”. Dideoxy sequencing in both
directions confirmed the identity of each mutant construct. The generated variants were
subsequently expressed in the E. coli strain BL21 (DE3)-RILP and purified by Ni-NTA
metal chelate chromatography and size exclusion gel filtration FPLC. All five variants
were purified to homogeneity as demonstrated by the appearance of single protein bands
with a molecular mass of 31 kDa following SDS-PAGE (Figure 33)
Representative UV/visible absorption spectra were obtained for oxidized samples
of wild-type cytochrome b5 reductase and each of the M126 variants (Figure 34A). The
spectra for each mutant was comparable to that of the wild-type domain with an aromatic
absorption maxima at 270 nm in the UV region of the spectrum, and peaks at 385, 461,
and a pronounced shoulder at 485-500 nm in the visible region all being signature peaks
of protein-bound flavin. Further examination of the global folding of the polypeptide
backbone and the environment of flavin prosthetic group was carried out for each M126
variant and wild-type cytochrome b5 reductase using UV and visible CD spectroscopy,
respectively (Figure 34 B and Figure 34C). All of the M126 variants displayed spectra in
the UV range (Figure 34B) that were representative of the wild-type domain, displaying a
positive CD maxima at 196 nm and negative maxima at 222 nm demonstrating that the αhelix and β-sheet architecture of the protein were not affected by the M126 mutations.
Alternatively, in the visible range of the CD spectra, only the M126C variant retained
visible CD spectra that was identical to wild-type cytochrome b5 reductase with positive
CD maxima at 310 and 390 nm and negative maxima at 460 and 485 nm and followed an
identical line shape. Although the M126F variant displayed both negative and positive
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Figure 33. SDS Poly-Acrylamide Gel Electrophoresis of Wild-Type, M126C,
M126F, M126G, M126P, M126S, and M126V Cytochrome b5 Reductases. 2µg each
of purified enzyme samples were resolved on a 15% polyacrylamide gel. M126V was
utilized as a positive control in the M126 series of variants. Lanes correspond to (S)
protein molecular weight markers labeled accordingly (kDa); (A) H4cb5r; (B) M126C;
(C) M126F; (D) M126G; (E) M126P; (F) M126S; (G) M126V.

CD maxima comparable to the wild-type domain as well as a similar line shape a minor
alteration in the flavin environment was observed with a blue-shift in the450-500 nm
region. A more significant perturbation in the flavin environment was observed for the
M126S, M126G, and M126P mutants in that the intensity of the M126S and M126G
spectra was diminished within the region of 400-500 nm while the M126P variant yielded
a reversed polarity, as shown in Figure 34C. Similar observations were witnessed in
previous studies of the S127P [80] and R91 [76] variants where the AMP moiety of the
FAD cofactor was displaced into the AMP pocket of the NADH-substrate binding site, a
term referred to as “flavin flexibility”. These results are not unexpected since M126
occupies a positively charged FAD cofactor binding pocket with both the amino acid
residues S127 and R91.
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Figure 34. Ultra-Violet and Visible Absorbance, and Circular Dichroism Spectra of
Wild-Type, M126C, M126F, M126G, M126P, and M126S Cytochrome b5
Reductases. (A) Oxidized samples of wild-type and mutant cb5rs (10 µM), (B) (7 µM),
and (C) (60 µM) FAD in 10 mM phosphate with 0.1 mM EDTA, pH 7.0 buffer. The
inset shows and expanded region of the visible spectrum where the flavin cofactor makes
a significant contribution. Individual spectra correspond to (____) H4cb5r; (____ ____)
M126C; (__ __ __) M126F; (_ _ _ _) M126G; (. . . . .) M126P; and (__.__.__) M126S.
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To examine the effects of the M126 variants on catalytic function, initial rate
kinetic analyses were carried out for NADH:FR and NADH:BR assays and correlated
well with the data obtained from the circular dichroism spectra. Values obtained for kcat
and KmNADH are represented in Table 12. NADH catalytic efficiencies, kcat/KmNADH, for
the M126 variants decreased in the order of M126F>M126C>M126S>M126G>M126P
with each retaining 24, 18, 7, 6 and <1%, respectively, of wild-type cytochrome b5
reductase activity. The effects of the perturbations upon the flavin environment seen in
the visible CD spectra are represented well within the Km values established in the
NADH:FR assays for the M126S, M126G, and M126P variants yielding KmNADH values
of 62, 72, and 751 µM, respectively. With respect to the NADH:BR assays, the catalytic
efficiencies

were

all

reduced

in

the

order

of

WT

cb5r>M126>M126F>M126S>M126G>M126P with only the kcat being affected with the
exception of M126P having a Km 46µM compared to the wild-type value of 13µM.
Differential spectroscopy was utilized to determine if the effects observed in the
spectral and kinetic analyses of the M126 variants were reflected in substrate utilization
through monitoring complex formations during titrations with the NADH-substrate
isoteric analog H4NAD or product NAD+ (shown in Figure 35 and Figure 36). In the
titrations performed with H4NAD the Ks values, shown in Table 13, all decreased on the
order of WT cb5r>M126F>M126C>M126S>M126G. A value for M126P was not able to
be established and no spectroscopic changes were observed even upon the titration with
1mM H4NAD. In addition to the decreased affinity displayed in the Ks values, the
M126C variant was the only mutation that retained the identical spectroscopic complex
formation like that of wild-type cytochrome b5 reductase with a positive maxima at 410,
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Table 12. NADH:FR and NADH:BR Kinetic Constants Obtained for M126C,
M126F, M126G, M126P, and M126S.
Mutant
kcat
(s-1)

NADH:FR
KmFeCN6 kcat/KmNADH
(µM)
(µM)
(s-1 M-1)

KmNADH

NADH:BR
KmCyt b5 kcat/KmCytb5
(µM) (µM)
(s-1 M-1)

kcat
(s-1)

KmNADH

H4cb5r

800 ± 21

6±1

8±1

1.4 ± 0.3 x 108

600 ± 10

2±1

13 ± 1

4.7 ± 0.5 x 107

M126C

641 ± 16

27 ± 2

7±1

2.4 ± 0.3 x 107

444 ± 24

3±1

15 ± 2

2.9 ± 0.5 x 107

M126F

531 ± 13

18 ± 2

7±1

3.1 ± 0.4 x 107

384 ± 26

3±1

15 ± 2

2.7 ± 0.6 x 107

M126G

550 ± 21

72 ± 6

7±1

7.7 ± 0.9 x 106

443 ± 43

2±1

26 ± 4

1.8 ± 0.5 x 107

M126P

46 ± 3

751 ± 66

8±1

6.2 ± 0.9 x 104

54 ± 7

5±1

46 ± 5

1.2 ± 0.3 x 106

M126S

527 ± 13

62 ± 4

7±1

8.6 ± 0.7 x 106

386 ± 37

4±1

19 ± 1

2.1 ± 0.6 x 107

450, 480, and 515 nm, and negative maxima at 395 and 500 nm. In contrast, the
introduction of a phenylalanine mutation generated a spectra that corresponded to a
complex formed in the titration performed in the presence of NAD+ with a positive
maxima of 410 and 510 nm and negative maxima at 430, 460, and 485 nm. Correlating
with the perturbations observed in the decreased visible CD spectra of the flavin
environment, spectral changes for the M126G and M126S variants demonstrated an
altered complex formation with positive maxima at 400 and 500 nm and negative
maxima begin represented by a negative maxima between 410 and 490 nm. Unlike the
altered complex formations observed for the titrations carried out in the presence of
H4NAD, the spectral changes observed for the differential spectroscopy in the presence
of NAD+ yielded positive maxima at 410 and 510 nm and negative maxima at 430, 460,
and 485 nm, identical to that of wild-type cytochrome b5 reductase. Values for the
titrations carried out in the presence of NAD+ are listed in Table 13. Ks values obtained
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Figure 35. Spectroscopic Titrations of H4cb5r, M126C, M126F, M126G, M126P,
and M126S cb5rs with H4NAD. Titrations of all mutants (50mM) were carried out as
previously described in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at 23
°C. Difference spectra were recorded following the addition of solution containing
H4NAD (30µM). The inset panel corresponds to a plot of the magnitude of the spectral
perturbations at the indicated wavelengths versus pyridine nucleotide concentration
where a difference spectrum was observed. Plots of the relative absorbance changes
observed are as follows: (A) H4cb5r; (B) M126C; (C) M126F; (D) M126G; (E) M126P;
and (F) M126S.
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Figure 36. Spectroscopic Titrations of H4cb5r, M126C, M126F, M126G, M126P,
and M126S cb5rs with NAD+. Titrations of all mutants (50mM) were carried out as
previously described in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at 23
°C. Difference spectra were recorded following the addition of solution containing
NAD+ (30µM). The inset panel corresponds to a plot of the magnitude of the spectral
perturbations at the indicated wavelengths versus pyridine nucleotide concentration
where a difference spectrum was observed. Plots of the relative absorbance changes
observed are as follows: (A) H4cb5r; (B) M126C; (C) M126F; (D) M126G; (E) M126P;
and (F) M126S.
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with NAD+ correlated exactly with the Ks values for H4NAD with the spectroscopic
binding

constants

showing

a

decreased

affinity

in

the

order

of

WT

cb5r>M126F>M126C>M126S>M126S>M126G>M126P, with no appreciable value
obtained again for the M126P variant even upon the addition of up to 5mM NAD+, a
concentration ~8-fold greater than that for wild-type cytochrome b5 reductase. These
results indicate that the conformational changes in the environment of the flavin
prosthetic group result in a decreased affinity for both H4NAD and NAD+ providing
evidence for a potential role for the M126 residue in catalysis.
Thermal denaturation profiles were also obtained for wild-type cytochrome b5
reductase and the M126 variants and are shown in Figure 37. The T50 values shown in
Table 14 clearly demonstrate a direct correlation with the subsequent data shown thus far.
The effect of the mutation upon the flavin environment with a decrease in catalytic
efficiency, reduced substrate binding affinity, and perturbed visible CD spectra for the
M126 variants is also reflected in a decreased thermostability when compared to the
wild-type cytochrome b5 reductase T50 value of 55 ºC. The M126 variant T50 values
decreased in the order of 52, 51, 47, 45, and 44 ºC for the M126F, M126C, M126S,
M126P, and M126G mutants, respectively. The decrease in thermostability demonstrated
that the degree at which there is a disruption in the environment of the flavin prosthetic
group directly correlated to the stability of the protein.
Finally, to asses the effects of the conformational disruptions of the flavin
environment upon the flavin reduction potential, oxidation-reduction potentials for the
FAD prosthetic group were established using the dye equilibration method both in the
presence and absence of NAD+ (shown in Figure 38). The standard redox potential (Eº′)
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Table 13. Spectral Binding Constants Obtained for Wild Type cb5r and the M126C,
M126F, M126G, M126P, and M126S Variants.

H4cb5r

Ks H4NAD
(µM)
45 ± 10

KsNAD+
(µM)
760 ± 30

M126C

139 ± 13

1071 ± 32

M126F

66 ± 1

781 ± 15

M126G

242 ± 9

4216 ± 139

M126P

ND

ND

M126S

214 ± 6

2966 ± 109

Mutant

for the FAD/FADH2 couple was derived from the Nernst plot and values obtained are
listed in Table 15. Both the M126C and M126F variants exhibited a midpoint potential
comparable to that of the wild-type domain (-272 mV) with values of -270 and -274 mV
and a slope of -30 mV, representative of an n=2 reaction, respectively, and indicating that
the substitution of cysteine or phenylalanine at position 126 had no significant effect on
the standard redox potential. However, the flavin redox behavior exhibited a more
dramatic shift for the M126S, M126G, and M126P variants all yielding midpoint
potentials of -258 mV although a slope of -30 mV was observed for each mutant. This
variation can be attributed to the alterations within the FAD cofactor environment
observed in the preceding data. Flavin midpoint potentials performed in the presence of
NAD+ were all dissimilar compared to the value obtained for wild-type cytochrome b5
reductase (-190 mV), yielding potentials of -206, -180, -198, -209, and -220 mV for the
M126C, M126F, M126G, M126S, and M126P variants, respectively. Each variant with
the exception of the M126P mutant displayed potentials comparable to that of
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Figure 37. Temperature Stability of cb5r and the M126C, M126F, M126G, M126P,
and M126S Mutants. Oxidized samples of M126C, M126F, M126G, M126P, M126S,
and wild-type H4cb5r (5 µM FAD) were incubated at the indicated temperatures, and
aliquots were withdrawn and assayed for both residual NADH:FR activity (closed
symbols) and intrinsic flavin fluorescence (open symbols) in 10 mM phosphate buffer,
containing 0.1 mM EDTA, pH 7.0 using excitation and emission wavelengths of 450 nm
and 523 nm, respectively. Points correspond to: (●,○) H4cb5r; (■, □) M126C; (▲, ∆)
M126F; (▼, ) M126G; (♦, ◊) M126P; and (+) M126S.
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Table 14. T50 Values of the Wild-Type Cytochrome b5 Reductase, M126C, M126F,
M126G, M126P, and M126S Variants.
Mutant

T50 (º C)

H4cb5r

55

M126C

51

M126F

52

M126G

44

M126P

45

M126S

47

cytochrome b5 reductase demonstrating the introduction of the nonpolar bulky side chain
of proline resulted in a greater perturbation of the flavin environment. Interestingly, the
slope derived for each variant in the presence of NAD+ also differed when compared to
the wild-type domain, producing slopes of -60 mV for the M126C, M126F, and M126G
mutants and -42 and -45 mV for the M126P and M126S variants, respectively, which
were indicative of an n=1 reaction.

Summary of the “124GRxxST127” Motif
Overall, these results provide direct evidence to support the importance of the
“124GRxxST127” motif for proper FAD cofactor incorporation and orientation. Residues
G124, K125, M126, and S127 are all located in the N-terminal portion of α-helix FαA,
the only α-helix found within the FAD binding domain of cytochrome b5 reductase. Each
residue also forms a structural framework for the proper positioning of the flavin
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Figure 38. Potentiometric Titrations of the M126C, M126F, M126G, M126P,
M126S, and Wild-Type Cytochrome b5 Reductases. Reductive dye titrations were
performed at 25 °C as described in “Materials and Methods” using phenosafranine as the
indicator dye in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0. Nernst
plots in the absence (A) and presence (B) of 2 mM NAD+. Plots correspond to (●)
H4cb5r; (■) M126C; (▲)M126F; (▼) M126G; (♦) M126P; and (+) M126S.
111

Table 15. Flavin Midpoint Potentials (E°′) Obtained for M126C, M126F, M126G,
M126P, M126S, and Wild-Type Cytochrome b5 Reductases.
Enzyme

E°′ FAD/FADH2
(mV)

Slope
(mV)

E°′ FAD/FADH2
(mV)

-NAD+
H4cb5r
M126C
M126F
M126G
M126P
M126S

-272
-270
-274
-258
-258
-258

Slope
(mV)

+NAD+
-30
-30
-30
-30
-30
-30

-190
-206
-190
-198
-209
-220

-30
-60
-60
-60
-42
-45

prosthetic group via a hydrophobic interaction with G124 and electrostatic interactions of
the backbone nitrogen of K125, M126, and S127 with the AO2, O1P, and O2P of the
FAD pyrophosphate moiety, respectively (shown in Figure 27A). Of the four residues,
S127 also possessed a side chain hydrogen bond with the FAD cofactor from the OG of
S127 to the O2P pyrophosphate moiety of FAD. Detailed analysis has demonstrated the
importance of the S127 residue through the crystal structure of the type II RCM mutant
S127P [80]. The introduction of a proline at position 127 leads to the displacement of the
ADP moiety of the FAD cofactor into the corresponding ADP binding site of the NADHbinding domain. Through this displacement, the FAD- cofactor acts as an effective
substrate inhibitor. This suggested that any other mutations introduced into the

G
S
Rxx T

motif would also lead to an alteration in the flavin environment causing the displacement
of the flavin prosthetic group and result in a significant decrease in the overall catalytic
efficiency of the protein.
The initial evidence that suggested that each of the residues within the “GRxxST”
motif was involved in maintaining proper flavin incorporation was obtained from the
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circular dichroism studies. Results from the spectra obtained in the far-UV region of the
CD (190-300 nm) indicated that none of the mutations introduced had any significant
effect on the overall global folding of the protein. However, the spectra displayed in the
near-visible region representing the environment of the flavin prosthetic group showed
significant perturbations.

For the G124 and K125 variants, alterations were more

prominent within the region of 300-400 nm and all displayed a blue-shift at 450-485 nm,
representative of an alteration in the hydrophilicity of the flavin environment. For the
M126 variants, minor perturbations were observed as a blue-shift for the M126C and
M126F mutants, whereas the M126S, M126G, and M126P variants all displayed a
decrease in spectral intensity from the region of 400-500 nm which was in good
agreement with the spectra previously published for the R91 and S127P variants [76, 80].
This indicated that the mutations introduced at position 126 not only led to an alteration
of the flavin environment but also to a possible displacement of the FAD- cofactor. This
can be attributed to the fact that, as mentioned, the M126 residue is located in the only αhelical segment in the FAD- binding domain and it has been shown that the introduction
of a glycine mutation into an α-helix can result in a change in the backbone structure
through the removal of any side chain, while the introduction of a proline generates a
kink in the backbone of an α-helix.
The perturbations observed in the visible CD spectra were all in good agreement
with the results obtained for the kinetic and thermodynamic properties of the various
mutants. Comparisons of the overall catalytic efficiencies revealed that the decreased
turnover was directly attributable to the reduced affinity, (Km), for the nucleotide NADH.
This was in good agreement with the kinetic results obtained for the S127P variant which
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displayed a Km value 9-fold greater than that of wild-type cytochrome b5 reductase. As
anticipated the results obtained from the NADH:BR assays demonstrated that the
mutations introduced at the G124 and M126 residues had little to no effect on the Kmcb5,
whereas the charge reversal variants K125D and K125E showed a significant decrease in
their overall catalytic efficiency. These results were in good agreement with previously
published studies that had defined K125 as one of four positively-charged lysine residues
that were involved in an ionic interaction with cytochrome b5 [112].
For the G124 variants, differential binding constants, (Ks), provided unexpected
results in regards to substrate binding affinity based on the increased Km values obtained
from the NADH:FR assay. In the titrations performed with the substrate analog H4NAD,
all differential spectra displayed a line shape similar to that of wild-type cytochrome b5
reductase, however, spectral binding constants derived from each spectra were lower than
that of wild-type cytochrome b5 reductase showing an enhanced binding affinity for each
G124 variant. In the titrations that utilized NAD+, the spectral binding constants for the
G124 mutants followed similar trends; in which all but G124K yielded Ks values lower
than that of the wild-type domain. However, the differential spectra displayed for each
variant were representative of the line shape observed in the presence of H4NAD. These
results indicated an altered mode of binding for the product, NAD+ that was a direct
result of the perturbations generated by the G124 variants within the environment of the
flavin prosthetic group. It can also be concluded that the decrease in the Ks values is not
indicative of enhanced binding of H4NAD and NAD+ but rather that, the disruptions of
the flavin environment prevent efficient substrate disassociation. The results for the
differential spectroscopy were as expected for the K125 and M126 series of variants
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where each displayed a decreased binding affinity which was in direct agreement with the
Km values obtained for the activity assays.
The predicted alterations of the FAD environment were also evident by the
perturbations detected in the oxidation-reduction potentials of the FAD/FADH2 couple
both in the absence and presence of NAD+. Each of the G124 variants displayed a
positive shift in the flavin redox potential in the absence of NAD+ and a negative shift in
the presence of NAD+. A slope of -30 mV was also obtained for each of the G124 Nernst
plots which was similar to that determined for the wild-type cytochrome b5 reductase
oxidation-reduction potential, indicating a similar n=2 electron transfer process.
However, the slopes derived from the Nernst plots in the presence of NAD+ were
severely compromised for the G124 series yielding slope of -10, -12, -15, and -20 mV for
the G124A, G124R, G124H, and G124K variants respectively. In contrast, the midpoint
potentials obtained for the K125A, K125D, and K125E variants were all comparable to
that of wild-type cytochrome b5 reductase with the exception of K125E which yielded a
midpoint potential of -200 mV in the presence of NAD+. Finally, the results from the
M126 series of mutants yielded oxidation-reduction potentials directly correlated with the
kinetic and thermodynamic data already obtained for the M126 variants. The M126
variants catalytic efficiencies, thermostability, visible-CD, and differential binding
constants all decreased in the order of M126C and M126F being comparable to the wildtype domain and then followed by M126S>M126G>M126P for each biophysical
parameter. This trend was also observed for the standard oxidation-reduction potentials
of each mutant, with M126C and M126F generating potentials comparable to wild-type
cytochrome b5 reductase and a positive shift observed in the titrations performed in the
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absence of NAD+ for M126S, M126G, and M126P. Data obtained for the M126G
mutant did not conform to this pattern yielding a potential in the presence of NAD+ of 198 mV while the M126S and M126P displayed potentials of -210 and -220 mV,
respectively. The midpoint potentials obtained were most likely a direct result of the
perturbations of the flavin environment and reflect potential displacement of the adenine
moiety of the flavin prosthetic group as suggested by the visible-CD spectra. These
observations, in conjunction with the poor substrate affinity, as demonstrated by the
initial rate kinetic analyses, would result in a highly unfavorable electron transfer and
flavin reduction process.

Analysis of the effects of the RCM variant M272- and generated variants
M272A/I/L/R on the CGxxxM motif.
Within the cb5r primary structure, several sequence motifs have been identified
that are involved in either flavin binding (“91RxYTSxxSN97”) or FAD/FMN specificity
(“124GRXXST127”) or function in modulating reduced pyridine nucleotide binding
(“180GxGxxP185” and “273CGxxxM278”). The second of the conserved motifs that are
involved in regulating pyridine nucleotide affinity, corresponds to a six amino acid
“273CGpppM278” motif that comprises the residues C273 to M278 in the carboxylterminal lobe of rat cb5r (Figure 40). Preceding this motif in the sequences of the majority
of higher eukaryote cb5r’s is a conserved methionine residue, M272, that has been
previously identified as absent in a patient with type II RCM [81].
High resolution X-ray structures have been obtained for the soluble forms of rat
[12], human [28], and pig [113] cb5r. Within the rat cb5r diaphorase domain (PDB
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ID=1I7P), M272 has been shown to be located at the terminus of the strand Nβ4 together
with the conserved “essential” cysteine residue, C273. This strand is part of a fivestranded anti-parallel β-barrel structure which contains a canonical Rossman fold and
comprises the pyridine nucleotide-binding lobe (residues K172 to F300) [12].
Analysis of the structure of the diaphorase domain complexed with NAD+ (PDB
ID=1IB0) has revealed that while M272 provides no direct electrostatic or hydrogen bond
contacts with either the nicotinamide or ribose moieties of the bound NAD+, the
subsequent residues, corresponding to C273 to M278, form a loop connecting Nβ4 with
the final α helical ‘return’ in the NADH binding domain and provide an extensive
framework of hydrophobic contacts that are involved in binding the reducing substrate
and specifically orienting the nicotinamide portion of the reduced pyridine nucleotide for
subsequent efficient hydride transfer to the FAD prosthetic group. Within the “CGxxxM”
motif, the conserved glycine, corresponding to G274, forms two critical hydrogen bonds.
To probe the role of M272 in cb5r structure and function and to examine the effects of
deleting this residue as previously identified in the type II methemoglobinemia variant,
we utilized site-directed mutagenesis as a tool to either delete the methionine residue at
position 272 in the rat cb5r diaphorase domain or substitute the methionine with the
amino acid residues, A, I, L and R. Residues that have been shown to commonly occur at
the equivalent position within other members of the FNR superfamily. Subsequently, we
primarily examined the effects of these deletions and substitutions on the spectroscopic
and thermodynamic properties of the FAD prosthetic group and the interactions the
mutant with the physiological reductant, NADH.
Mutant constructs encoding the five different cb5r variants, M272-, A, I, L and R,
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Figure 39. Multiple Sequence Alignment of cb5r Primary Structures. (A) Selected
eukaryotic cb5r amino acid sequences were retrieved from GenBank, aligned using the
ClustalX algorithm [108] and the alignment optimized for maximum sequence
conservation. Only the portions of the sequences surrounding the conserved pyridine
nucleotide-binding “273CGPPPM278” motif (underlined) are shown for clarity. Beginning
and ending residue numbers within the translated GenBank sequences are indicated by
superscripts while the methionine residue corresponding to M272 in R. norvegicus cb5r is
shown in bold face. The consensus sequence is also shown below with identical residues
indicated by “*” and similar residues indicated by “:”.
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H.
P.
M.
M.
B.
S.
C.
R.
M.
G.
X.
F.
T.
D.
X.
M.
C.
A.
A.
L.
C.
D.
C.
D.
C.
D.
Y.
N.
E.
M.
G.
P.
C.
K.
C.
T.
S.
S.
S.
V.
N.
A.
Z.
O.
C.

SPECIES
sapiens
troglodytes
mulatta
fascicularis
tauros
scrufa
familiaris
norvegicus
musculus
gallus
laevis
rubripes
nigroviridis
rerio
tropicalis
domestica
briggsae
mellifera
gambiae
major
neoformans
discoideum
elegans
melanogaster
albicans
hansenii
lipolytica
crassa
gossypii
alpina
zeae
falciparum
glabrata
lactis
maxima
brucei
pombe
japonicum
cerevisiae
fordii
tabacum
thaliana
mays
sativa
comosus

SEQUENCE
EPLVLMCGPPPMIQYAC283
EPLVLMCGPPPMIQYAP
EPLVLMCGPPPMIQYAC
EPLVLMCGPPPMIQYAC
EPLVLMCGPPPMIQYAC
EPLVLMCGPPPMIQYAC
267
EPLILMCGPPPMIQYAC283
267
ETLILMCGPPPMIQFAC283
EPLILMCGPPPMIQFAC
DVLILMCGPPPMIQYAC
DVLILMCGPPPMVQYAI
DTLILMCGPPPMIQFAC
DTLILMCGPPPMIQFAC
DSMILMCGPPPMIQFAC
DVVVLMCGPPPMIQFAC
DTMILMCGPPPMIQFAC
DSAVLMCGPPPMINFAC
DTMVLMCGPPPMINFAC
NSLVLMCGPPPMVNYAC
KVMALMCGPPPMVQMAI
GHKVLMCGPPPMITAMK
QTMVIMCGPPMMNKAMT
DSAVLLCGPPPMINFAC
DTIVLLCGPPPMINFAC
DTNLLLCGPPPMVSAMK
ATNLLLCGPPPMISAMK
NTKLLLCGPPPMISALK
DVKILLCGPPPMISGLK
SAQLLLCGPPPMVSSAK
DIKVLLCGPPPMVSAMS
DSKVFLCGPPGMVNASK
DTLILLCGPPPMTSSIK
DVQLLVCGPPGMVSSVK
GVQLLVCGPPPMVSSIK
DALILVCGPPGMMKHIC
KAILLVCGPPGFMKTIS
ETKVLICGPTPMVNSLR
DTITLICGPPPFIEFAC
NVQILICGPPAMVASVR
DIQILRCGPPPMNKAMA
DIQILRCGPPPMNKAMA
DIQILRCGPPPMNKAMA
DIQILRCGPPPMNKAMA
DIQILRCGPPPMNKAMA
DIQILRCGPPPMNKAMA
267
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A

B

M272
FAD
C273
Figure 40. Graphical Sequence Alignment and Structural Representation of Amino
Acid Residue M272. (A) Graphical representation (sequence logo) of the amino acid
residues present at positions 267 to 283 in the primary sequences of 55 cb5r sequences
deposited in GenBank. The logo consists of stacks of symbols (one stack for each
position in the sequence) with the overall height of the stack indicating the sequence
conservation at that position and the height of the symbols within the stack indicating the
relative frequency of each amino acid at that position. (B) Schematic diagram of a portion
of the R. norvegicus cb5r X-ray structure (PDB=1IB0) showing the arrangements of the
amino acids that comprise the sequence region containing the conserved “273CGxxxM278”
motif and residue M272 that precedes the motif. Amino acid residues are shown in
“stick” representation using the CPK color scheme while the appropriate portion of the
peptide backbone, corresponding to residues I270 to C283, is displayed as a ribbon
diagram. The location of the FAD prosthetic group and complexed NAD+ are also shown
in “stick” representation using the CPK color scheme.
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the latter corresponds to the most frequently encountered amino acid residues occurring
at positions equivalent to M272 in the various cb5r sequences identified in GenBank and
also within other members of the FNR superfamily of pyridine nucleotide-dependent
flavoprotein transhydrogenases, were generated through directed mutagenesis of the
original four-histidine tagged cb5r expression construct. Nucleotide sequencing
confirmed the fidelity of each construct and each of the mutant proteins was subsequently
expressed in the E. coli strain BL21(DE3)-RIL and purified to homogeneity by a
combination of Ni-chelate chromatography and gel filtration FPLC. Evaluation of the
expression yields of the various mutants indicated that the different M272 variants were
expressed at levels comparable to that of the wild-type domain, with the exception of
M272L which was obtained in significantly decreased yield (approximately 30% of wildtype), suggesting decreased stability. All five M272 variants were purified to apparent
homogeneity as evident by the presence of single protein bands following SDS-PAGE
analysis of the different mutants as shown in Figure 41, which also indicated molecular
masses comparable to that of the native enzyme (Mr approx. 32 kDa).
The oxidized forms of all five purified M272 variants were yellow in color
indicating the incorporation of a flavin prosthetic group and confirming that M272 did
not provide any backbone or side-chain contacts that were essential for protein folding
and the stable incorporation of the flavin prosthetic group.
UV/visible absorbance spectra were obtained for oxidized samples of each mutant
and wild-type cb5r and are compared in Figure 42A. The M272-, M272A, M272I, M272L
and M272R variants each exhibited absorption spectra comparable to that of the wildtype enzyme with an aromatic absorption maximum detected at 272 nm in the UV region
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Figure 41. SDS-PAGE Analysis of the Different M272 cb5r Variants. Samples of the
different M272 variants (2 µg each) and wild-type cb5r, obtained from the terminal FPLC
purification step, were resolved on a 12.5% polyacrylamide gel : Lane A, wild-type cb5r;
lane B, M272-; lane C, M272A; lane D, M272I; lane E, M272L; lane F, M272R. The
arrows indicate the positions of selected molecular weight markers with the indicated
molecular masses (kDa).
of the spectrum, and a peak at 461 nm with a associated pronounced shoulder in the range
of 485-500 nm in the visible region of the spectrum, attributable to protein-bound flavin.
None of the visible spectra of any of the M272 variants were blue- or red-shifted with
respect that of the wild-type protein, as has been previously demonstrated for mutations
of other residues, such as R91 and Y93 [77] [76], suggesting that none of the M272
substitutions or its deletion had any significant influence on the spectroscopic properties
of the FAD prosthetic group. Blue shifts in the visible absorbance spectra of flavoproteins
have previously been attributed to changes in the hydrophilicity of the flavin environment
near the N(5) locus of the isoalloxazine ring [114] [115] while red shifts have been
observed for other mutants such as the previously characterized T94H.
To assess the secondary structural content of each of the M272 variants, CD
spectra were recorded in the UV wavelength range (190-300 nm). As shown in Figure
122

1.6

0.3

Absorbance

1.4
1.2

0.2

1.0

0.1

0.8
0.6

0.0
320

0.4

355

390

425

460

495

A

0.2
0.0
250

530

300

350

400

450

500

550

600

4

4

2

2

0

0

-2

-2

C

B
-4
190

250

300

350

400

450

500

-4
550

Molar Ellipiticity (x 104)

6
Molar Ellipticity (x 10 )

W avelength (nm )

W avelength (nm )
Figure 42. UV/Visible Absorption and CD Spectra of cb5r and the Various M272
Mutants. (A) UV/visible absorption spectra were obtained for oxidized samples of the
various G272 mutants together with wild-type cb5r at equivalent flavin concentrations
(1.7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. The inset
shows an expanded region of the visible spectrum where the flavin prosthetic group
makes a major contribution. (B) UV CD spectra were recorded using enzyme samples (7
µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible
CD spectra were recorded using enzyme samples (50 µM FAD) in 10 mM phosphate
buffer, containing 0.1 mM EDTA, pH 7.0. Individual spectra correspond to; M272- (___
___ ___
); M272A (__ __ __); M272I (- - - -), M272L (. . . . .); M272R (__.__.__) and wild-type
cb5r( _____ ).
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42B, all of the cb5r variants exhibited positive CD from 190-210 nm and negative CD
from 210-250 nm with all the spectra retaining both positive and negative intensities very
similar to that of the wild-type domain. The absence of any significant differences
between the UV CD spectra of the wild-type and mutant proteins suggested conservation
of the overall secondary structure architecture and that none of the M272 residue
substitutions or its deletion had any deleterious effects on the global folding of the
diaphorase domain.
To examine the influence of the various M272 residue substitutions or deletion on
the stabilities of the resulting proteins, thermal denaturation profiles were generated for
the various mutant forms and compared with those obtained for wild-type cb5r and are
shown in Figure 43. Alterations in both the intrinsic flavin fluorescence emission
intensity (λem=523 nm) and retention of NADH:FR activity following incubation of the
proteins at temperatures ranging from 0–100 °C were monitored. Changes in the intrinsic
fluorescence of the cofactor or the retention of NADH:FR activity following thermal
denaturation has been shown to be an effective indicator of the stability of the core
structure of the protein. The various T50 values, the temperature at which 50% of
maximum fluorescence or 50% retention of NADH:FR activity was detected, increased in
the order M272R < M272A < M272- < WT < M272L < M272I, with all variants
exhibiting T50 values in the range between 46 and 57 °C, which suggested that none of
the substitutions had a dramatic effect on the thermal stability of flavin binding with the
exception of the M272R variant. The M272I and L variants exhibited T50 values of
approximately 57 °C, in good agreement with the value of 55 °C obtained for wild-type
cb5r. The deletion (M272-) and A variants exhibited slightly decreased T50 values of 51
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Figure 43. Thermal Stability Profiles for the Various M272 cb5r Mutants. Oxidized
samples of the various M272 variants together with wild-type cb5r (5 µM FAD) were
incubated at the indicated temperatures and aliquots were withdrawn and assayed for both
residual NADH:FR activity and intrinsic flavin fluorescence in 10 mM phosphate buffer,
containing 0.1 mM EDTA, pH 7.0, the latter using excitation and emission wavelengths
of 450 nm and 523 nm, respectively. The plots correspond to M272- (, ); M272A
(U,▲); M272I (▼, V); M272L (, ); M272R (+, +) and wild type cb5r (z,{).
NADH:FR activities were scaled relative to a sample of each protein that had been
maintained at 0 oC while intrinsic flavin fluorescence was scaled to a sample of free FAD
(5 µM) which was assigned a fluorescence intensity of 100%.
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°C and 50 °C respectively, while the R mutation caused a decrease to 47 °C, indicating
the most altered structure. These results suggested that the majority of the M272
substitutions had only modest effects on the thermal stability of the different cb5r
variants.
Initial-rate kinetic analyses were performed on all five cb5r M272 variants to
evaluate the effects of the various residue substitutions on NADH utilization. Values
derived for kcat and Km for both NADH:BR and NADH:FR activities of the various
mutants are given in Table 16, together with the corresponding values obtained for wildtype cb5r.
With the exception of the M272L variant which retained 84% of wild-type activity with a
corresponding two-fold decrease in affinity for NADH, the remaining four variants
exhibited both substantially decreased NADH:FR activities together with either modest
or substantial decreases NADH affinities with the M272- variant showing the most
dramatic changes. NADH catalytic efficiencies, as indicated by kcat/KmNADH, were
observed to decrease in the order WT > M272L = M272I > M272A > M272R > M272with the latter variant retaining a level of NADH:FR efficiency that was five orders of
magnitude less than that of the wild type protein. Of the five M272 variants, both the
deletion mutant and the M272R variant were determined to have the lowest affinities for
NADH.
To confirm that substitution or deletion of the M272 residue primarily affected
the protein’s affinity for either the physiological reducing substrate NADH, or the
product of the redox half-reaction, NAD+, we utilized differential spectroscopy of the
flavin cofactor absorbance to determine spectroscopic binding constants, Ks, for the
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Table 16.
Comparison of the Kinetic Constants Obtained for Wild-Type
Cytochrome b5 Reductase, M272-, M272A, M272I, M272L, and M272R.
Mutant
kcat
(s-1)
H4cb5r

800 ± 21

M272-

NADH:FR
KmFeCN6 kcat/KmNADH
(µM)
(µM)
(s-1 M-1)

KmNADH
6±1

0.4 ± 0.1

8±1

70 ± 11

1.4 ± 0.3 x 108

7±1

5.9 ± 1.2

NADH:BR
KmCyt b5 kcat/KmCytb5
(µM) (µM)
(s-1 M-1)

kcat
(s-1)

KmNADH

600 ± 10

2±1

13 ± 1

4.7 ± 0.5 x 107

444 ± 24

3±1

15 ± 2

2.9 ± 0.5 x 107

384 ± 26

3±1

15 ± 2

2.7 ± 0.6 x 107

M272A

x 103

M272I

406 ± 11

11 ± 1

8±1

3.7 ± 0.6 x 107

443 ± 43

2±1

26 ± 4

1.8 ± 0.5 x 107

M272L

503 ± 10

9±1

8±1

5.5 ± 0.6 x 107

54 ± 7

5±1

46 ± 5

1.2 ± 0.3 x 106

M272R

670 ± 5

12 ± 1

7±1

5.5 ± 0.2 x 106

386 ± 37

4±1

19 ± 1

2.1 ± 0.6 x 107

478 ± 13

6±1

8±1

1.4 ± 0.3 x 106

NADH- analog, H4NAD and

NAD+ (Figure 44). Changes in the FAD absorption

spectrum following binding of H4NAD to the respective proteins were observed for the
M272L, M272I and M272A variants, however, no spectroscopic changes were detected
for either the M272- or M272R variants, suggesting substantially altered affinities. For
the M272L, I, and A variants, characteristic spectral changes were observed with
lineshapes comparable to those recorded for the wild-type enzyme following complex
formation with H4NAD.
Similar behavior was observed for the differential spectra obtained from the titrations of
the various mutants with NAD+. While the M272A, I and L mutants generated spectra
that were comparable both in lineshape and intensity to those obtained for wild-type cb5r,
no differential spectra were obtained for either the M272- or M272R variants at
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concentrations of NAD+ up to 10 mM, indicating either substantially decreased affinities
for both mutants or an altered mode of NAD+ binding (Table 17).

Figure 44. Flavin Difference Spectra Obtained Following Binding of Either H4NAD
or NAD+ to the Various M272 cb5r Mutants. Difference spectra were obtained for the
different M272 variants and wild-type cb5r at equivalent flavin concentrations (50 µM
FAD) in 20 mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0 following titrations
with either H4NAD (left panels) or NAD+ (right panels) as described in “Methods”. The
insert panels correspond to plots of the magnitudes of the observed spectral perturbations
(peak to trough measurements at the indicated wavelengths) versus ligand concentration.
Plots of the relative absorbance changes observed are as follows: A and B: H4cb5r; C and
D: M272A; E and F: M272I; G and H: M272L; I and J: M272- (Titrations of M272R
yielded spectra identical to those of M272-). The corresponding Ks values are given in
Table 17.
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Table 17. Spectral Binding Constants Obtained for Wild Type cb5r and the M272-,
M272A, M272I, M272L, and M272R Variants.

H4cb5r

Ks H4NAD
(µM)
45 ± 10

KsNAD+
(µM)
760 ± 30

M272-

ND

ND

M272A

98 ± 11

891 ± 51

M272I

204 ± 10

1078 ± 66

M272L

106 ± 7

2293 ± 125

Mutant

M272R

ND

ND

*ND indicates that either there was no detectable activity or no detectable spectroscopic change associated
with the purified cb5r variant.

To examine whether the substitution or deletion of residue M272 influenced
NADH

utilization

through

modulation

of

the

flavin

oxidation-reduction

midpointpotential, potentiometric titrations were performed using the dye equilibration
method for wild-type cb5r and the different M272 variants in the presence of
phenosafranine (Eo’= -252 mV) as indicator dye. Flavin midpoint potentials (Eo’, n=2)
were determined for the enzymes alone and in complex with NAD+. The spectra obtained
during representative titrations of the M272A variant in the absence of NAD+ are shown
in Fig. 6A. Qualitative analysis of the individual spectra obtained from the various
titrations indicated that the majority of the phenosafranine was reduced prior to FAD
reduction for the majority of the M272 variants and wild-type cb5r in the absence of any
pyridine nucleotide, suggesting the flavin midpoint potentials were more negative than
that of phenosafranine, for all the cb5r variants examined except for the M272- mutant.
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For the M272- variant, the spectra indicated that both the protein and dye were
effectively reduced simultaneously, suggesting a significantly more positive potential for
the FAD/FADH2 couple in this mutant than observed for wild-type cb5r or any of the
other M272 mutants.
In contrast to the results obtained for the different M272 variants in the absence of
NAD+, titrations performed in the presence of NAD+ revealed very different redox
behavior. Analysis of the spectra obtained for the M272A, I and L variants together with
wild-type cb5r indicated that all four proteins were reduced well in advance of the
phenosafranine dye, suggesting that complex formation significantly perturbed the flavin
midpoint potentials to values more positive than that for phenosafranine for these three
mutants. In contrast, the presence of NAD+ had a markedly decreased effect on the
potential of the FAD/FADH2 couple in the M272R variant and effectively, no effect on
the M272- mutant, suggesting little perturbation or modulation of the FAD redox
potential in these two variants.
The flavin redox potentials (n=2) for the different M272 variants and wild-type
cb5r alone or as the enzyme-nucleotide complex were determined from the Nernst semilog plots shown in Figure 45. The standard midpoint potentials obtained for the
FAD/FADH2 couple in both the wild-type enzyme (Eo’= -272 mV) and the M272A, I and
L variants (Eo’= -271 mV to -275 mV) were approximately equivalent for all three
proteins in the absence of any pyridine nucleotide, the values spanning a range of only 4
mV. In contrast, the flavin midpoint potential in the M272- and M272R variants were
determined to be 27 mV and 12 mV, respectively, more positive than the corresponding
midpoint potential observed for the wild-type cb5r.
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Figure 45. Comparison of the Oxidation-Reduction Midpoint Potentials for the FAD
Prosthetic Group in the Different M272 Variants. Reductive dye-equilibration
titrations of wild-type and the different M272 variants of cb5r (40 µM FAD) were
performed as described under “Methods” in 100 mM phosphate buffer, containing 0.1
mM EDTA, pH 7.0 in the presence of phenosafranine (15 µM, Eo’=-252 mV). Individual
spectra were collected at 2-3 min intervals during the time course of the titrations. (A):
Selected spectra obtained during the titration of the M272A mutant. (B): Nernst plots
obtained for the FAD/FADH2 couple (n=2) are shown for the titrations of the various
M272 cb5r mutants in the absence of NAD+ and correspond to: M272- (+, Eo’=-245+5
mV), M272A (∆, Eo’=-271+5 mV), M272I (V, Eo’=-274+5 mV), M272L (□, Eo’=275+5 mV), M272R (◊, Eo’=-258+5 mV) and wild-type cb5r (○, Eo’=-272+5 mV). (C)
Nernst plots obtained for the FAD/FADH2 couple (n=2) are shown for the titrations of
the various M272 cb5r mutants in the presence of NAD+ and correspond to: M272- (+,
Eo’=-244+5 mV), M272A (▲, Eo’=-192+5 mV), M272I (▼, Eo’=-192+5 mV), M272L
(■, Eo’=-191+5 mV), M272R (♦,Eo’=-220+5 mV) and wild-type cb5r (●, Eo’=-190+5
mV).
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The decreased affinity for NAD+ that was determined for both the M272R and
M272- mutants was also reflected in alterations in the shifts and slopes of the Nernst
plots when compared to the wild-type domain. In contrast, while the presence of NAD+
resulted in no perturbation of the FAD/FADH2 redox potential or change in slope for the
M272- mutant, for the M272R variant, the degree of perturbation was substantially
decreased which was coupled with no apparent change in slope of the Nernst plot
suggested that nucleotide binding did not result in any appreciable semiquinone
formation. In the presence of NAD+, the redox potential of the FAD/FADH2 couple in the
wild-type enzyme was positively-shifted by +77 mV (Eo’= -195+5 mV) which was
comparable to the magnitude of the positive shifts observed for the potentials of the
M272A, I and L variants. In contrast, substantially small shifts were observed in the
potentials of the FAD/FADH2 redox couple in both the M272R and M272- mutants,
which corresponded to +37 mV and +1 mV, respectively.
To assess the potential structural changes that would be anticipated to result from
the deletion of the M272 residue, we utilized homology modeling to construct a model of
the M272- variant using the experimental wild-type structures as templates. The
superposition of the structures of the wild type enzyme and the M272- deletion mutant
are shown in Figure 46. The modified loop containing the “CGxxxxM” NAD(P)H
binding motif was strongly anchored by its connection to an interior β strand. In the wild
type structure, M272 and C273 both occupy positions close to those expected for β strand
extensions, but the final flanking β strand does not extend sufficiently far enough to reach
these residues and they are slightly displaced relative to the neighboring interior strand
residues, making any backbone hydrogen bonds very weak. The residue preceding M272
134

Figure 46. Comparison of a Structural Model of the M272- Mutant and the WildType cb5r Diaphorase Domains. The X-ray structures obtained for the rat cb5r
diaphorase domain in the absence (PDB ID = 1I7P) and complex with NAD+ (PDB ID =
1IB0) were used as templates to generate a structural model for the M272- variant. (A)
The overall backbone architecture of the wild-type (yellow) and M272- mutant (red) are
superimposed and displayed as a cartoon ribbon model. The FAD prosthetic group is
shown in “ball and stick” representation with individual atoms colored using the “CPK”
convention. (B) An expanded portion of the PDB 1IB0 structure is displayed that shows
the spatial relationship between the region of the polypeptide sequence corresponding to
residues M272 to M278 and the bound NAD+.
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is a full participant in interior sheet hydrogen bonding. Thus, the removal of residue
M272 in the deletion mutant forces the subsequent cysteine residue (C273) to occupy the
position comparable to that of M272 in the wild-type structure. Consequently, this
deletion shortens the loop connecting the β strand with the following α-helical return.
A primary consequence of this structural alteration is represented in figure 46
where the displacement of the loop backbone is shown by the path of the green ribbon
that corresponds to the mutant structure in comparison to the red ribbon that corresponds
to the experimental wild-type structure. The wild type polypeptide makes five hydrogen
bonds with NADH (a sixth is supplied by bound water); two of these would be disrupted
by displacement of the loop, and the hydrophobic interactions between NAD+ and the
proline residues would also be weakened. Possible secondary effects could also result
from the structural alterations.
To examine the predictions generated by the modeling studies of the M272- variant and
the comparison with the experimental structures of the wild-type enzyme, we examined
the binding of two NAD+ analogs, 5’-ADP-ribose and 5’-ADP, which correspond to
successively truncated derivatives of NAD+, using differential spectroscopy. The
structural model derived for the M272- variant indicated that if the loop region containing
the “CGxxxxM” motif was displaced relative to its position in the wild-type structure, the
major predicted impact would be to decrease the affinities for both 5’-ADP-ribose and 5’ADP, since the X-ray structure of wild-type cb5r in complex with NAD+ has revealed that
the “CGxxxxM” motif is primarily involved in interactions with the adenosine portion of
NAD+ where it contributes an extensive network of hydrophobic contacts. The
differential spectra shown in Figure 47, revealed that while both NAD+ fragments form
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Figure 47. Difference Spectra and Spectral-Binding Constant Determination for
Wild Type Cytochrome b5 Reductase and the M272- Variant with various Pyridine
Nucleotide analogs. Enzyme samples (50 µM FAD) in 10mM MOPS buffer, containing
0.1 mM EDTA, pH 7.0 were titrated with the indicated pyridine nucleotides {Panel A –
wild-type cb5r + NAD+, Panel B – M272- + NAD+, Panel C - wild-type cb5r + ADP
ribose, Panel D – M272- + ADP ribose, Panel E - wild-type cb5r + 5’ ADP, Panel F –
M272- + 5’ ADP} as described in “Materials and Methods”. The difference spectra
obtained during the titrations are shown. The inset panels correspond to a plot of the
spectral perturbations (peak to trough subtraction) versus pyridine nucleotide
concentration.
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spectroscopically-detectable complexes with the M272-variant, suggesting either
substantially-decreased affinities for both 5’-ADP-ribose and 5’-ADP or that both ligands
were bound in very different conformations than their respective orientations in the wildtype complexes, confirming the results that were predicted from the M272- modeling
studies that suggested that the displacement of the hydrophobic “CGxxxxM” loop would
have a substantial adverse impact on the affinity for NADH and the various analogs.

Summary of the Recessive Congenital Methemoglobinemia Variant M272An extensive number of mutations have been identified in the DIA1 gene that
codes for cb5r and result in RCM. Previous studies of the majority of the known cb5r
methemoglobinemia mutants that utilized a novel cb5/cb5r fusion protein have indicated
that the M272- variant was the most compromised mutant in terms of specific activity
[40]. Davis et al. have shown that using the NCR expression system, the M272- variant
only retained <0.01% of the wild-type NADH:CR specific activity.
The model structure described in the preceding results section demonstrates that
effects involving the “CGxxxM” motif are unavoidable in the M272- mutant. These
effects could account for the substantially-weakened binding of NADH to the M272mutant, when compared to the NADH-affinities of the other M272 variants, if the
combination of hydrogen-bonding to the phosphate groups and hydrophobic interactions
between NAD(H) and this motif are a significant factor in NADH binding.
In the wild type protein, the hydrophobic C273 side chain is positioned
approximately 4.2 Å from the si-face of the FAD isoalloxazine ring system, and is in Van
der Waals contact with the nicotinamide moiety of NAD+. This suggested the possibility
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that C273 is involved in controlling the equilibrium between the unstacked configuration
of bound NADH and the charge transfer complex. In the M272- deletion mutant, the
cysteine side chain would be displaced into approximately the position of the M272 wildtype side chain, and the next residue, G273, would be unable to compensate because it
effectively lacks a side chain.
Secondary effects could also play a role in the reduced affinity of the deletion
mutant for NADH. Such effects could be propagated through small displacements in the
neighboring loops which make up nearby sections of the NADH binding site. For
example, a small reorientation of the α-helical region following the “MCGxxxM” motif
could reduce the space available for binding the adenine moiety, forcing some
reorganization of the loop containing F251, the stacking residue for adenine in the wildtype structure.
The possible contribution of secondary effects of this kind could be investigated
by measuring the affinity of phosphorylated adenenines for the site. In homologues such
as cytochrome P450 reductase and Ferredoxin:NADP+ reductase, partial NADPH analogs
such as 2’-AMP and 2’5’-ADP are inhibitors (and in some cases activators) because they
compete with NADPH. The FAD and pyridine nucleotide binding sites in these enzymes
have features which cb5r lacks, including a stacking residue supplied by the carboxylterminal region for the FAD isoalloxazine and interdomain hydrogen bonds to the
pyridine nucleotide.
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Characterization of the type I Recessive Congenital Methemoglobinemia mutant
P275L
Using the high-resolution x-ray structural model of the soluble rat cb5r diaphorase
domain, [21] which has been solved in both the native state and complexed with NAD+
and shares 95% sequence conservation with the human variant, it was possible to make
predictions regarding the effects of naturally occurring mutations on the function of cb5r.
With the development of a heterologous expression system [21] [79] it was possible to
confirm these predictions and to provide important insights into the structure-function
relationships of variants with a view to dissecting the mechanisms involved in the
development of both types of RCM. For example, previous studies of the S127P type II
variant using the rat model were the first to provide detailed structural evidence to
explain the effects of this mutation in terms of perturbation of the conformation of the
bound FAD prosthetic group substantially decreasing the enzyme’s catalytic efficiency
[80].
We have identified an infant, cyanotic at birth, who was found to be compound
heterozygous for a novel mutation, P275L, and the previously described G291D mutation
[107] [85]. Expressing the G291D variant had indicated that the enzyme activity and
thermostability of the cb5r variant were decreased [79], but it was unknown if the two
mutations together would have a synergistic effect. The rat model indicated that the P275
residue was located in a highly conserved region that interacted with the NADH reducing
substrate [21]. To understand how substitution of P275 would affect the function of cb5r,
the P275L variant was generated using our heterologous expression system and enzyme
activity, thermostability, and substrate affinity were determined.
141

The propositus was the first live child of non-consanguineous parents of
English/Scottish and Northern European with Cherokee Indian descent. He was born at
full term from spontaneous vaginal delivery to a 31-year-old mother with a history of
depression, Crohn’s disease and anklyosing spondylitis.

Bextra for anklyosing

spondylitis and Wellbutrin for depression were ceased when the mother became pregnant
but she remained on Prozac for depression and Asacol for Crohn’s disease.

The

pregnancy was otherwise unremarkable but a nuchal cord was present at delivery. Apgar
scores were recorded as 7 at 1 minute and 8 at 5 minutes. At 14 hours of age, the infant
was noted to be cyanotic even though his O2 saturations for hemoglobin were in the range
of 90% and the methemoglobin level was found to be 13.2%.

The infant was

administered a dose of intravenous methylene blue and the methemoglobin level
promptly fell to 1.8%. It slowly increased over the next two weeks to reach 10.2%.
Several checks over the next few months indicated that he had a baseline methemoglobin
level ranging between 10.2% and 11.2%. Measurement of cb5r activity detected a level
of 0.5 IU/g Hb (normal range 8.2-19.2 IU/g Hb) at two and seven weeks and on
subsequent measurement at 14 months was 0.6 IU/g Hb. Both parents were found to
have normal cb5r activity with measurements of 13 and 18 IU/g Hb for the father and
mother respectively. Clinically, he had some mild perioral cyanosis but remains well at
14 months without medication.
The DIA1 gene of the cyanotic infant was sequenced and a novel C to T change in
exon 9 (C27161T; NCBI accession number: NT_011520) and a G to A change, also in
exon 9 (G27209A; NCBI accession number: NT_011520) were detected, as shown in
Figure 48.

These nucleotide changes predicted P275L and G291D mutations.
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Sequencing both phenotypically normal parents revealed that neither mutation had arisen
de novo in the infant with the father and the mother being heterozygous for the P275L
and G291D mutations, respectively. The G291D variant has been described before [78]
in the original family described by Gibson [44] and a second Northern Ireland family
[107]. It is likely that the G291D variant had arisen independently in Northern Ireland
and America, but performing haplotype studies may indicate if there is indeed a common
origin for the G291D variant. Both mutations are located in the NADH-binding lobe of
cb5r and it is unknown if the two mutations together would have a synergistic effect.
Using the rat model, it was possible to predict that since P275 is located in a conserved
sequence motif corresponding to “273CGPPPM278” it is important for binding and correct
positioning of the NADH reducing substrate, thus the P → L mutation would adversely
affect functionality. Thus, substitution of proline with leucine would be expected to
result in the leucine side chain extending into the NADH-binding cavity thus sterically
precluding NADH binding in the normal wild-type position.

A mutant construct

encoding the P275L cb5r variant, which corresponded to the third residue in the
conserved “CGPPPM” sequence motif, was generated using site-directed mutagenesis of
the original four-histidine tagged cb5r construct. Dideoxy sequencing confirmed that the
fidelity of the construct and the mutant protein was subsequently expressed in the E. coli
strain BL21(DE3)-RIL and purified by metal-chelate affinity chromatography and gel
filtration FPLC. Evaluation of the expression yield of the P275L variant indicated an
expression efficiency comparable to that of the wild-type cb5r domain, indicating the
production of a stable protein product which could be purified to apparent homogeneity
as indicated by the presence of a single protein band following
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GGACCACGTGGNCCACCCCAC

GTGTGGCCNCCCACCCATGAT

27,153
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27,998
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27,218
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GTGTGGCCCCCCACCCATGAT
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GGACCACGTGGNCCACCCCAC

F

GTGTGGCCNCCCACCCATGAT
27,153

27,218

GGACCACGTGGGCCACCCCAC
27,173
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Figure 48. Detection of the C27161T and G27209A Mutations in the DIA1 Gene.
Sequencing of exon 9 of the DIA1 gene detected two heterozygous base changes of C to
T at nucleotide 27,161 (A) and G to A at nucleotide 27,209 (D) in the propositus as
indicated by arrow in chromatogram. The father (B and E) was heterozygous for the
G27209A change while the mother (C and F) was heterozygous for the C27161T
mutation. Bases are as follows: G = black; A = green; T = red; C = blue.
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SDS-PAGE analysis (Figure 49). The P275L cb5r variant and the native enzyme were of
comparable molecular mass, while MALDI-TOF analyses revealed the presence of a
characteristic peak in the low mass region of the spectrum with a m/z of 792, indicative of
the presence of FAD as the sole prosthetic group. These findings suggested that residue
P275 did not provide backbone or side-chain contacts that were essential for the stable
incorporation of the FAD prosthetic group into cb5r.
UV/Visible absorbance spectra were obtained for both an oxidized sample of the
P275L variant and wild-type cb5r as a control and are presented in Figure 50A. The
P275L variant exhibited a spectrum comparable to that of the wild-type enzyme with an
aromatic maximum observed at 273 nm in the UV region of the spectrum, and a peak at
461 nm with an associated pronounced shoulder in the range of 485-500 nm in the visible
region of the spectrum, attributable to protein-bound flavin.
To compare the secondary structural content of the P275L variant with that of the
wild-type protein, circular dichroism (CD) spectra were recorded in the UV wavelength
range (190-300 nm). As shown in Figure 50B, the P275L variant exhibited positive CD
from 190 to 210 nm and the negative CD from 210 to 250 nm with the spectrum retaining
both negative and positive intensities very similar to those of the wild-type domain. The
absence of any significant differences between the spectra of the mutant and wild-type
protein suggested secondary structural conservation and that the P to L residue
substitution had no deleterious effects on the folding of the diaphorase domain. Similar
results were observed for the corresponding visible CD spectra. CD measurements were
performed in the near UV/Visible range (300-600 nm) in order to probe the possible
effects of the P275L mutation on both flavin conformation and polarity of the prosthetic
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Figure 49. SDS-PAGE Analysis of the P275L cb5r Variant. Samples (2 µg protein)
obtained following isolation of the P275L variant and wild-type cb5r were analyzed using
a 15 % polyacrylamide gel as described in “Methods”. Individual lanes correspond to: S,
protein molecular weight markers; A, P275L variant; B, wild-type cb5r.
group microenvironment. As shown in Figure 50C, the spectrum of the P275L mutant
was unperturbed when compared to that of wild-type cb5r, exhibiting positive and
negative maxima at approximately 400 and 460 nm, respectively, suggesting no
significant change in either the polarity of the flavin environment or the conformation of
the bound prosthetic group.
To examine the influence of the P275L residue on the stability of the resulting
protein, thermal denaturation profiles were generated for both the P275L and wild-type
cb5r by measuring changes in both intrinsic flavin fluorescence emission (λex = 450 nm
and λem = 523 nm) and retention of NADH:ferricyanide reductase (NADH:FR) activity
following incubation of the proteins at temperatures ranging from 0 °C to 100 °C (Figure
51). Thetemperature (T50) at which 50% of maximum fluorescence was detected or 50%
of the protein’s NADH:FR activity was retained, were effective indicators of the stability
of the core structure of the protein. The T50 value obtained for the P275L variant was
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Figure 50. UV/Visible Absorption and CD Spectra of the P275L cb5r Mutants. (A)
UV/visible absorption spectra were obtained for oxidized samples of the P275L mutant
and wild-type cb5r, as a control, at equivalent flavin concentrations (10 µM FAD) in 10
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. The inset shows an expanded
region of the visible spectrum where the flavin prosthetic group makes a major
contribution. (B) UV CD spectra were recorded using enzyme samples (7 µM FAD) in 10
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible CD spectra were
recorded using enzyme samples (50 µM FAD) in 10 mM phosphate buffer, containing
0.1 mM EDTA, pH 7.0. Individual spectra correspond to P275L ( - - - ); wild-type cb5r
( ___ ).
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approximately 2 °C lower than that of wild-type cb5r, suggesting that the residue
substitution had no significant effect on the thermal stability of the mutant protein.
To further confirm that the proline to leucine substitution had no substantial
effects on the flavin environment, oxidation-reduction potentials were determined for the
FAD/FADH2 couple (E°′, n = 2) in both the P275L variant and the wild-type cb5r using
dye-equilibration potentiometery in the presence of phenosafranine as a redox indicator.
Representative spectra obtained during the redox titration of the P275L mutant are shown
in Figure 52A, and provide an example of the nature of the spectral changes observed
during the dye-equilibration redox titrations while the corresponding Nernst plots
obtained for both P275L and wild-type domain, both in the absence and presence of
NAD+, are presented in Figure 52B. The redox potential of the P275L variant was within
10 mV of wild-type cb5r in the absence of NAD+, confirming that the mutation had little
effect on the thermodynamic properties of the FAD prosthetic group. However, in
contrast, the redox potential obtained for the P275L variant in the presence of NAD+ was
significantly more negative than that obtained for the wild-type domain in the presence of
NAD+, indicating a decreased affinity of the mutant for binding the pyridine nucleotide.
As a measure of catalytic efficiency, both NADH:FR and NADH:BR activities
were determined for the P275L variant and compared with that of wild-type cb5r. Kinetic
constants derived from these assays are reported in Table 18, and indicated that the
P275L mutant exhibited a decreased NADH:FR turnover number compared to that of
wild-type cb5r.Comparison of the specific activities of the mutant and wild-type cb5r
indicated that the mutant retained 92% of wild-type NADH:FR activity. However, the
Michaelis constant (Km) for NADH utilization increased 437 fold, from 6 µM to 2.6 mM,
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Figure 51. Temperature Stabilities of the P275L cb5r Mutant. Samples of the purified
P275L mutant and wild-type cb5r (20 µM) were incubated in microfuge tubes as
described in “Methods”. Flavin fluorescence emission spectra were determined at each
temperature and the emission maxima at 524 nm plotted as a percentage of total
fluorescence. Total flavin fluorescence was determined by measuring a similar dilution of
the remaining stock solution following heating at 100 º C for 30 min. P275L ( ); wildtype cb5r ({). Residual NADH:FR activities were determined at 340nm for each
temperature as described in “Methods” and correspond to P275L () and wild-type cb5r
(z).
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Figure 52. Potentiometric Titrations of the P275L cb5r Mutant. Reductive dyeequilibration titrations were performed at 25 oC as described under “Methods” using
phenosafranine (Eo’=-252 mV) as the indicator in 100 mM phosphate buffer, containing
0.1 mM EDTA, pH 7.0. (A) Representative spectra obtained during the titration of P275L
in the absence of NAD+ are displayed. (B) The Nernst plots of log
([oxidized]/[reduced])FAD versus potential correspond to P275L in the absence (, Eo’= 264+5 mV) and presence ( , Eo’=-212+5 mV), respectively of 2 mM NAD+. Also
shown are the Nernst plots obtained for wild-type cb5r as a control in the absence (z,
Eo’=-272+5 mV) and presence ({, Eo’=-192+5 mV), respectively, of 2 mM NAD+.
Flavin reduction was monitored at 410 nm, an isosbestic wavelength for phenosafranine
reduction and phenosafranine reduction was monitored at 530 nm, an isosbestic
wavelength for flavin reduction. Flavin midpoint potentials for the FAD/FADH2 couple
(n=2) were determined from the Nernst plots and yielded the indicated standard reduction
potentials (Eo’). Only selected data points obtained from each of the titrations are shown
for clarity.
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indicating that the dominant effect of the mutation was a substantial decrease in the
affinity for the reducing substrate. In contrast, the Michaelis constant for the artificial
electron acceptor ferricyanide was similar to that of wild-type cb5r, suggesting that the
mutation did not affect the binding of this artificial oxidizing substrate. The effect of the
proline to leucine substitution on the overall NADH:FR catalytic efficiency of the
enzyme, reflected in the kcat/KmNADH value, was to retain only 0.2% of wild-type
NADH:FR catalytic efficiency.

These results suggested that the lower catalytic

efficiency observed for the mutant was the result of the decreased affinity for NADH,
rather than any decreased affinity for cb5.
Assays were also performed to ascertain if the proline to leucine substitution had
any effect on the selectivity of the enzyme for either NADH or NADPH. As shown in
Table 18, the NADPH-dependent diaphorase activity decreased together with the affinity
for NADPH. However, the specificity constant, defined as the ratio of the catalytic
efficiencies with NADPH and NADH, increased 5-fold when compared to the value
obtained for the wild-type enzyme, indicating that P275 plays only a very modest role in
regulating NADH/NADPH specificity.
To confirm the effects of the P275L substitution on the affinities for either
NADH or NAD+, spectral binding constants (Ks) were determined using differential
spectroscopy. Representative spectra obtained from the P275L mutant and the wild-type
enzyme with either H4NAD or NAD+ is shown in Figure 53. While perturbations of the
flavin visible absorbance spectrum were detected for the wild-type enzyme, no complex
formation could be detected for the P275L variant with either compound, reflecting the
substantially decreased affinity for either H4NAD or NAD+.
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Table 18. Comparison of the Kinetic and Spectroscopic Binding Constants Obtained
for the P275L Variant of cb5r.

Mutant

P275L
Wild Type

NADH:FR

NADH:BR

kcat
KmNADH
(s-1)
(µM)

kcat/KmNADH
(s-1 M-1)

733+7 2623+460

2.8+0.1x105

67+18

800+21

1.4+0.3x108

600+17 12+1

6+1

kcat
KmCyt b5
(s-1) (µM)
4+1

NADPH:FR
kcat

(s-1)

Specificity
Constant
∆a

KmNADPH kcat/KmNADPH
(µM)
(s-1 M-1)

0.45

1123

4.0x102

1.4x10-3

33

924

3.6x104

2.7x10-4

Summary of they Type I RCM Variant P275L
The identification of the novel P275L RCM variant represents the discovery of
the eighth mutation in exon 9 of the DIA1 gene. Five variants (V252M, R258W, P264L,
P275L, and G291D) and a deletion mutant (E255-) [82-85, 106, 116] have been found to
be associated with type I RCM while two other deletion mutants (M272- and F298-) [31,
81] “273CGPPPM278” that is present in the majority of known cb5r sequences and is also
found in other members of the ferredoxin:NADP+ reductase superfamily of flavoprotein
transhydrogenases [5]. The X-ray structure of the rat cb5r diaphorase domain complexed
with NAD+ (PDB code: 1IB0) has revealed that P275 is part of a solvent-accessible loop
region located between sheet Nβ5 and helix Nα4 within the carboxy-terminal pyridine
nucleotide-binding lobe [21]. Within this structure, NAD+ has been shown to bind in an
extended conformation along a plateau that is formed by three proline residues, P275P277. The conformation of the bound NAD+ is shaped largely by P275 and bends around
it with the pyrophosphate moiety packed against it and with the nicotinamide proximal
ribose packed parallel to the proline ring (Figure 54B), suggesting that substitution of
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Figure 53. Spectroscopic Titrations of the P275L Mutant with H4NAD and NAD+.
Titrations of the P275L cb5r variant (50 µM FAD) were performed in split cell optical
cuvettes in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0, at 23 º C.
Difference spectra were recorded, following additions of a concentrated solution of either
H4NAD (50 mM) or NAD+ (100 mM) to both sample and reference cuvettes, after the
complete cessation of all absorbance changes. The inset panels correspond to plots of the
magnitude of the spectral perturbations at the indicated wavelengths versus pyridine
nucleotide concentration where a difference spectrum was observed. The plots of relative
absorbance changes observed during the titrations are as follows: (A and B), P275L in the
presence of H4NADH and NAD+. (C and D) wild-type cb5r in the presence of H4NADH
and NAD+.
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P275 would be anticipated to have profound effects on both binding and subsequent
orientation of the nucleotide. The results of the biophysical characterization of the P275L
variant are in full agreement with this prediction. The proline to leucine substitution was
observed to have no detectable effects on either the spectroscopic or thermodynamic
properties of the flavin prosthetic group in the absence of NAD+. In addition, protein
folding and stability were unaffected by the mutation. In contrast, the proline to leucine
substitution exhibited a profound effect on both the affinity of cb5r for the reducing
substrate and its catalytic efficiency.
Homology modeling of the P275L structure suggested that substitution of the
hydrophobic leucine side chain would not be expected to perturb the overall folding and
structural organization of the protein as shown in the overlay of the ribbon diagrams for
the P275L and wild-type proteins in Figure 54A. However, the linear isobutyl side chain
would be anticipated to protrude into the NADH-binding site when compared to that of
the wild-type proline structure, as shown in the electrostatic surface plots in Figure 54B
and Figure 54C, resulting in steric hindrance and decreased binding affinity. These
predictions are in agreement with the results of both the initial-rate kinetic and pyridine
nucleotide Ks analyses. The absence of any spectral changes observed in either the
H4NAD or NAD+ titrations, suggested that the Ks’s for these two compounds would be
expected to be greater than approximately 1 and 5 mM , respectively, which are
substantially greater than the values of 46 and 663 µM, respectively, obtained for the
wild-type domain.
The molecular mechanisms responsible for the striking difference in phenotype
between type I and type II RCM have not yet been satisfactorily explained. Studies of
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P275

A

B

C

D

Figure 54. Homology Model of the P275L cb5r Variant. (A) Superposition of the rat
cb5r X-ray structure (yellow; PDB code 1IB0) and the homology modeled P275L (red)
structure. Both structures are shown as ribbon diagrams that represent the regions of
secondary structure. The FAD prosthetic group, complexed NAD+, and residue P275,
indicated by the arrow, are shown in “stick” representation using the CPK coloring
scheme. (B) Rendering of the sequence region, corresponding to I270 to F281, that
surrounds residue P275. The peptide backbone is drawn in ribbon configuration while
the proline (gray) and leucine (magenta) side chains at position P275 in the position 275
in the wild-type and mutant proteins are shown in “stick” representations. Also shown is
the complexed NAD+ in “stick” configuration with “CPK” coloring. (C and D)
Renderings of the sequence region, corresponding to I270 to F281, which surrounds
residue P275. The peptide backbone is shown in ribbon configuration while the proline
(C) and leucine (D) side chains at position 275 in the wild-type and mutant proteins
together with the complexed NAD+ are shown in an electrostatic surface representation
with negatively and positively charged regions colored in red and blue, respectively.
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naturally occurring mutations of cb5r using the heterologous expression system will
permit accumulation of data on the structure-function relationships of the enzyme. It is
of interest that some mutations have been found in both types of disease, while the
majority appear to be confined to one type. The novel P275L is the fifth single amino
acid substitution in the protein domain encoded by exon 9. In general these mutations
affect the affinity and activity of cb5r for NADH and may primarily or uniquely affect the
heme iron reductase function of the enzyme. However, cb5r has pleiotropic functions and
mutations in the more 5′ regions of the gene may disrupt some of these thereby causing
neurological impairment.

Identification and characterization of the novel FAD-binding lobe G75S mutation in
cytochrome

b5

reductase:

An

aid

to

determine

recessive

congenital

methemoglobinemia status in an infant.
Recently, we identified a four-month old infant with a novel G to A change in the
last base of exon 3 in the DIA1 gene. This resulted in the substitution of glycine with
serine at residue 75 in the FAD-binding lobe of cytochrome b5 reductase. The infant was
compound heterozygous for the previously characterized V252M mutation [82-84] which
is located in the C-terminal NADH-binding lobe of cytochrome b5 reductase. Being
compound heterozygous for mutations that would impair both the FAD and NADH
function of cytochrome b5 reductase would suggest the more severe clinical form of
RCM. Thus, to provide insight at the molecular level and potentially to assist in the
diagnosis of recessive congenital methemoglobinemia status, we generated and
characterized the G75S, V252M and the corresponding double G75S/V252M cytochrome
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b5 reductase variants using the rat heterologous expression system [79, 105]. The patient
was compound heterozygous for the G75S and V252M cytochrome b5 variants and thus
synthesized both individual variants. However, while the homozygous double mutant did
not occur in the patient, we were interested in generating the double mutant as an initial
approach to investigate potential synergistic effects on either the structural or functional
properties of the enzyme when both mutations occurred together in the same protein.
Although the human erythrocytic form of cytochrome b5 reductase was recently
described [20], the rat system is the only variant that has been used to characterize all the
known methemoglobin amino acid mutations in terms of their effects on the expression,
relative activities, and stability of the various proteins [79]. In addition, there is 95%
sequence similarity between these two species with any non-conserved amino acid
substitutions occurring in functionally insignificant regions of the protein.
The kinetic, protein stability, and cofactor oxidation-reduction potential
properties were determined for all three variants and compared to the properties of wild
type cytochrome b5 reductase and other methemoglobinemia-causing mutations,
including E255-, G291D, and D239G [79, 105].
The proposita was the second child of non-consanguineous parents of
Mediterranean descent. Cyanosis was noted at birth accompanied by reduced oxygen
saturation determined by pulse oximetery but normal pO2 on arterial blood gas analysis
and no evidence of cardiopulmonary abnormality. Methemoglobinemia was detected at a
level of 14.4%. At the age of 4 months, the infant was referred for assessment of
persistent methemoglobinemia. Physical examination revealed no developmental delay
or microcephaly.

Erythrocyte cytochrome b5 reductase activity was assayed
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spectrophotometrically at 340 nm as the rate of oxidation of NADH in the presence of
potassium ferricyanide as previously described [117].

Measuring cytochrome b5

reductase activity indicated that the infant showed a marked reduction with an activity of
only 0.5 U/gHb while both the father (4.9 U/gHb) and the mother (5.0 U/gHb) had ~50%
of the residual enzyme activity as defined by the adult reference range of 7.2-13.9 U/gHb.
Sequencing of the DIA1 gene in the infant revealed a novel G to A change in the
last base of exon 3 (G15,635A; genomic sequence NCBI NT_011520) and a G to A
change in exon 9 (G 27,091A; genomic sequence NCBI NT_011520), resulting in amino
acid exchanges of glycine to serine at residue 75 and valine to methionine at residue 252,
respectively (Figure 55).

Screening the parents indicated that the father was

heterozygous for the G75S variant, and the mother was heterozygous for V252M. The
G75S mutation is located in the amino-terminal FAD-binding lobe of cytochrome b5
reductase, as shown in Figure 56, while the V252M mutation is present in the carboxyterminal NADH-binding domain.

Thus, the infant was compound heterozygous for

mutations in both the prosthetic group and substrate binding lobes of cytochrome b5
reductase. In contrast to the G75S mutation, the V252M variant has been previously
described either in the homozygous state in both types I and II patients [82, 84] or in
combination with the I215T mutation [83], which is also located in the NADH-binding
lobe. To determine how these two radically different mutations would affect the function
of cytochrome b5 reductase, both the G75S and V252M variants and the corresponding
double mutant were generated using our heterologous expression system.
E. coli BL21 RIL cells harboring the expression plasmids for either rat G75S,
V252M or G75S/V252M cytochrome b5 reductase variants were grown, disrupted and the
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three mutant proteins were purified using a combination of Ni-NTA agarose affinity and
gel filtration chromotographies as previously described [76].

Qualitative analysis

indicated that all three mutants were obtained in substantial quantities and were expressed
with efficiencies comparable to that of wild-type cytochrome b5 reductase. All three
proteins were yellow in color indicating flavin incorporation and were purified to
apparent homogeneity as indicated by the appearance of single protein bands following
SDS-PAGE analysis as shown in Figure 57. The three cytochrome b5 reductase variants
exhibited molecular masses of approximately 32 kDa confirming the production of full
length proteins.
Spectroscopic analysis, including UV/visible absorption and CD spectra, revealed
that G75S, V252M, and G75S/V252M variants retained identical spectroscopic
properties to those of the wild-type protein with UV/visible absorption maxima at 276,
386, and 461 nm, respectively, that indicated a full complement of FAD incorporation
and that the flavin was present in an environment spectroscopically indistinguishable
from that of the native domain (Figure 58A). UV and CD spectra indicated an absence of
any significant change in protein architecture suggesting comparable protein folding
(Figure 58B and Figure 58C). Thus, neither the G75S nor V252M, or a combination of
both mutations did not appear to adversely affect the global folding of the respective
proteins while the substantial similarities in the visible CD spectra indicated that the
flavin prosthetic groups were in a similar environment in all the proteins examined.
In contrast, both NADH:FR and NADH:BR activity assays revealed that
theG75S, V252M and G75S/V252M double mutant exhibited substantially decreased
activity, as shown by the kinetic constants given in Table 19. The G75S variant
160

Figure 55. Detection of the G15,635A and G27,091A Mutation in the DIA1 Gene.
Sequencing of exon 3 of the DIA1 gene revealed a heterozygous change of G to A at
nucleotide 15,635 in the father (A) and daughter (C) indicated by an arrow in the
chromatogram on the negative strand, when compared to normal sequence of the mother
(B). Sequencing of exon 9 of the DIA1 gene detected a heterozygous base change of G to
A at nucleotide 27,091 in the mother (E) and daughter (F) indicated by an arrow in the
chromatogram when compared to the normal sequence of the father (D). Bases are as
follows: G – Black; A – green; T – red; C – blue.

exhibited a specific activity or catalytic constant, kcat, corresponding to approximately
17% of the wild-type domain activity, while the affinity for the reduced pyridine
dinucleotide was only slightly decreased as indicated by the 1.5 fold increase in the
Michaelis Constant (Km) for NADH, indicting that the G75S variant primarily exhibited a
defect in the rate of hydride transfer rather than substantially impaired NADH binding.
Overall, the G75S variant retained only 11% of the catalytic efficiency, as indicated by
thespecificity constant (kcat/KmNADH), of native cytochrome b5 reductase. These results
could be contrasted with those obtained for the V252M variant which exhibited only a
modest decrease in specific activity, corresponding to an approximate 20% reduction,
161

Figure 56. X-Ray Crystallographic Structure of Cytochrome b5 Reductase. A
ribbon diagram of the structure of the R. norvegicus cytochrome b5 reductase diaphorase
domain (PDB = 1IB0) complexed with NAD+ is depicted showing the structural elements
that comprise the FAD- and NADH-binding lobes and the “hinge” interconnecting
region. The FAD-binding lobe is depicted in blue, the NADH-binding lobe is depicted in
red with the “hinge” region depicted in green. The FAD-prosthetic group and the bound
NAD+ molecule are shown in “ball and stick” representation using the Corey-PaulingKoltun convection. Te two residues that have been identified in the methemoglobinemia
mutants, G75 and V252 are also shown in “ball and stick” representation.
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Figure 57. SDS-PAGE Analysis of Wild Type Cytochrome b5 Reductase and the
G75S, V252M, and G75S/V252M Variants. Purified proteins (2 µg each protein)
obtained from the final FPLC purification step of all three mutants together with a sample
of wild-type cytochrome b5 reductase were resolved on a 12.5% polyacrylamide gel.
Lane A, wild-type cytochrome b5 reductase; Lane B, G75S; Lane C, V252M; Lane D,
G75S/V252M; Lane S, molecular weight standards. The positions of selected molecular
weight markers are indicated by molecular masses (kDa).
however, as anticipated for a mutation in the NADH-binding lobe, the affinity (Km) for
NADH was decreased approximately 9-fold, indicating that the V252M retained only 9%
of the catalytic efficiency of wild-type cytochrome b5 reductase. The results obtained for
the G75S/V252M double mutant were intermediate between those of the two single
mutants suggesting the effects of the two individual mutations were not synergistic.
Comparison of the kcat and Km values obtained for all three mutants revealed that while
the primary effect of the G75S mutation was to decrease the catalytic efficiency of the
enzyme, in contrast, the V252M mutation primarily decreased the affinity for the
reducing substrate NADH, which resulted in approximately equivalent specificity
constants for both mutants. It should be noted that the values obtained for the specificity
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Figure 58. Comparison of the UV/Visible Spectroscopic Properties of Wild-Type
Cytochrome b5 Reductase and the G75S, V252M, and G75S/V252M Variants.
Oxidized samples of G75S, V252M, G75S/V252M, and wild-type cytochrome b5
reductase (10-60 µM FAD) were analyzed using ultra violet/visible absorbance (A) and
circular dichrosim (B and C) spectroscopies, respectively, in 10 mM phosphate buffer,
containing 0.1 mM EDTA, pH 7.0. Individual spectra correspond to G75S (____ ____),
V252M (__ __ __), G75S/V252M (……), and wild-type cytochrome b5 reductase (______).
The insert shows expanded portions of the visible regions of the spectra.
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Table 19. Comparison of the Kinetic Constants Obtained for the G75S, V252M,
G75S/V252M and Wild-Type Cytochrome b5 Reductases.
Mutant
kcat
(s-1)

NADH:FR
KmFeCN6 kcat/KmNADH
(µM)
(µM)
(s-1 M-1)

KmNADH

NADH:BR
KmCyt b5 kcat/KmCytb5
(µM) (µM)
(s-1 M-1)

kcat
(s-1)

KmNADH

H4cb5r

800 ± 21

6±1

7±1

1.4 ± 0.3 x 108

600 ± 10

2±1

13 ± 1

4.7 ± 0.5 x 107

G75S

133 ± 26

9±1

7±1

1.5 ± 0.1 x 107

60 ± 3

4±1

14 ± 3

1.5 ± 0.1 x 107

V252M

633 ± 14

52 ± 5

7±1

1.2 ± 0.2 x 107

285 ± 14

3±1

13 ± 2

1.2 ± 0.2 x 107

G75S/V252M

187 ± 17

17 ± 1

8±1

1.1 ± 0.1 x 107

85 ± 3

3±1

14 ± 3

1.1 ± 0.1 x 107

constants of all three mutants were an order of magnitude lower than the corresponding
value obtained for the wild-type enzyme, reflecting the significant effect of the mutations
of the catalytic functionality of the enzyme.
The modest increase in the Km for NADH observed for the G75S variant was
confirmed upon the measurement of the spectral binding constants (Ks) [77] for both
H4NAD and NAD+. In contrast to the results previously obtained for the wild-type
domain which have yielded Ks values of 45±10 and 760±30 µM for H4NAD and NAD+,
respectively, identical experiments performed with the G75S variant, yielded Ks values of
59 µM and 85 µM, respectively, confirming the modest decrease in affinity for the
reduced form of the pyridine nucleotide (Figure 59).

However, the significantly

decreased Ks value obtained for NAD+ indicated that the mutant exhibited a substantially
greater affinity for the reaction product, which would be expected to result in decreased
enzyme activity owing to a decreased rate of product disassociation. In contrast, values
obtained for both H4NAD and NAD+ were significantly elevated for the V252M mutant,
confirming the results obtained for the activity assays.
165

To assess the impact of the G75S and V252M substitutions on protein folding,
thermal stability studies were performed monitoring both the loss of NADH:FR activity
and the increase in intrinsic flavin fluorescence for both the single and double mutants.
Both parameters are indicative of relative protein unfolding and can be effectively used to
monitor alterations in protein stability. As shown in Figure 60, the G75S, V252M and
G75S/V252M variants exhibited T50 values of approximately 48 °C, 53 °C, and 45 °C,
respectively, which may be compared to the value of 57 °C the wild-type domain,
suggesting that both the glycine to serine and valine to methionine substitutions resulted
in significant changes in the stability of the mutant proteins when compared to native
cytochrome b5 reductase.

Oxidation-reduction potential measurements for the

FAD/FADH2 couple (n = 2), were determined using the xanthine/xanthine oxidase dye
equilibration method utilizing phenosafranine (E°′ = -252 mV) as the indicator dye.
While we were unable to determine the redox potential for the flavin prosthetic group in
either the G75S or the G75S/V252M variants owing to substantial protein instability and
aggregation during the titration experiments, a value for the V252M mutant was obtained
reflecting the stability of this variant. The spectral changes accompanying reduction of
the V252M variant during the course of the dye mediated titration were directly
comparable to those previously published for the wild-type cytochrome b5 reductase
suggesting very similar flavin redox potentials for the two proteins. The corresponding
Nernst plots, shown in Figure 61, which relate to the concentrations of the oxidized and
reduced forms of the flavin cofactor to the observed solution potential [77], revealed that
the flavin midpoint potential for the FAD/FADH2 couple (n = 2) in the V252M variant
was -276 mV, which was essentially unchanged from the midpoint potential of -274 mV
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Figure 59. Flavin Difference Spectra Obtained Following Binding of Either H4NAD
or NAD+ to Wild-Type Cytochrome b5 Reductase or the Various G75S and V252M
Mutants. Difference Spectra were obtained for both wild-type cytochrome b5 reductase
(A and B) and the G75S (C and D), V252M (E and F), and G75S/V252M (G and H)
variants at equivalent flavin concentrations (50 µM FAD) in 20 mM MOPS buffer,
containing 0.1 mM EDTA, pH 7.0 following titrations with either H4NAD (left panels) or
NAD+ (right panels) as described in “Materials and Methods”. The insert panels
correspond to plots of the magnitudes of the observed spectral perturbations (peak to
trough measurements at the indicated wavelengths) versus ligand concentration. The
corresponding Ks values are given in Table 20.
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Table 20. Spectral Binding Constants Obtained for Wild Type cb5r and the G75S,
V252M, G75S/V252M Variants.
Mutant

Ks H4NAD
(µM)

KsNAD+
(µM)

H4cb5r
G75S
V252M
G75S/V252M

45 ± 10
59 ± 4
428 ± 55
134 ± 7

760 ± 30
85 ± 6
14,001 ± 2251
956 ± 83

obtained for the wild-type cytochrome b5 reductase. However, in the presence of NAD+
or NADP+, the redox potential of the FAD/FADH2 couple was shifted to -232 mV and 190 mV, respectively, which reflected and confirmed the decreased affinity of the
V252M mutant for NAD+ compared to the native enzyme.

Summary of the novel FAD-binding lobe G75S mutation in cytochrome b5 reductase
The G75S and V252M mutation identified in exons 3 and 9 respectively represent
radical amino acid substitutions in distinctly different regions of the polypeptide chain
that are primarily responsible for either FAD or NADH binding, respectively.
Identification of the G75S variant represents the discovery of a new mutation in the DIA1
gene, the V252M variant has been previously reported [82-84] in both type I and type II
individuals, but biophysical studies on a recombinant form of the V252M variant have
not been previously described. To understand the effect of these mutations on the
function of cytochrome b5 reductase and the development of recessive congenital
methemoglobinemia, we generated and characterized the G75S variant together with the
V252M and the G75S/V252M double mutant using a rat cytochrome b5 reductase
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Figure 60.
Comparison of the Thermostability Properties of Wild-Type
Cytochrome b5 Reductase and the G75S, V252M, G75S/V252M Variants. Oxidized
samples of G75S, V252M, G75S/V252M and wild-type cytochrome b5 reductase (5 µM
FAD) were incubated at the indicated temperatures, and aliquots were withdrawn and
assayed for both residual NADH:FR activity (open symbols) and intrinsic flavin
fluorescence (closed symbols) in 10 mM phosphate buffer, containing 0.1 mM EDTA,
pH 7.0 using excitation and emission wavelengths of 450 nm and 523 nm, respectively.
The plots correspond to (●,○) H4cb5r; (■, □) G75S; (▲, ∆) V252M; and (♦, ◊)
G75S/V252M.
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Fig. 61. Comparison of the thermodynamic properties of wild-type cytochrome
b5reductase and the V252M variant. Reductive dye-equilibration titrations of both
wild-type and the various of cytochrome b5 reductase mutants (40 µM FAD) were
performed as described under “Materials and Methods” in 100 mM phosphate buffer,
containing 0.1 mM EDTA, pH 7.0 in the presence of phenosafranine (15 µM, Eo′ = −252
mV) as indicator dye. Individual absorption spectra were collected at 2- to 3-min
intervals during the time course of the titration and the corresponding Nernst plot
obtained for the FAD/FADH2 couple (n = 2) is shown for the titration of the V252M
variant (O, Eo′ = −276 mV). Also shown is the corresponding plot for wild-type
cytochrome b5 reductase ( , Eo′ = −272 mV). Redox potentials are given with respect to
the Standard Hydrogen Electrode and are considered accurate to ±5 mV.
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heterologous expression system. The double mutant does not represent the situation in
the patient, but we were curious to examine the impact of both mutations on the protein
structure of cytochrome b5 reductase. Although the G75S mutation is located in the
FAD-binding lobe, it did not affect the global folding of the protein or the incorporation
of the flavin cofactor. Instead the G75S mutation caused reduced protein stability and
impaired

NADH

activity,

thus

resulting

in

type

I

recessive

congenital

methemoglobinemia.
The G75S variant is the fourth example of an amino acid substitution that results
in a mutation (GGC to AGC) in exon 3, which codes for a portion, comprising residues
I52 to G75, of the amino-terminal FAD-binding lobe of cytochrome b5 reductase. Other
mutations previously identified within the FAD-binding lobe include R58Q, P65L and
L72P [31, 48, 82, 118]. All three mutations in exon 3 give rise to the type I form of RCM
which is the more benign form of the disease.
The x-ray structure of the soluble domain of rat cytochrome b5 reductase [21],
both in the absence and presence of NAD+, indicated that residue G75 is situated at the
apex of a broad loop structure that precedes the Fβ3 strand which comprises part of a
FAD-binding six stranded, anti-parallel β-barrel structure.

Inspection of the rat

cytochrome b5 reductase structure revealed that while G75 makes no direct contacts with
either the FAD prosthetic group or the bound NAD+ nucleotide, the residue is situated at
a relatively solvent-accessible cleft within the structure and is contacted by a number of
bound water molecules.

A multiple sequence alignment, shown in Figure 62, has

revealed that G75 is part of a highly conserved region of the amino acid sequence that
corresponded to residues “70LGLPxGxH77” that is present in the majority of cytochrome
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b5 reductase sequences identified so far and also includes H77 which provides
hydrophobic interactions with the flavin isoalloxazine ring. In addition, modeling studies
of the interaction of human cytochrome b5 reductase with cytochrome b5 have suggested
that the conserved histidine 77 is hydrogen bonded to the b5 propionate group in the
cytochrome b5 reductase- cytochrome b5 complex [20].
Homology modeling of the G75S variant suggested that substitution of the more
bulky serine side chain for the glycine hydrogen atom would be expected to result in
steric constraints which would require displacement of the Nβ7 strand that forms the
initial part of the “linker” or “hinge” region that joins the FAD- and NADH-binding
lobes. Perturbation of the organization of this “linker” region would be anticipated to
result in decreased diaphorase activity owing to a change in registration between the two
structural lobes as previously reported for other “linker” domain RCM mutants, such as
P144L [82], P144S [119], and L148P [48]. In addition, alterations in the organization of
the two lobes would be expected to decrease the stability of the protein which has also
been previously documented for the P144L and L148P variants [105]. The relative
importance of a glycine residue at position 75 in the primary structure is also reinforced
by its conservation in the majority of the other protein sequences that form part of the
ferredoxin:NADP+ reductase (FNR) super-family of flavoprotein transhydrogenases,
including FNR, phthalate dioxygenase reductase and assimilatory NADH:nitrate
reductase [5].
In contrast to the G75S mutation, the V252M substitution was determined to have a
markedly less severe impact on either the structure or function of cytochrome b5
reductase. Unlike G75, residue V252 is not situated in a region of particularly well
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conserved primary sequence and can be found to occur as valine, isoleucine or proline
residues in cytochrome b5 reductase homologues, although the marked preference
appears to be for the presence of an alipathic hydrocarbon side chain at this position in
this sequence, as shown in Figure 62.
Within the rat cytochrome b5 reductase structure, V252 is part of a surfaceaccessible loop region located midway between strand Nβ4 and helix Nα3 [21]. While
V252 makes no direct backbone or side chain contacts with either the FAD- or bound
NAD+, this loop region forms part of the NAD+ binding site and aids in correctly
orienting the side chain of F251 over the adenine moiety of the substrate. Carbon CG2 of
the isopropyl side chain of V252 is only 5.3 Å away from the adenine O2 atom of the
NAD+. In addition, the V252 amide nitrogen atom participates in a water-mediated
hydrogen bond to the NAD+ AO2* atom. Thus, substitution of V252 by the considerably
more bulky side-chain of methionine would be unlikely to have any dramatic effects on
either the properties of the FAD prosthetic group or the specific activity of the protein but
could decrease the affinity for NADH due to potential steric interactions which would
disrupt the structure of the loop region and decrease the interaction with the adenine
moiety.

This prediction is in good agreement with the results obtained from the

NADH:FR activity studies which indicated a nearly 10-fold increase in the Km for
NADH.
Previously, we have identified other mutations in the carboxy-terminal
NADH-binding lobe of cytochrome b5 reductase, including D239G, E255-, and G291D
[78, 105, 107], whose biochemical properties can be compared with those of the V252M
variant. The V252M variant was found to retain the spectroscopic properties typical of
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Fig. 62. Multiple Sequence Alignment of Selected Cytochrome b5 Reductase
Primary Structures. Published amino acid sequences for cytochrome b5 reductases from
various species were obtained from GenBank using the corresponding accession
numbers, aligned using the CLUSTAL X algorithm [108] and the alignment manually
adjusted for maximum sequence conservation. Only portions of the sequences
surrounding the residues equivalent to G75 and V252 in H. sapiens cytochrome b5
reductase are shown with the conserved “G” and “V/I” residues underlined. Superscripts
indicate the positions of the starting residues for the two sequence portions within the
respective primary sequence. Shown below the alignment is a “sequence logo” [109] that
consists of stacks of symbols (one stack for each position in the sequence) with the
overall height of the stack indicating the sequence conservation at that position and the
height of the symbols within the stack indicating the relative frequency of each amino
acid at that position.
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the wild-type protein and to exhibit a full complement of FAD incorporation with the
flavin prosthetic group present in an environment spectroscopically indistinguishable
from that of the native domain. This was similar to the spectroscopic properties and FAD
complement of the other NADH-binding lobe variants [105, 107].

In contrast,

NADH:FR activity assays revealed the V252M mutant retained substantial diaphorase
activity, as indicated by a specific activity corresponding to 80% of the wild-type
domain, similar to D239G at 94%, while the E255- and G291D variants only retained
38% and 58% of wild-type activity, respectively.
There was reduced affinity towards the NADH substrate but no change in cofactor
selectivity as with D239G [107] and no significant change in the thermostability of the
V252M variant when compared to wild-type cytochrome b5 reductase. Thus, loss of the
non-polar side chain at residue 252 does not affect thermostability or enzyme activity but
reduces affinity towards the NADH substrate, indicating the key role that this region of
the primary structure plays in substrate affinity. It is interesting to note that a change in
the Km for NADH alone is sufficient to cause the development of type I RCM. Since the
NADH cofactor is required for the reduction of soluble cytochrome b5 and in turn
methemoglobin reduction.
In summary, characterization of the individual G75S and V252M cytochrome b5
reductase variants together with the G75S/V252M double mutant indicated decreased
catalytic activity rather than total loss of enzyme function as predicted by the suggested
type I recessive congenital methemoglobinemia phenotype of the infant. In addition, the
results for the G75S/V252M double mutant were intermediate between those of the two
individual variants suggesting that the effects of the two individual mutations were not
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synergistic. All three cytochrome b5 reductase variants displayed an approximately 10fold decrease in catalytic efficiency combined with decreased protein stability, albeit
slight for V252M, which would be expected to manifest as potentially increased
methemoglobin concentrations. In conclusion, these studies provide insight into the
development of type I as opposed to type II disease and may be a potential diagnostic tool
in young infants to aid in defining recessive congenital methemoglobin status.
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4. CONCLUSIONS AND FUTURE DIRECTIONS

The studies presented here were intended to provide additional structural and
functional insight into the highly conserved motifs found within cytochrome b5 reductase,
and other members of the FNR superfamily, in respect to FAD-binding and NADHbinding as well as their catalytic function. This was accomplished through two alternate
approaches. The first approach involved the generation of variants of the amino acid
residues found within the conserved motifs based on alternative residues observed to
occur at the same position in other members of the FNR family as well as within other
species, charge reversal mutants, and the introduction of a positive charge as in the case
of the G124 variants.

The second approach incorporated the analyses of naturally

occurring recessive congenital methemoglobinemia mutants that are located within, or in
close proximity to, the conserved motifs. Through this method of characterization we
were able to establish a role for each of the previously uncharacterized amino acid
residues found in the FAD- and NADH-binding motifs as well as determine the
molecular basis for disease for each of the RCM variants.
Previous studies based on the “RxYSTxxSN” motif had established it as being
highly conserved within the β-barrel structure in the FNR superfamily of enzymes [39].
Work by Kirksey et al. determined that in monoamine oxidase B the equivalent arginine
residue beginning the motif possessed a necessary charge for proper incorporation of the
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FAD- cofactor [120].

More recently, a role for the R91, P92, and Y93 has been

established [76, 77]. It was demonstrated that these residues were not in fact “essential”
for flavin incorporation, yet R91 and Y93 were both required for the modulation of the
biophysical and catalytic properties of cytochrome b5 reductase as well as maintaining the
proper active site structure. The work presented here determined a role for the remainder
of the motif to include: T94, P95, V96, and S97. While the V96S and S97N variants
yielded results that were comparable to wild-type cytochrome b5 reductase, indicating
that these residues were not essential for proper flavin incorporation or catalysis, the
introduction of a T94H variant involved the removal of the polarity of a hydroxyl group
and caused a significant perturbation with respect to the environment of the flavin
prosthetic group.

The introduction of the imidizole side chain resulted in a steric

hindrance effect directly affecting the interaction of the T94 residue with that of the FAD
isoalloxazine ring and displacing it away from the FAD binding site. This was further
confirmed in the analyses of the spectroscopic binding constants, where the T94H variant
displayed a greater affinity for the product NAD+ but a reduced affinity for the H4NAD
substrate analog. Inhibition studies concluded that upon substrate binding the NAD+
product was not able to disassociate efficiently from the NADH-binding site which may
be due to the displacement of the flavin. Similar, yet not as dramatic, effects were
observed for the P95I and P95G variants. Interestingly, we were never able to generate a
stable protein for either the T94G or T94P variants. We believe that this is due in part to
the fact that the introduction of a glycine leads to a relaxation in the secondary structure
of the protein and the introduction of a proline causes a kink in the backbone structure.
Due to its highly conserved position these dramatic alteration to the T94 residue would
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lead to the generation of an unstable form of the protein that was unable to properly
incorporate the flavin prosthetic group.
Further analysis of the “RxYSTxxSN” motif was accomplished through the
characterization of the naturally occurring RCM double mutant P92H/E255-.

The

examination of this variant not only afforded an opportunity to determine the properties
of a RCM mutant occurring within a highly conserved motif but also allowed us to
investigate the effects of a mutation found in both the FAD-binding and NADH-binding
domains of cytochrome b5 reductase. The substitution of a proline by a histidine at
residue position 92 leads to the introduction of an imidizole side chain that would result
in a steric hindrance with the isoalloxazine ring of the flavin prosthetic group. The
results of this steric hindrance lead to a significant decrease in the efficiency of substrate
utilization as well as a dramatic perturbation of the environment of the flavin causing a
partial displacement of the cofactor as observed in the potentiometric titration with a
positive shift towards that of free flavin.

The E255- variant has been previously

characterized and has been demonstrated to have a profound effect on the NADH-binding
motif “CGxxxM” that results in a decrease in substrate affinity and a reduction of the
catalytic efficiency of over 50% [79]. Thus, the combination of the P92H and E255variants in the double mutant combined the effects of the P92H on the FAD-binding
domain and the E255- on the NADH-binding domain resulting in a 103 decrease in the
overall catalytic efficiency.
The analysis of the crystal structure of cytochrome b5 reductase exposed the
critical importance of the “GRxxST” motif which has been proposed to be involved in the
regulation of FAD or FMN specificity [5]. Each of the four residues found within this
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motif are shown to be directly involved in proper FAD-binding and orientation through
hydrophobic or electrostatic interactions. Additionally, the residues of this motif are
located within the only α-helical segment found within the FAD-binding lobe of
cytochrome b5 reductase. Therefore, any mutations of the residues of this motif would
have a significant impact on the environment of the flavin prosthetic group. This was
previously demonstrated through the characterization of the type II RCM variant S127P
[80], in which the ADP moiety of the flavin prosthetic group was displaced into the
NADH-binding domain, thereby acting as its own inhibitor. This work represented the
first application of site-directed mutagenesis to the G124, K125, and M126 residues
found within the cytochrome b5 reductase “GxxST” motif to gain insight into the roles of
each of these residues in regulating flavin binding and orientation.

Significant

perturbations were first observed in the visible CD spectra for each of the variants. The
most dramatic effect was determined for the M126 variants which displayed spectra
comparable to that of the previously described S127P variant, indicating that, much like
the S127P mutation, alterations of the M126 residue also lead to the displacement of the
ADP moiety of the FAD- cofactor.

The perturbations were also found to effect a

decrease in the overall catalytic efficiency for all of the variants in regards to both
turnover and substrate binding. Interestingly, in establishing the differential binding
constants for the “GxxST” variants, the introduction of a positive charge at position 124
displayed an enhanced affinity for both H4NAD and NAD+ yet showed an altered
conformation of binding for the NAD+ product. This indicated, that much like that of the
T94H variant, the substrate is not able to bind as efficiently yet is not able to disassociate
due to the perturbation of the flavin prosthetic group caused by the introduction of a
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positive charge on residue G124. Finally, evidence suggests that the disruption of the
flavin environment leading to a displacement of the FAD- cofactor were supported by the
shifts observed in the values of the midpoint potentials obtained in the presence of NAD+
which all displayed a negative shift towards that of the potential of free flavin. The
results from the kinetic, thermodynamic, and spectral data clearly demonstrate that any
alterations introduced into the “GxxST” motif of cytochrome b5 reductase lead to a partial
displacement of the flavin prosthetic group resulting in a reduction in the overall catalytic
efficiency and electron transfer.
The characterization of the naturally-occurring RCM variants M272- and P275L
allowed for the determination of the importance of the conserved NADH-binding motif
“CGxxxM” motif as well as establishing a molecular basis for disease for each of the
variants. The M272 residue has no direct interaction with the NADH substrate yet it
directly precedes the highly conserved residue C273, which has been determined to be an
“essential” residue within the “CGxxxM” motif. The deletion of residue M272 has also
been shown to give rise to type II RCM [81] and initial kinetic analyses has demonstrated
that this mutation has the lowest catalytic efficiency observed thus far for any
methemoglobinemia variant [40]. The deletion of this residue results in a frame-shift of
the entire nucleotide binding motif which displayed a significant decrease in the substrate
binding affinity as well as a reduction in the catalytic efficiency. As demonstrated in the
determination of the spectral binding constants, no spectroscopic changes were observed
for the M272- variant even at very high concentrations of substrate. Interestingly, the
same effects were witnessed for the M272R mutation. The introduction of the arginine
side chain was hypothesized to protrude towards the C273 residue resulting in a
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disruption of the essential contacts that C273 makes with the NADH substrate leading to
the decreased substrate binding affinity. The effects upon substrate affinity as well as the
modulation of electron transfer by the M272- and M272R variants was observed in the
potentiometric titrations performed in the presence of NAD+.

For the wild-type

cytochrome b5 reductase a shift of +77 mV was observed for the FAD/FADH2 couple in
the presence of NAD+, however, this shift was significantly decreased for the M272- and
M272R variants, further confirming that substrate binding had been severely
compromised.
Residue P275 is a critical residue found within the “CGxxxM” motif that
functions in proper NADH-binding and orientation of the pyridine nucleotide. Through
analysis of the crystal structure of cytochrome b5 reductase in complex with NAD+ it was
observed that the bound NAD+ conforms itself and actually bends around the P275
residue. The mutation of the proline to that of a leucine, as determined in a patient
exhibiting a type I RCM phenotype, demonstrated the critical role that this amino acid
residue plays. The initial rate kinetic analyses provided the first evidence of the effects of
the introduction of a leucine at position 275. Surprisingly, the P275L variant displayed
an activity that was comparable to that of wild-type cytochrome b5 reductase, however,
the Km for NADH utilization was increased 437 fold compared to that of wild-type cb5r,
indicating a dramatic decrease in the affinity for the NADH substrate. To further confirm
the reduced affinity for NADH, spectral binding constants were determined for both the
analog H4NAD and the reaction product NAD+.

In this experiment, no complex

formation could be detected even upon the addition of concentrations of substrate that
were 10-fold greater than that required for saturation of the wild-type enzyme.
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Additionally in the potentiometric titrations, the redox potential in the absence of NAD+
was comparable to the value obtained for wild-type cytochrome b5 reductase, indicating
that the P275L variant had no effect on the FAD- cofactor. However, upon the addition
of NAD+ the potential was significantly more negative, confirming that the replacement
of the proline residue with a leucine does in fact lead to a decreased affinity for the
NADH substrate that is capable of giving rise to type I RCM. It is evident from these
results that any alterations in the highly conserved “CGxxxM” motif can significantly
affect the overall catalytic efficiency of cytochrome b5 reductase and the correct
maintenance of the motif is imperative in proper NADH substrate binding and
orientation.
Finally, the characterization of the naturally occurring double mutant
G75S/V252M again allowed us to examine the effects of a RCM mutation that occurs in
both the FAD-binding and NADH-binding domains and use this information as a
potential aid to determine the methemoglobinemia status (type I or type II) upon the first
onset of the disease. Although the patient was actually heterozygous for the double
mutation, we decided to generate the double mutant as a homozygote in order to examine
the possible synergistic effects. Previous studies have described the V252M as giving
rise to type I RCM [40, 84]. It was then our prediction that the G75S variant would also
be capable of demonstrating characteristics of that of type I RCM, yet the combination of
the two mutations affecting both the NADH-binding and FAD-binding domains would
give rise to the more severe type II RCM. However, although both the single and the
double mutants displayed a decrease in catalytic efficiency, the double mutant actually
yielded results that were intermediate between that of the two single mutants. This
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information can therefore provide valuable insight towards the early diagnosis of RCM
type I versus type II status in an infant.
This data provides valuable insight into the structural and functional properties of
the highly conserved motifs of cytochrome b5 reductase that are involved in FAD- or
NADH-binding and orientation as well as a determination of the molecular basis of the
disease recessive congenital methemoglobinemia.

These results support logical

conclusions based on the kinetic, spectral, thermodynamic, and molecular modeling
properties of each of the generated variants. However, in order to complete this work and
support our conclusions, crystal structures of the variants, both in the absence and
presence of NAD+ should be obtained. This would provide the most concrete evidence to
support the conclusions presented in this work. The evaluation of the naturally occurring
methemoglobinemia variants M272- and P275L provided us with a clear definition of the
importance of the “CGxxxM” motif in regards to NADH substrate binding and
orientation. In order to fully elucidate the role of each residue though, a project is already
underway that will involve alanine scanning of the entire motif. The data presented here
in this research provided a broad analysis of the motif whereas the alanine scanning data
will provide information on the structural and catalytic role of each individual residue.
Additional work could also be carried out involving the “GRxxST” motif. The
generation of the G124, K125, and M126 variants established the critical role that each
residue plays towards the proper incorporation of the cb5r flavin prosthetic group. To
gain a broader understanding of the roles of these residues, a series of double and triple
mutants could be generated and only the most interesting variants selected for further
characterization.

As previously mentioned, the
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G
R124

residue not only forms a

hydrophobic interaction with the FAD- cofactor of cb5r but also has been proposed to
regulate FAD/FMN specificity within members of the FNR superfamily. To investigate
this, flavin analog substitution could be performed utilizing the G124R variant. From
this a Ks for FAD, FMN, and various other analogs could be determined.
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